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ALYSON PATRICIA BLACK. A Novel Platform for Multiplexed N-glycoprotein 
Biomarker Discovery for Hepatocellular Carcinoma by Antibody Panel Based N-glycan 
Imaging (Under the direction of ANAND MEHTA) 
 
 The vast majority of biomarkers used in the detection of cancer are glycoproteins, 
and numerous studies have indicated that the N-glycosylation of serum glycoproteins 
changes with the development of hepatocellular carcinoma (HCC). However, current 
biomarkers for HCC are lacking in sensitivity and specificity, and there is a need for 
higher throughput techniques to discover more powerful biomarkers. The majority of 
methods that do analyze N-glycans and their protein carriers generally require large 
amounts of sample preparation and/or look at only one protein at a time, which is a 
barrier for translating discoveries to the clinic. In response to this need for multiplexed 
biomarker analysis of protein-specific N-glycan changes, we developed a novel platform 
for the simultaneous analysis of potentially 100s of N-linked glycoproteins from biofluids 
with the goal of discovering new clinically-relevant cancer biomarkers. This new mass 
spectrometry imaging platform for multiplexed N-glycoprotein biomarker was applied to 
multiple cohorts of cirrhotic and HCC patient serum samples. An antibody panel 
encompassing antibodies for seven glycoproteins was used in the analysis of two cohorts 
consisting of 100 patients. These data were used to create biomarker algorithms 
incorporating protein-specific glycan signatures and clinical information. These models 
produced AUROCs of 0.9289 and 0.9278 for differentiating HCC from cirrhosis, which 
were significant improvements on the currently used biomarker AFP. We also expect that 
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this platform can be expanded for biomarker discovery of other types of cancers and 
diseases from numerous types of biofluids.  
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1.1 Hepatocellular Carcinoma  
1.1.1 Etiology and Disease Progression 
Hepatocellular carcinoma (HCC) is a malignancy of hepatocytes that arises within 
the liver. HCC is the 5th most common cancer, but the 3rd leading cause of cancer death 
globally with approximately 700,000 fatalities annually.1–3  The severity of this cancer 
arises from its difficulty to detect and treat. Patients often do not present with symptoms 
of disease until it is progressed. HCC occurs in the background of underlying liver 
disease such as cirrhosis often associated with chronic viral infections, obesity, metabolic 
disease, and excessive alcohol consumption.4,5 Viral infections linked to HCC include 
Hepatitis B and C, which cause chronic inflammation and contribute to DNA alterations.4 
Obesity-associated nonalcoholic fatty liver disease/nonalcoholic steatohepatitis has also 
recently been considered a major etiology of HCC.6 Excessive alcohol consumption 
damages the liver and leads to cirrhosis. Cirrhosis is an inflammatory condition of the 
liver characterized by fibrosis, nodular regeneration, and abnormal hepatic 
architecture.4,5,7 Liver function is affected due to scar tissue congestion of sinusoids, 
encasement of hepatocytes, and shunting of portal and arterial blood flow to central 
veins.5 Advanced cirrhosis is accompanied by hepatic encephalopathy, portal 
hypertension, and ascites.5,7  
Hepatitis B and C infections are responsible for the majority of HCC cases. These 
viruses can cause either acute infections or long-term chronic disease.8 While these 
viruses often lead to similar results, they are distinct in their biology and incidence. 
Hepatitis B is a DNA virus that is most common in Southeast Asian and African 
countries, while Hepatitis C is an RNA virus more commonly found in Western nations 
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and Japan.9  These viral infections can remain undetected in patients for years as they are 
often asymptomatic – further liver disease and HCC may take years to develop.8,10 The 
mechanisms by which these viral infections cause oncogenesis are not completely 
understood, but significant oxidative and ER stress as well as induced hepatocyte 
regeneration can contribute to various hallmarks of cancer.8 Ultimately, persistent 
infection leads to a constant state of inflammation in the liver. 
 Inflammation of the liver is strongly associated with the development and 
progression of HCC. In fact, 80-90% of HCC cases arise in the presence of chronic 
inflammation.4 This inflammatory microenvironment promotes fibrosis, epithelial-to-
mesenchymal transition, hepatocyte proliferation, angiogenesis, and lowers 
immunosurveillance of cancer cells.11 The inflamed liver contains elevated levels of 
many immune cells such as NK cells, T cells, B cells, and macrophages – along with the 
large population of Kupffer cells already residing in the liver.11 The inflamed liver is rich 
in chemokines recruiting immunosuppressive cells such as regulatory T cells and M2 
macrophages, which can play a significant role in shielding developing HCC cells from 
destruction by the immune system.4 Studies have observed a correlation between 
regulatory T cell concentration in the liver and prognosis/overall survival in HCC 
patients.12,13 Increased immune infiltrate also can promote cancer progression through 
increased cellular turnover and formation of ROS.14 Platelets have also been implicated 
in assisting HCC progression and are often elevated in HCC patients.15 While platelets’ 
effector functions lead to wound-healing in a normal physiological state, these same 
functions may promote tumor cell proliferation and metastasis.4,15,16 For example, 
platelets secrete a variety of growth factors while also inhibiting anti-tumor immune cells 
4 
 
such as macrophages and natural killer cells.4,15 Additionally, activated platelets can 
secrete glycosyltransferase enzymes, primarily sialyltransferases, which can modify the 
N-glycan profile of circulating glycoproteins.17 
Extracellular matrix remodeling is another product of an inflammatory 
microenvironment and plays an important role in chronic liver diseases as well as cancer. 
Secretion of matrix metalloproteinases allows for tumor growth and favors a metastatic 
environment.4 Cancer-associated myofibroblasts are differentiated from hepatic stellate 
cells and contribute to cancer progression through continued recruitment of 
immunosuppressive cells, secretion of angiogenic factors, and, importantly, extracellular 
matrix remodeling.11 Extracellular matrix remodeling from the fibrosis found in many 
chronic liver diseases creates a stiffer microenvironment, which has been shown to 
contribute to cancer cell proliferation and chemotherapeutic resistance.18 
The genetics of HCC have been characterized by multiple groups and some 
significant patterns have emerged. Key mutations generally found in HCC are the TERT 
promoter, tumor protein p53 TP53, and b-catenin CTNNB1.19–21 TERT promoter 
mutations are fundamental for the immortalization of cancer cells and are the most 
common somatic mutations found in cancer as well as the most common mutation in 
HCC (60%).19–22 As a key tumor suppressor protein, p53 functional mutations promote 
carcinogenesis and are found in 25-30% of HCC patients.21 b-catenin is a key player of 
the Wnt signaling pathway that regulates cell proliferation and differentiation, and 
mutated CTNNB1 acts as an oncogene to drive cell transformation.23 While these 3 are 
not the only gene alterations observed in HCC, they are the most prevalent.21 In addition 
to HCC tissue, a multicenter study illustrated that gene expression of the adjacent 
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surrounding tissue may actually be more predictive of patient survival.24 This again 
highlights the important role of the tumor microenvironment as the elevated genes were 
associated with inflammation and, in particular, targets of IL-6.  
The aggressiveness of HCC can be correlated to its genomic profile, which 
Hoshida et al. have used to designate 3 distinct subtypes of HCC.25 Activation of the Wnt 
pathway was observed in Subtype 1, however without the classic CTNNB1 mutation.25 
Instead, these tumors overexpressed TGF-β target genes, which affect the Wnt pathway 
by altering localization of b-catenin within the cell.25 This subtype of HCC is highly 
aggressive and associated with poorer patient survival. It is important to note that 
elevated levels of AFP are not common in these patients, which highlights the need for 
additional serum biomarkers to detect this deadly cancer.25 The second HCC subtype 
characterized does correlate with increased AFP levels while also producing large, 
aggressive tumors.25 Increased Myc/Akt pathway activation along with suppression of 
IFN target genes were observed in Subtype 2 tumors. Other groups have also described a 
positive association between AFP levels and Akt expression.26 Both Subtype 1 and 2 
harbored increased p53 mutations, as is common to many aggressive cancers. In contrast 
to the other two subtypes, Subtype 3 tumors are smaller, well-differentiated and correlate 
to better survival.25 These tumors contained the majority of CTNNB1 mutations while 
often retaining normal p53 function.25 Together, these genomic classifications can 
provide insight for therapeutic targets as well as emphasize the need for a panel of HCC 
biomarkers able to reliably detect this heterogenous cancer. 
Worldwide HCC occurs in men significantly more than women, this is attributed 
to the effect of testosterone of hepatocyte cell cyle.1,6 The survival rate of people with 
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primary liver cancers is very low, with a 0.95 ratio of mortality to incidence.6 The low 
survival rates have been attributed to late diagnosis and limited treatment options.27 
Although liver transplantation is the preferred option for surgical treatment of HCC, the 
paucity of organ donors means that partial hepatic resection is a common treatment.2 
Unfortunately, even with advances in surgery and patient care, reported 5-year survival 
rates are around 50%.28 The incidence of HCC has shown a drastic increase in the United 
States over the last 35 years,3,29 mainly attributed to hepatitis C virus infection and rising 
obesity/metabolic challenges.6  
1.1.2 Standard of Care 
There are numerous systems of staging the progression of HCC in a patient, but 
the American Association for the Study of Liver Diseases (AASLD) currently 
recommends the Barcelona Clinic Liver Cancer (BCLC) system to evaluate prognosis.1,30 
This system incorporates liver function, tumor burden, and patient’s performance status 
(PS), which is their ability to do daily life activities.1,30 Including liver function status in 
this score is beneficial as most HCC is found with underlying cirrhosis and liver disease. 
The clinical parameter Child-Pugh score represents the patient’s liver status and ranges 
from A-C, with C being the poorest liver function. An outline of the BCLC staging 





Figure 1. The Barcelona Clinic Liver Cancer staging system for HCC prognosis. This 
chart describes the clinical characteristics that lead to each stage of HCC. This chart was 
adapted from the AASLD Guidelines for HCC Staging and Diagnosis.1 PS =  
performance status
 
As a highly lethal cancer, successful treatment options for HCC are few and are 
divided into curative and non-curative therapies. Curative therapies include ablation, 
resection, or orthotopic liver transplant – all of which have potential for a lasting anti-
tumor response and improved survival.1 Surgical resection or ablative strategies can be 
therapeutically valuable options for patients with small lesions and well-managed liver 
disease.3 Candidates for resection are those without severe cirrhosis and who have 1-3 
unilobar lesions (<3cm for multiple lesions or <5cm for one lesion), and this therapy is 
recommended over radiofrequency ablation.3 Ablative techniques are performed by 
injecting chemicals (such as ethanol) into the tumor or increasing the local temperature of 
the tumor with radiofrequency, microwave, or laser.1 These are primarily effective for 
tumors with underlying cirrhosis in the liver, as the tissue stiffness allows the therapy to 
remain localized to the tumor. Unfortunately, only about 10% of HCC patients are 
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acceptable for resection,2 and there is significant risk of recurrence or de-novo tumor 
development following the resection or ablation of HCC lesions.28 The most effective 
treatment option for HCC patients is liver transplantation, as it rids the patient of both the 
cancer and the underlying liver disease. Transplantation thus provides the best outcomes 
for patients, with 5-year survival rates of 70% and low risk of recurrence.28 However, the 
major limits to liver transplantation are the shortage of organ donors as well as the 
stringent criteria for transplantation.2,7 Even though liver transplantation is often viewed 
as a cure for HCC, intra-hepatic tumor recurrence can occur and is especially a risk for 
those patients with large initial tumors.31  
Noncurative therapies for HCC exist that may improve survival by slowing tumor 
progression.1 These include locoregional interventions like transarterial 
chemoembolization (TACE), transarterial radioembolization (TARE), and stereotactic 
body radiation therapy (SBRT) along with systemic chemotherapy.1 Locoregional 
therapies are minimally invasive procedures performed by interventional radiologists by 
accessing liver vasculature through the femoral artery. These therapies are primarily 
recommended for patients with BCLC stage A or B disease.1 For advanced stage HCC, 
primarily stage C, locoregional therapies are not recommended and systemic 
chemotherapy is pursued instead.1 Chemotherapeutic options for HCC are limited and the 
frontline agent for those with non-ablatable tumors is the multi-kinase inhibitor sorafenib, 
sold under the brand name Nexavar.  Sorafenib is a general tyrosine and serine/threonine 
protein kinase inhibitor with activity against vascular endothelial growth factor (VEGF) 
and platelet-derived growth factor (PDGF) receptors as well as intracellular kinases B-
Raf and Raf-1.32 Regorafenib is also a multi-kinase inhibitor that is approved for the 
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treatment of HCC as a second-line to sorafenib.1,33 Agents that specifically target one 
growth receptor, such as enhanced VEGFR inhibitors have failed to show activity against 
HCC.32 It is noted, however, that sorafenib’s activity against HCC is limited, with 
improved survival times of only a few months.34 Immunotherapy techniques for treating 
HCC are also being explored, with the recent FDA approval of atezolizumab plus 
bevacizumab for unresectable HCC as well as the the PD-1 inhibitor nivolumab for 
advanced HCC.1,4,35,36 Numerous other immunotherapies are currently in clinical trials 
including other checkpoint inhibitors, antibodies, and adoptive cell transfer.4,35 These 
bleak current treatment options – both in their availability and efficacy – highlight the 
necessity for early detection of HCC. 
1.1.3 Detection and Diagnosis 
The current clinical gold standards for detection of HCC are magnetic resonance 
imaging (MRI), ultrasound (US), and computed tomography (CT) scans to detect lesions. 
US is the preferred primary method of detection as there is not significant evidence for 
the effectiveness and cost-effectivness of CT and MRI.1,3 Current clinical guidelines 
recommend that at-risk patients with cirrhosis and hepatitis B/C or NAFLD with 
underlying cirrhosis be entered into a surveillance program.1,3,37 This consists of routine 
(every 6 months) examination by US with or without a serum biomarker. Some US 
examinations provide clear evidence of HCC (lesions ≥10 mm), no HCC (benign lesions 
that are clearly cysts or lack of any focal abnormalities) while others are nondiagnostic 
due to ambiguity.1,3,37,38 If small nodules (<10 mm) are present, a “watch and wait” 
approach is generally taken with the patients returning in 6 months for another scan.1,3,37 
This often leads to significant emotional distress on those patients and their families. A 
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retrospective analysis performed in 2011 indicated shockingly low sensitivity of US to 
detect small lesions of HCC, with sensitivity being improved upon the addition of MRI 
and or CT scans.39 The proposed sensitivity levels of US, CT, and MRI were 46%, 65%, 
and 72%,39 which are far below desirable levels for disease detection. 
Needle biopsies for HCC diagnosis are not recommended by the current clinical 
guidelines for the majority of lesions, however they remain common in many medical 
centers.1,3 These are performed by image-guided percutaneous or transjugular access. 
Guidelines do recommend needle biopsies for lesions that are atypical for HCC and are 
classified as probable HCC by contrast imaging.1,3 Characteristics of HCC in contrast 
images include arterial phase hyperenhancement, washout, 50% increase in size within 6 
months, and capsulation of the lesion.1,3,37,38 Illustrations of hyperenhancemant, 
capsulation, and washout by contrast CT imaging are shown in Figure 2. Tumors 
showing all these characteristics can be diagnosed as HCC from the imaging alone.1,38 
Lesions that exhibit only some of those characteristics are those that require biopsy.1,3,38 






Figure 2. Depiction of Contrast CT imaging of an HCC tumor. A. Hyperenhancing tumor 
in the arterial phase. B. Appearance of tumor capsule in the venous phase. C. Washout of 
tumor in the delayed phase. S = Spine, K = Kidney, Sp = Spleen 
 
1.1.4 Biomarkers of HCC 
A prognostic biomarker is a biological molecule that can predict the occurrence of 
a disease state – often before any noticeable lesion or physical abnormality may arise, 
creating significant pressure on biomarkers to indicate what is to come. Thus, the 
commonly-held view of biomarkers as stand-alone clinical tests for early detection may 
be unrealistic. However, combining current clinical modalities with prognostic 
biomarkers could have significant benefit for detection, and a surveillance program study 
found that US screening combined with the glycoprotein biomarker alpha-fetoprotein 
(AFP) significantly increased the sensitivity of US screens from 43.9% to 90.2%.40 The 
combination of US and AFP became one of the most widely-used screening methods for 
HCC, but now clinical guidelines recommend using US with or without AFP.3,39,40 Not 
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all HCC tumors secrete AFP, which limits its sensitivity.7 Basal levels of AFP in healthy 
individuals are generally <10 µg/L, but can climb to 107 µg/L in HCC individuals.7 The 
clinical grey areas with using AFP as a diagnostic arise in the range of 10-500 µg/L AFP, 
which could be associated with HCC or uncomplicated liver disease.7  
Along with prognostic biomarkers for detection, predictive biomarkers for HCC 
are also needed to suggest an individual’s response to treatment. These predictive 
biomarkers could serve to assist clinicians in selecting appropriate candidates for liver 
resection/transplantation as well as predicting disease recurrence.28 Described below are 
two current techniques for identifying biomarkers of HCC: proteomics and glycomics. 
Multiple markers have been observed via each method, yet their clinical impact is little to 
none at present. 
The liver secretes many proteins into the blood, allowing for non-invasive 
collection of proteins for analysis. Various proteomic methodologies have been proposed 
to identify proteins that are altered in the serum of those with HCC, and most have 
involved the comparative analysis of several patient groups: healthy subjects, those 
infected with hepatitis B or C, those with liver cirrhosis, and those with both liver 
cirrhosis and HCC. By utilizing sensitive machines and methods, often some form of 
mass spectrometry or liquid chromatography, low abundance proteins that change with 
cancer development can be found and related to the cancer. Using such methods, proteins 
such as peroxiredoxin 3, osteopontin, and AFP have been identified as potential markers 
of HCC, with upregulation of these proteins observed in HCC patient samples compared 
to healthy individuals or those with liver disease.41–44 As mentioned previously, AFP is 
currently used as a biomarker in the clinic alongside ultrasound, yet it lacks the 
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specificity and sensitivity to stand alone as a powerful biomarker. Another serum protein 
that has shown potential as a biomarker is des-gamma carboxyprothrombin (DCP), and 
studies suggest it to be a more powerful biomarker than AFP for larger tumors as well as 
those arising from viral etiology.45,46 Recent experiments have begun to utilize 
combinations of protein markers to create more sensitive biomarker panels, for example 
combining AFP with another serum protein, fibronectin 1.47 This multi-marker panel 
approach illustrates that detection performance can be improved by integrating 
separately-characterized protein biomarkers.  
Glycomics is the profiling of glycans (sugar structures) attached to larger 
molecules such as proteins. The variety of glycan structures that may be attached to a 
protein creates a post-translational diversity often ignored. There is significant evidence 
illustrating that glycan structures are altered in the presence of cancer,48,49 and thus there 
is great potential for glycomic biomarkers as cancer-specific alterations attached to 
normal serum proteins. In regard to liver cancer, glycomic methodologies have long been 
used to either improve or discover biomarkers of liver cancer. Initial work showed that 
AFP with an attached core fucosylated glycan was a better marker of HCC than AFP 
alone, and it became a USFDA approved biomarker known as AFP-L3.50,51 There is now 
substantial evidence to suggest that increased fucosylation occurs directly in the tumor 
and also that it plays a role in cancer development.52  One major issue with AFP-L3 is the 
protein to which the glycans are attached. That is, total AFP has a sensitivity of ~40-60%, 
a value which is not improved by the examination of the fucosylated glycoform.45 
Glycoforms are just a subset of the total AFP protein level, thus the sensitivity is not 
necessarily improved. However, as the results with AFP-L3 indicate that fucosylation is a 
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highly specific HCC modification, groups have combined this glycomic information with 
proteomics to identify other proteins with glycan changes that could be used as 
biomarkers of liver cancer.53–59  
 In the desperate search for biomarkers of HCC progression, there is also a need 
for new biomarker discovery techniques as well as the development of biomarker 
algorithms. Recent work has highlighted diagnostic algorithms that either utilize AFP 
alone60,61 or AFP along with other novel biomarkers such as fucosylated kininogen59,62 to 
greatly improve detection of early stage HCC. Other attempts to improve on AFP’s 
performance as a biomarker include immunochips as microfluidic63 or Raman 
spectroscopy devices.64 Another biomarker discovery technique, known as liquid 
biopsies, has recently grown in popularity with the isolation of cell-free DNA. A pilot 
study reported using cell-free DNA in urine as a marker for recurrence of HCC, with 
results illustrating the detection of recurrence up to 9 months before detectable by MRI.65 
While this study looked at recurrence, the method may have relevance for initial HCC 
detection as well. Another group studied the size profiles of cell-free DNA in circulation, 
and they observed a difference in the length of DNA molecules from those patients with 
HCC.66 Most recently, a test referred to as CancerSEEK was created using both cell-free 
DNA and proteins as biomarkers to look at various cancers, one of them being liver 
cancer.67 This test shows the benefit of combining various forms of biomarkers; however, 
its design highlights a key issue in HCC biomarker discovery and development: 
biomarkers aren’t needed to differentiate between healthy individuals and those with 
HCC. Instead, biomarkers are needed for screening and surveillance of those patients 
who already have underlying liver disease.  
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Hepatocellular carcinoma is a highly lethal cancer that is difficult to treat. Since 
most cases arise from prior pathologies, biomarker surveillance in high-risk individuals is 
an essential approach for early detection and improved patient outcome. The most 
effective treatment for HCC remains early detection. When the cancer is caught early, 
patients have a significantly increased survival outcome. Therefore, biomarkers for early 
detection of HCC are paramount for the goal of reducing disease mortality. While there 
exist many potential biomarkers for differentiating between HCC and non-cancerous 
patients, few of these markers are currently being used in the clinic for screening and 
detection purposes. Current identified biomarkers include genomic, proteomic, and 
glycomic signatures, however they lack diagnostic power to perform as clinical markers 
due to poor sensitivity and/or specificity. Even the USFDA approved marker AFP-L3 
suffers from low sensitivity. Yet a shift in mentality is needed for researchers and 
clinicians to recognize the place of biomarkers as indicators of future disease 
development. The predictive nature of biomarkers suggests that there is a low probability 
of discovering one catch-all biomarker to detect HCC with extremely high sensitivity and 
specificity. This is also limited by the heterogeneity of tumors and individuals. 
Instead, combining biomarkers with clinical modalities such as ultrasound or 
creating panels of various combined biomarkers appear the most effective routes for 
increased sensitivity and specificity of detection. In order to continue identifying 
biomarkers for HCC to add to these panels, high-throughput methods for analysis of 
human samples such as tissue and serum are needed. Advances in mass spectrometry, 
genomics, and array methodologies are the future for discovering more effective 




1.2 N-linked Glycosylation 
1.2.1 Synthesis of N-glycans 
N-linked glycosylation is one of the most common post-translational 
modifications and consists of the covalent addition of an oligosaccharide (glycan) to an 
asparagine residue on a protein. This process begins in the endoplasmic reticulum (ER) 
and is often referred to as a co-translational modification as it occurs alongside protein 
translation prior to protein folding in vertebrates.68 Unlike translation, glycosylation is 
not template driven, and instead occurs through coordinated enzymatic reactions of 
adding and trimming sugar residues on the glycan structure. Though this process begins 
in the ER, the majority of N-glycan processing steps happen as the glycoprotein traverses 
the Golgi apparatus.68 
There are nine monosaccharides that can be added to vertebrate N-glycans. They 
are isomeric versions of hexose (Hex) and N-acetylhexosamine (HexNAc), deoxyhexose 
(dHex), neuraminic acid (NeuAc and NeuGc), and xylose. Hexose monosaccharides are 
6-carbon sugars galactose, glucose, and mannose, which all have a molecular weight of 
180.0634 Da. N-acetylhexosamine are 6-carbon sugars with the addition of an acetyl 
group and include N-acetylgalactosamine and N-acetylglucosamine, which have a 
molecular weight of 221.0899 Da. Deoxyhexose is a 6-carbon deoxy sugar termed fucose 
with a molecular weight of 164.0685 Da. N-acetylneuraminic acid, also known as sialic 
acid, is a charged monosaccharide with molecular weight 309.1060 Da. Another form of 
sialic acid is non-human and known as N-glycolylneuraminic acid with a molecular 
weight of 325.2693 Da. Other sugars include xylose, which is a five-carbon sugar found 
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only on plants with a molecular weight of 150.0528 Da. These monosaccharides are 
shown in Figure 3 with the colored symbols that are used to represent them. It is 
important to note that glycosidic linkages forming between these sugars results in loss of 
water, which decreases the added mass value of the sugar by 18 Da.  
 
Figure 3. Monosaccharides present on vertebrate N-glycans. 
The synthesis of N-glycans is a sequential and ordered process. The order of this 
sequence is controlled by location – enzymes acting in the first part of the pathway are 
found in the cis and medial Golgi compartments followed by the later enzymes in the 
trans Golgi. Additionally, the appropriate nucleotide sugar donors must be localized to 
the same areas. Glycosidase enzymes remove sugars from the structure and 
glycosyltransferase enzymes add sugars to the structure. The N-glycan product of each 
enzymatic reaction tends to be a substrate or acceptor for the subsequent enzyme. The 
physiological stage of the cell can affect expression of glycosidase and 
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glycosyltransferase enzymes involved in N-glycan synthesis and thus impact the N-
glycan structures produced.68,69  
N-glycan biosynthesis begins with the formation of a 14-sugar oligosaccharide 
(Glc3Man9GlcNAc2) attached to a dolichol phosphate anchored to the cytoplasmic face of 
the ER membrane, Figure 4. This oligosaccharide structure is then covalently transferred 
to an asparagine residue with the sequence motif Asn-X-Ser/Thr (X is any amino acid 
except proline) by the enzyme oligosaccharyltransferase (OST).68 This 14-sugar N-glycan 
structure is trimmed as the glycoprotein undergoes folding quality control checks with the 
ER chaperone proteins calnexin and calreticulin. Calnexin and calreticulin are lectin-like 
chaperones that bind monoglucosylated N-glycans. Continued cycling of the final 
glucose is often performed until protein folding is complete.68,69 This binding retains the 
glycoprotein in the ER until proper folding is complete and the final glucose residue is 
removed from the N-glycan.70 This quality control process serves as the rate-limiting step 
for a glycoprotein’s secretion.70 Before exiting the ER, one mannose residue is trimmed 
from the N-glycan and the glycoprotein then transfers to the Golgi via a coated vesicle. 
 
Figure 4. Initial stages of N-glycan biosynthesis within the ER as protein folding occurs. 
OST = oligosaccharyltransferase, MOGS = a-glucosidase I, GANAB = a-glucosidase II, 




Within the Golgi apparatus, the newly folded glycoprotein is further processed by 
a series of glycosidases and glycosyltransferases, Figure 5. As the remaining mannoses 
are removed, GlcNAc residues are added to create antennae, followed by galactoses. 
Each GlcNAc antenna is referred to as a branch; unless the GlcNAc residue is added to 
the central core mannose that is then referred to as a bisect. Additional residues such as 
fucose and sialic acids can also be added, with generic additions of the sugars from their 
nucleotide donors shown in Figure 5.  Fucose residues have the potential to add to the 
core GlcNAc residue (core fucosylation) or a branched antenna (outer arm fucosylation). 
A more in-depth illustration of potential branching and modifications of complex N-
glycans is shown in Figure 6. While these modifications are shown as discrete pathways 
in this figure, it is important to note that these reactions can occur alongside each other 
within the Golgi and in varied orders. Many enzymes are responsibility for the diversity 
of modifications on N-glycans. Especially relevant to this project are enzymes FUT8, 




Figure 5. N-glycan biosynthesis within the Golgi apparatus. MAN2A1/2 = a-
mannosidase 2, MGAT1 = a-1,3-mannosyl-glycoprotein 2b-N-
acetylglucosaminyltransferase, MGAT2 = a-1,6-mannosyl-glycoprotein 2b-N-
acetylglucosaminyltransferase, UDP = uridine diphosphate, GDP = guanosine 





Figure 6. Modifications of complex N-glycans. FUT = fucosyltransferase, B4GALT = b-
1,4-galactosyltransferase, MGAT3 = b-1,4-mannosyl-glycoprotein 4b-N-
acetylglucosaminyltransferase, MGAT4 = a-1,3-mannosyl-glycoprotein 4b-N-
acetylglucosaminyltransferase, MGAT5 = a-1,6-mannosyl-glycoprotein 6b-N-
acetylglucosaminyltransferase, ST3GAL = b-galactoside a-2,3-sialyltransferase, 
ST6GAL = b-galactoside a-2,6-sialyltransferase, CMP = cytidine monophosphate, GDP 
= guanosine diphosphate, UDP = uridine diphosphate 
 
Peptide sequence and protein conformation have a role in the N-glycosylation of a 
protein. Not all of a protein’s potential glycosylation sites are occupied.69 The amino acid 
X found in the glycosylation sequence can significantly affect glycosylation due to steric 
or chemical interactions. Large hydrophobic amino acids such as tryptophan can hinder 
transfer of the oligosaccharide.69 Negatively charged amino acids such as aspartate and 
glutamate may actually increase the efficiency of oligosaccharide transfer.69 The most 
efficient glycosylation has been observed with amino acids like serine that have a nearby 
hydroxyl group.69 The secondary structure of the protein plays an important role in the 
competing actions of glycosylation and folding, and the majority of potential 
glycosylation sequences are located in the bends of b-sheets.69 The presence of N-glycans 
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can impact the final conformation of a glycoprotein.68,69 In turn, the tertiary structure 
affects the type of N-glycans present due to their accessibility to processing enzymes. 
Highly processed N-glycans such as those containing multiple branches, fucose, and 
sialic acids, are often found on more accessible parts of the protein. However, N-glycan 
structures present on a single glycoprotein can vary widely, indicating that glycosylation 
is affected by more than just a protein’s inherent sequence and conformation.69 
N-glycan biosynthesis and processing is significantly affected by the homeostasis 
of the cell. Nucleotide sugar metabolism, enzyme competition, and speed of the 
glycoprotein passing through the ER and Golgi can all impact the N-glycan structures 
found on a glycoprotein.68 Addition of specific sugars residues is dependent on the 
availability of nucleotide sugar donors UDP, GDP, and CMP. These nucleotide sugars 
are synthesized in the cytoplasm and depend on nucleotide sugar transporters on the 
membranes of the ER and Golgi in order to participate in N-glycan biosynthesis.68 UDP-
GlcNAc is an end product of the hexosamine biosynthetic pathway (HBP). This HBP is a 
nutrient sensing pathway that fluctuates in response to cellular uptake of glucose, 
glutamine, and glucosamine; which make it a key player in the altered metabolism of 
cancer cells.71 As multiple glycoproteins may be simultaneously travelling through the 
Golgi, there is competition for the active sites of processing enzymes. This can result in 
early termination of some N-glycan structures because the product of one enzymatic 
reaction is often required for the subsequent enzyme. 68,69 Transit time through the Golgi 
can also impact the resulting glycoforms on a protein by altering the time for interaction 
between the glycoprotein and glycan processing enzymes.69 A slower transit through the 
Golgi likely leads to higher levels of branches and polylactosamine extensions.69 
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Together, these variables can all impact the diversity of N-glycan structures synthesized 
by a cell. 
1.2.2 Biological Functions of N-glycans 
 N-glycans are involved in a variety of significant biological process. The main 
functions of N-glycans have been categorized as structural and modulatory properties, 
specific recognition/binding, and molecular mimicry.72 The importance of N-glycans is 
evidenced by the complex glycan layer found decorating all cells within multicellular 
organisms to serve as the interface between the cell and extracellular environment. 
Positioning N-glycans at this interface has obvious physical benefits due to the relative 
hydrophilicity and flexibility of these chemical structures, but also allows N-glycans to 
play important functional roles in the cell’s interaction with its environment. This is also 
accomplished through diverse N-glycan structures found on secreted glycoproteins. 
Structurally, N-glycans create a molecular shield on glycoproteins and the surface 
of cells to protect from degradation, antibody binding, and pathogen attachment.68 
Circulating serum glycoproteins are often prevented from uptake and degradation by 
terminal sialic residues on their N-glycans.68 N-glycans also can maintain proteins in 
proper conformation and solubility, especially during the protein folding stages within the 
ER, where they reduce aggregation and provide hydrophilic regions to keep the protein in 
solution.69,73 The structural impact of N-glycans can affect protein binding functions like 
an on/off switch in the case of certain receptor interactions, for example, the ubiquitous 
epidermal growth factor receptor (EGFR) requires N-glycans for proper trafficking to the 
cell surface as well as ligand binding.74 Further tuning of EGFR activity may be 
accomplished by specific N-glycan motifs interacting with carbohydrate-binding proteins 
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such as galectins.74 Core fucosylation of EGFR has been shown to increase EGFR 
signaling.75 Generally, N-glycans act to fine-tune a protein’s function rather than a binary 
on/off.72 Through these modulations, N-glycans increase the diversity of possible 
receptor-ligand interactions.  
As bulky and chemically distinct modifications, N-glycans play an important role 
in specific recognition and binding. Many binding sites recognize a combination of 
protein and N-glycan, requiring certain N-glycan structures to be present for high affinity 
binding.72 N-glycans themselves can also serve as ligands, such as the sialyl Lewis x 
structure recognized by P-selectin for adhesion to vascular endothelium.72 Additionally, 
mannose receptors, found primarily on macrophages, Kupffer cells, liver sinusoidal 
endothelial cells, and dendritic cells, play important roles in innate and adaptive 
immunity by clearing pathogens and regulating glycoprotein levels in the blood through 
endocytosis/phagocytosis of bound proteins.76,77 Circulating glycoprotein levels, as well 
as platelet levels, are also mediated by asialoglycoprotein receptors on hepatocytes, 
which bind to exposed galactose residues on desialylated N-glycans.78 In liver disease 
such as cirrhosis, alterations in asialoglycoprotein receptor distribution have been 
reported on hepatocytes, leading to less of these receptors on the surface of the cells.79 
This dysregulation of the receptors likely contributes to increased concentration of 
glycoproteins in serum, which would heighten the inflammatory state of the liver.79,80   
Though N-glycan structure is partially conserved across species, variation in the 
terminal sugar residues can exist, even among species as similar as humans and mice. 
Pathogen-associated molecular patterns can be made up with non-human N-glycan 
signatures and easily recognized by the host’s immune system for clearance. Pathogens 
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can exploit these species differences to mimic the host N-glycans and avoid detection by 
the immune system.72 This molecular mimicry can occur by lateral gene transfer, uptake 
and incorporation of host glycans, and evolving similar synthesis pathways.72 
1.2.3 N-glycans in Cancer 
 Due to their involvement in many important biological processes, N-glycans can 
promote the progression of many diseases such as cancer. The fundamental hallmarks of 
cancer described by Weinberg and colleagues have all since been linked to various types 
of glycosylation.81,82 These hallmarks include: sustaining proliferative signaling, evading 
growth suppressors, avoiding immune destruction, enabling replicative immortality, 
tumor-promoting inflammation, activating invasion and metastasis, inducing 
angiogenesis, genome instability and mutation, resisting cell death, and deregulating 
cellular energetics.81 Cancer cells up or downregulate the expression of many of the 
enzymes responsible for N-glycan biosynthesis, which leads to changes in the N-glycan 
structures found in this disease. Many of the N-glycan structural changes observed in 
cancer cells follow a pattern: increased sialylation, fucosylation, and branching are 
especially of note. These occur through the upregulation of ST6Gal1, ST3Gal1, Fut1-11, 
and Mgat4/5, respectively. 
 Sustaining proliferative signaling is a characteristic of cancer cells that can be 
affected by N-glycosylation.82 A study on the epidermal growth factor receptor EGFR 
found that removing N-glycosylation resulted in a constitutively active receptor.83 
Increased branching has also been shown to promote proliferative signaling activity of 
growth factor receptors.84  Alterations in branching and core fucosylation caused 
dysfunctional signaling in EGFR, transforming growth factor receptor (TGF-bR), and 
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glucose transporter (GLUT-2).85 Bulky glycoproteins containing branched N-glycans or 
large numbers of N-glycosylation sites have also been shown to increase cell growth by 
integrin dependent growth factor signaling.86 Increased and sustained growth signaling 
can result in the development of tumor masses and invade surrounding tissue. 
 A metabolic shift in cancer cells from oxidative phosphorylation to aerobic 
glycolysis was first observed in the 1920s and has since been accepted as a hallmark of 
cancer.81,82 This shift, termed the Warburg effect, leads to an increased glucose uptake in 
cancer cells, which in turn metabolic processes such as the hexosamine biosynthetic 
pathway. Abnormally high levels of UDP-GlcNAc from the HBP may cause the elevated 
branching often found on tumor glycoproteins. 
  Programmed cell death is one of the body’s primary ways to combat cancer cell 
formation and proliferation. Due to their ability to modulate receptor-ligand interactions, 
N-glycans can impact cell death signaling pathways and allow cancer cells to resist 
programmed cell death.82 For example, sialic acid residues on Fas receptor blocks the 
internalization of and signaling via this extrinsic pathway death receptor.82,87 Sialylation 
also prevents the initiation of apoptosis by macrophage death receptor tumor necrosis 
factor 1 (TNFR1).82,87 In a study using HCC cells, researchers found that elevated Mgat5 
expression, and thus highly branched N-glycans, inhibited apoptosis via activation of 
EGFR and p21-activated kinase 1 (PAK1) inhibition of anoikis.88 
 Invasion and metastasis cause the aggressive and deadly effects of most cancers 
as malignant cells detach from a primary tumor and migrate throughout the body. This 
process depends on cell-cell interactions that regulate attachment, invasion, and 
endothelial extravasation. As all cell surfaces are decorated with N-glycans, these 
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moieties likely play foundational roles in cell-cell interactions that allow cells to lose 
attachment and metastasis to occur. Sialic acids have been observed to affect a cell’s 
ability to move and invade surrounding tissue.89,90 Highly branched N-glycans also have 
been shown to increase metastatic potential, and knockout of Mgat5 in mice has been 
observed to decrease mammary tumor metastasis.82,89,91 Mgat5 expression can also 
contribute to polylactosamine structures forming on the branches, which have also been 
implicated in cancer metastasis.82,89 Core fucose residues can also promote metastasis, as 
studies have observed increased expression of FUT8, the sole enzyme responsible for this 
modification, in melanoma, breast cancer, lung cancer, and hepatocellular 
carcinoma.19,52,92–94 
 Angiogenesis is one of the ways tumors co-opt a normal physiological process to 
allow them to keep up with elevated oxygen demands by recruiting increased blood 
supply. Sialic acids have been implicated in the angiogenic process, and a study showed 
that the function of platelet endothelial cell adhesion molecule (PECAM), a key regulator 
of angiogenesis, was dependent on the presence of sialic acid for downstream signaling.95 
Additionally, sialic acid residues on the vascular endothelial growth factor receptor 
(VEGFR) promote VEGF binding and receptor activation.96,97 These types of N-glycan 
structures can contribute to tumor resistance to anti-VEGF therapy by blocking Galectin-
1 binding.98 
 While immune responses are a way for the body to destroy cancer cells, 
inflammation can also contribute to tumor progression by creating a pseudo state of 
constant wound healing.81 Chronic inflammation can promote some of the other cancer 
hallmark such as genomic instability, angiogenesis, metastasis, proliferation, and 
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avoiding immune destruction.81,82 N-glycosylation is a key mediator of immune 
responses and inflammation.82 The pro-inflammatory glycoprotein cyclooxygenase-2 
(COX-2) contains high mannose N-glycans which appear to moderate its activity by 
regulating its turnover.99 The incorporation of diet-derived non-human NeuGc into 
glycoproteins can cause inflammatory responses known as xenosialitis.100 Inflammation 
can also alter the glycome through the action of cytokines such as IL-6, TNF-a and IL-1b 
that may induce increased expression of glycosyltransferases such as ST3Gal3-4, 
ST6Gal1, and FUT5-7.101 
 As described above, N-glycans have a role in many biological processes that can 
play a significant part in cancer development, progression, and metastasis. They can 
significantly contribute to the various hallmarks of cancer such as cell signaling, 
metabolic shift, avoiding cell death, invasion, angiogenesis, and chronic inflammation. 
When studying proteins in the context of cancer, the diversity of N-glycan structures 
found on them cannot be ignored. 
1.2.3.1 N-glycan Changes in Hepatocellular Carcinoma 
 As a cancer of the liver, there are numerous N-glycan changes on liver-secreted 
serum proteins that have been observed in HCC patients. The long-used biomarker for 
HCC, alpha-fetoprotein (AFP), is a glycoprotein that exhibits increased fucosylation with 
disease progression that is a more effective biomarker than just the protein levels 
alone.51,102 Fucosylation is perhaps one of the most pronounced N-glycan changes that 
has been observed in the serum and on proteins in the presence of HCC. The importance 
of fucosylation in HCC progression has been observed with FUT8, the enzyme 
responsible for catalyzing core fucosylation of N-glycans. Experiments with FUT8 
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knockouts showed significant reduction in growth factor signaling via the epidermal 
growth factor (EGF) and hepatocyte growth factor (HGF) receptors, as well as inhibited 
tumor formation in mice.52 Additionally, a recent genomic analysis of HCC showed 
overexpression of the FUT8 gene, highlighting the likelihood for increased core 
fucosylation to be found on glycoproteins of HCC patients.19  
 Highly branched N-glycans and elevated expression of Mgat5 have been observed 
in HCC patients and cell lines. A study of 99 HCC tissues revealed that 74.7% of patients 
stained positively for Mgat5 compared to surrounding normal tissue.103 Interestingly, the 
elevation of Mgat5 was more prominently observed in early stage differentiated HCC 
samples compared to the later stage de-differentiated tissue.103 However, other studies 
reported higher Mgat5 levels in sera of patients with more progressed and metastatic 
HCC, which they hypothesize to contribute to HCC invasiveness.104 Other glycomic 
tissue studies on tumor microarrays also showed increased branched N-glycans in 
patients with more severe HCC.105 At the transcript level, Mgat5 showed a significant 
fold increase in mice with DEN-induced HCC.106 As discussed above, increased 
branching on N-glycans can also confer HCC cells with resistance to apoptosis through 
PAK1/EGFR signaling.88  
These data suggest that specific glycan alterations are key drivers for HCC 
carcinogenesis, making them important biomarkers as well as potential therapeutic 
targets. There are several key glycan motifs that have been observed to be increased in 
HCC patients. These are listed in Table 1 along with identified proteins that carry these 
alterations. As is typical for many cancers, increased branching, fucosylation, and 
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sialylation have all been detected in HCC serum or tissue. Glycosylation profiles of the 7 




Table 1. Key N-glycosylation motif changes observed in HCC. 
Glycosylation Motif Proteins Involved References 
Branching Mgat5, Alpha-1-antitrypsin 
Haptoglobin, Hemopexin, 
Transferrin, Serum, Tissue 
Ito103 Kizuka107 
Blomme106,108 Liu88 








fetoprotein, Apolipoprotein D, 




Immunoglobulin M, GP73, 
Ceruloplasmin, Kininogen, 
Transferrin, Serum, Tissue 














1.2.4 Glycomics and Analysis of Serum N-glycans 
 Glycomics refers to the comprehensive study of all glycans that are found in a 
cell, biofluid, tissue, or whole organism. The glycome is considered to be more complex 
than either the genome or proteome due to microheterogeneity and dynamic nature of 
glycosylation.68 The dynamic nature of the glycome provides insight into how cells 
quickly respond to stimuli and physiological changes as well as the immense diversity in 
biological responses. Glycomic analyses are often performed of human serum that look at 
all of the glycans found in serum.124 Human serum glycoproteins are produced by the 
liver and B-lymphocytes, which means that altered liver function or immune status are 
likely to be reflected on these glycoproteins. 
These studies are done on glycans released from their protein carriers, which can 
still illustrate a lot about the physiology of that person but do lack functional information 
from the protein carrier. Protein-specific analysis of N-glycans – glycoproteomics – is 
more intensive and often requires the assistance of antibodies or gels to separate out 
glycoproteins from a complex mixture prior to N-glycan analysis.125 Figure 7 shows the 
different levels of glycomic analysis that is performed. The difficulty of analysis 
increases along with the complexity of analysis, with compositional analyses being the 




Figure 7. Different levels of glycomic analysis. This figure was adapted from Ruhaak et 
al.126  
 
1.2.4.1 High Performance Liquid Chromatography 
 High performance liquid chromatography (HPLC) relies on column and solvent 
chemistry to separate molecules based on their molecular properties. The separation is 
accomplished through elution times that are staggered based on the molecules’ retention 
in the column. Columns can be comprised of particles with various chemical properties, 
depending on the properties of the analyte. Reverse phase columns with long carbon 
chains bound to silica (C18 columns) are often used for HPLC analysis of glycans. Due 
to the micro nature of the HPLC columns, glycans must be released from their protein 
carriers prior to analysis, as well as fluorescently labelled. Labels are generally added to 
N-glycans via reductive amination.126,127 HPLC of N-glycans is often performed on 






Lectins are glycan-binding proteins that are present within humans and almost all 
living organisms.68 They bind glycan motifs with some degree of specificity, generally 
recognizing terminal sugar residues.68 In humans, lectins are important for recognition of 
both self and non-self glycoproteins. Lectin binding of glycans mediates protein 
movement and clearance, cell adhesion, and immune responses.68 For example, many 
serum glycoproteins contain terminal sialic acid residues that prevent their recognition by 
the lectin asialoglycoprotein receptor. When that sialic acid is removed, the exposed 
galactose residues are then bound by the lectin and the protein is removed from the 
serum. Many types of lectins exist, binding glycan motifs such as sialic acids, fucoses, 
and branching. Lectins are useful analysis tools because of their ability to bind glycans 
specifically and reversibly. However, their specificity and affinity for their ligands is far 
less than antibodies (Kd = 10-4-10-7 M compared to Kd = 10-8-10-12 M, respectively).129,130 
As analysis tools, lectins can be used to bind glycoproteins or released glycans. 
This is useful for enriching samples by targeting desired N-glycan motifs and retaining 
them out of a complex solution such as serum – often done using affinity 
chromatography.131 Lectins can also be used for detection in assays similar to ELISA, 
where the lectin is fluorescently-tagged and functions as a “secondary” to detect 
glycoproteins with a target motif. This is further discussed in Section 1.2.4.4. In the field 
of glycomics, lectins are often used along with one of the other analysis techniques 





1.2.4.3 Mass Spectrometry 
 Mass spectrometry (MS) is a powerful technique for analyzing glycan species by 
their mass-to-charge ratio, which corresponds to their molecular weight. Only small 
amounts of material are required for MS analysis, as the various platforms have very low 
limits of detection.126 However, the sensitivity of N-glycan detection by MS is decreased 
by the low ionization efficiency of released N-glycans, but can be improved with certain 
chemical derivatization strategies such as permethylation and esterification.126 Glycans 
can be ionized and then separated and detected by a variety of MS platforms such as 
liquid chromatography (LC), electrospray ionization (ESI), and matrix-assisted laser 
desorption/ionization (MALDI). LC methods are often coupled with MS in order to 
separate N-glycan isomers prior to mass detection, but this does decrease the throughput 
of the method.126  
N-glycan ions can be further characterized by tandem MS, which fragments a 
parent ion to better resolve its structural make-up.126 Fragmentation of the parent ion can 
be performed by collision-induced dissociation (CID), ultraviolet photodissociation 
(UVPD), electron dissociation (ExD), or infrared multiphoton dissociation (IRMPD).126 
Glycoproteomic analyses are also done by MS/MS, which can identify the protein carrier 
as well as the specific sites of N-glycosylation. However these approaches remain 
technically difficult and yield extensive data to be parsed through.126,132 The detection 
limit of glycoproteomic experiments is decreased due to the variety of peptides that may 
be present with each glycoforms as well as the diversity of glycoforms occupying each 
site.126 There is a need for a simpler method for protein-specific N-glycan analysis – 
simpler in both sample preparation as well as data analysis. 
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 Enrichment techniques can be used to isolate specific glycoproteins or interest or 
N-glycan motifs of interest prior to MS analysis.131 Lectins, as discussed above, and bind 
N-glycan motifs and pull these structures out of a more complex sample. Antibodies to 
glycoproteins can be used to target the protein carrier for N-glycan analysis. 
1.2.4.3.1 MALDI Mass Spectrometry Imaging 
The technology of matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry (MS) is a widely-used soft ionization method for analysis of biological 
samples.126,133,134 Unique advantages to MALDI MS compared to other types of MS 
include tolerance for contaminants and formation of singly-charged ions.135 Traditionally 
this technique has been performed by mixing complex samples containing the analyte 
with a light-absorbing chemical, the matrix, and spotting the solution to a target plate.136 
Desorption and ionization occur as a laser is fired at the target, transferring energy from 
the matrix to the analyte, ionizing the analyte.136 This indirect method of ionizing the 
analyte is referred to as soft ionization and results in little to no fragmentation as the 
matrix absorbs the majority of the laser’s energy. This is important in N-glycan analysis 
for labile bonds such as sialic acid residues, which are still known to be labile from laser 
desorption and is an unwanted fragmentation mechanism.126 The chemical properties of 
the matrix therefore have significant impact on the energetics of the desorption and 
ionization of the sample. For analysis of glycans, the matrix is generally spiked with an 
alkali metal such as sodium because free or underivatized N-glycans can be ionized by 
forming an adduct with this metal.135 
Following ionization, ions are then guided into the mass spectrometer and 
analyzed by a detector. The detector varies by instrument type but is used to calculate 
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mass to charge ratios (m/z) based on the ions’ flight time or angular frequency. A more 
in-depth discussion of the Fourier Transform Ion Cyclotron Resonance (FT-ICR) detector 
used in this project is discussed below in Section 1.5. These calculations generate a 
spectrum showing the intensity of each m/z value. Since most MALDI ions are singly-
charged, the m/z values generally represent the ion’s mass, M.135 However, M+H isomers 
and metal adduct species (such as M+Na) are also typical. 
1.2.4.3.2 Tissue Imaging and Spatialomics by MALDI MSI 
MALDI mass spectrometry imaging (MSI) has emerged in recent decades to 
become a powerful technique for analyte detection and localization across tissue sections 
with high mass accuracy.134,137–141 Rather than mixing a sample with matrix and spotting 
it to a target, MSI uses samples already attached to a slide and matrix is sprayed 
uniformly across the slide with an automated sprayer. The MALDI laser is stepped across 
the tissue as specific x,y coordinates at a specified raster (spatial resolution) between each 
pixel. Analyte desorption/ionization occurs at each pixel, resulting in an entire mass 
spectrum collected from each individual point. The collected mass spectra are combined 
into an overall mass spectrum that can be visualized as a two-dimensional heat map of an 
analyte’s intensity across a sample.  
MALDI MSI analyses are not confined to analyzing just one analyte, but 
potentially hundreds can be detected in just one imaging run along with localization 
information. MALDI MSI methodology has been applied to many different “omics” 
fields including peptidomics, glycomics, metabolomics, materiomics, and its localization 
information in these applications can be referred to as spatialomics.142 MALDI MSI can 
act as a molecular histology technique to probe many targets across a tissue 
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section.134,143,144 Our lab has previously developed a method for the spatial analysis of N-
glycans across tissue sections145–151 and related workflows have been implemented and 
adapted by multiple labs.152–159 This method allows for N-glycans to be linked to specific 
regions of a tissue, such as fibrotic versus non-fibrotic liver tissue as seen in Figure 8. A 
scan of the tissue after H&E stain is shown in A. N-glycans could be localized to regions 
of fibrosis, B, or surrounding non-fibrotic tissue, C. The ability to correlate N-glycan 
species with tissue regions could have significant clinical impact in the discovery of 
biomarkers or therapeutic targets. Tissue imaging studies have shown N-glycan features 
associated with various diseases, discussed in more detail in Section 1.4. 
 
Figure 8. MALDI MSI of an HCC tissue. A. H&E stain of HCC tissue. B. N-glycan 
FA2G2 localized to the fibrotic region. C. N-glycan M6 localized to the surrounding 
non-fibrotic tissue.  
 
1.2.4.4 Plate-based Arrays 
Plate-based arrays gained popularity with the rise of genomics – DNA 
microarrays became a powerful technique for both sequencing and identifying single 
nucleotide polymorphisms.160 Protein microarrays followed, creating a platform for high-
throughput screens of gene expression as well as receptor-ligand binding.161 This 
technology was first applied to glycans in 2002, with various groups creating arrays for 
answering biological questions.162–164 Plate-based glycan arrays are useful high-
throughput tools for probing glycosylation changes as well as interactions of glycans with 
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their binding partners.125 These arrays allow for simultaneous analysis of various glycans 
and/or glycoproteins with minimal sample preparation. There are now a variety of 
platforms and detection methods for these plate-based arrays, and they are being applied 
to solve biological questions. The information gained from a glycan array is ultimately 
dependent on the detection method used. The key categories of plate-based arrays for 
glycan analysis are lectin arrays, glycan arrays, and antibody arrays. These categories are 
not discrete, in fact many groups have developed methods combining the different 
techniques. Currently lacking is a way to accurately compare data across different array 
platforms, partly due to the variety of detection methods.  
Lectin arrays are common due to lectins’ popularity in glycobiology research. 
Lectins can be immobilized to a well and capture glycoproteins by their glycan motif or 
they can be used as secondary binders to detect which immobilized glycoproteins have a 
certain N-glycan motif.130,165–167 Some key problems with using lectins in these arrays are 
the low affinity of lectins (Kd = 10-4-10-7 M) as well as their variety of isoelectric 
points.130 Since the array format necessitates multiple lectins used simultaneously, the pH 
of the assay is likely to be suboptimal for some of the lectins and thus further reduce 
affinity. Another concern of using multiplexed lectin arrays are the ions necessary for 
lectins to bind their targets efficiently – many lectins require different ions such as Mn2+ 
and Ca2+, which is difficult to match across all the lectins and leads to decreased capture 
of glycoproteins. Additionally, lectins do not provide true compositional information 
about the glycans, but rather identify glycan motifs that are present. 
Glycan microarrays are a method of probing glycan-protein interactions. In these 
arrays, glycans are immobilized to a slide or plate and then glycan binding proteins 
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(GBPs) are added and assessed for binding. These arrays often report data as just a 
positive or negative result, without quantitative information about binding. Glycans are 
more challenging to immobilize onto slides than nucleotides or proteins, so numerous 
methods have been used to derivatize the sugar groups onto glass slides. Many different 
styles of glycan arrays exist, yet cross-platform discrepancies are still a problem, 
particularly for weaker affinity binding partners.168 In 2014, Wang et al. performed a 
cross-platform study using 6 different glycan array platforms in order to compare 
differences in printing procedure, slide chemistry, glycans, and detection procedure.168 
The biggest problem facing this study was choosing a method to compare detected 
signals across all the arrays. Their results confirmed the impact of thresholding on data 
interpretation, as their developed universal threshold method did not detect the moderate 
to weak binding interactions. 
Antibody arrays are tools to look at select glycoproteins rather than the whole 
glycome. These methods capitalize on the specificity of each antibody:antigen binding 
interaction to simultaneously target many proteins in one sample using many antibodies. 
These antibody array platforms can be increasingly miniaturized and multiplexed to 
contain over 18,000 antibodies.169 Key advantages to this technique are specific antigen 
capture, small sample consumption, and a multiplexed format to analyze multiple 
glycoproteins in parallel. However, these platforms are limited by the specificity and 
affinity of each antibody used, requiring validation prior to analysis and ultimately 
limiting the number of binding agents that can actually be used.170,171 One study tested 
the applicability of a 300-antibody microarray for protein biomarker research and found 
that the majority of the array performed with <10% CV, which was then applied to 
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ovarian cancer patient serum.169 An antibody array using lectins as a detection method 
was created by Haab et al. in 2007 and applied to clinical samples for biomarker 
discovery.172–174 Antibody Lectin Sandwich Array was coined by Haab et al. in 2010 and 
this antibody/lectin method was later applied to clinical samples to probe glycosylation of 
proteins captured by the antibodies.172,174 They used exoglycosidases to trim residues off 
the glycans and then were able to detect exposed features with lectins. This sequential 
digestion provided insight into the structure of the glycans, with the ultimate goal of 
understanding more about protein glycosylation. Researchers used chromatography and 
MALDI mass spectrometry to orthogonally confirm the results of the chip and found the 
results to be in agreement for the motif predictions of sialic acid and branching. After 
validating their assay, human plasma samples were applied to the chip to illustrate the 
potential this method has in clinical biomarker discovery.172 Similar work has been done 
by other groups combining antibody arrays and lectins for high-throughput glycoprotein 
biomarker discovery.167 However, these studies remain limited in the amount of 
information they can gather about glycosylation changes on serum proteins.  
 
1.3 Acute Phase Proteins and Immunoglobulin G  
1.3.1. Overview of Acute Phase Proteins 
Acute phase proteins are an important focus for HCC biomarker research as their 
expression and glycosylation has been well-documented to be altered in the presence of 
cancer. Acute phase proteins are secreted by hepatocytes in response to pro-inflammatory 
cytokines such as TNF-a, IL-1b, and IL-6, with IL-6 being the predominant stimulator of 
an acute phase response.175–177 This rapid (within 24-48 hrs) secretion of immune-
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modulating and bactericidal proteins gives the liver an important role in immune 
responses.176–178 Serum levels of acute phase proteins (APPs) can either be decreased or 
increased in an acute phase response, categorizing them as either negative or positive 
APPs respectively.175,177,178 Most APPs change in concentration by at least 25% in an 
acute inflammatory response.177 APPs can also be classified based on their function as 
protease inhibitors, transport proteins, coagulation proteins, and complement proteins. 
Complement proteins, a key cascade of proteins that form a membrane attack complex to 
destroy pathogens, are produced primarily by hepatocytes.176 Along with complement 
proteins, some APPs act as opsonins to mark pathogens for phagocytosis.176 Another way 
that APPs function in immunity is to act as protease inhibitors, inactivating excess 
proteases from lysed cells or pathogens, and in this way modulating the body’s immune 
response.176 
Many APPs have anti-oxidative properties, which is especially relevant in the 
context of cancer development and progression. Iron is the key player in many of these 
oxidative reactions, and therefore multiple APPs are involved with sequestration and 
transport of iron or heme to protect tissues from oxidative damage. Additionally, 
increased levels of free iron can promote bacterial growth within the body, so 
maintaining iron in a bound state prevents its uptake by microorganisms.176,179 Iron 
chaperoning and transport is primarily mediated by transferrin but indirectly by 
hemoglobin-binding glycoprotein haptoglobin and heme-binding glycoprotein 
hemopexin.  
While an essential immune defense, the acute phase response can have negative 
consequences on the body. In general, the response is terminated by negative feedback 
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regulation within 4-7 days if there is no further stimulus.178 Extreme elevations in APPs 
can lead to sepsis and septic shock.177 Chronic elevation of APPs due to diseases such as 
cancer can contribute to metabolic disorders and ultimately wasting of the body.177 The 
functions of these proteins can also contribute to cancer progression through 
angiogenesis, increased cell growth, and metastasis. Many APPs are used diagnostically 
to indicate the presence of various diseases such as rheumatoid arthritis, lupus, 
cardiovascular and viral or bacterial infections.177,178 
 The majority of APP expression is controlled at the transcriptional level.177 Basal 
levels of APPs are regulated by transcription factors such as hepatocyte nuclear factors 
(HNFs) and CCAAT enhancer-binding proteins (C/EBPs), which are upregulated during 
an immune response.176 Most APPs are found to be elevated in patients with chronic liver 
disease such as cirrhosis.176 Another way that APP functions are modulated is through 
glycosylation, as the majority of APPs are glycoproteins, containing a diversity of N-
glycan structures.177 
Glycosylation of acute phase proteins has been widely studied in the context of 
disease as it can modify the proteins’ stability, circulation, immune response, and 
interactions with receptors.180 Many studies have observed disease-related changes in 
APP glycosylation by looking at an individual protein or surveying the entire N-glycome 
of a patient’s plasma or serum. Examples of diseases with notable N-glycan changes on 
APPs include inflammatory diseases such as lupus, colitis, pancreatitis, rheumatoid 
arthritis, and liver cirrhosis.114,181 Age and sex also can affect a protein’s glycosylation, 
with differences such as increased branching in females, increased fucosylation in males 
and decreased galactosylation with age observed.182–185 Most notable of these changes is 
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the agalactosylated form of IgG that is highly correlative of age and being explored as a 
measure of the body’s overall aging. 182–185  
 
 
1.3.2 Alpha-1-acid glycoprotein: Function and N-glycosylation 
 Alpha-1-acid glycoprotein (A1AG or AGP) is a 42kDa positive acute phase 
glycoprotein secreted by hepatocytes.180,186 These protein is found in serum at 0.4-1.5 
mg/mL and has been observed to exist in females at lower concentrations than 
males.180,187 In an acute phase response, AGP acts to downregulate the complement 
system to limit the deposition of complement as well as inhibit neutrophil activity in an 
anti-inflammatory manner.180,188 AGP also has multiple binding sites capable of binding 
to endogenous or exogenous lipophilic compounds and is an important pharmacokinetic 
modulator to consider in the treatment of patients with elevated serum levels of this 
protein.180,188 The expression of this positive APP is increased by inflammatory cytokines 
IL-6, IL-1, IL-8, TNF-a, as well as glucocorticoids.188 
AGP contains 5 N-glycosylation sites at residues 15, 38, 54, 75, and 85, which 
commonly contain bi, tri, or tetra-antennary glycans.188,189 These structures may also be 
sialylated and fucosylated by an alpha-1,3 linkage to form the sialyl Lewis X antigen 
(sLeX).188,189 The glycosylation of AGP has been shown to directly impact its 
immunomodulatory functions, primarily though sialyl Lewis X motifs.180,190,191  It is 
hypothesized that sialyl Lewis X structures on AGP compete with leukocytes for E-
selectin binding, which would inhibit adhesion and extravasion of these immune cells.188 
This likely also contributes to the increased vascular complications found in diabetic 
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patients containing AGP with increased sLeX structures.192 The level of inflammatory 
response also impacts the glycosylation of AGP, with decreased branching seen in acute 
inflammation and increased branching and fucosylation observed in patients with chronic 
inflammation.189 This trend of elevated fucosylation has been seen in patients with liver 
cirrhosis and may even act as a marker for chronic liver inflammation.193,194 In addition to 
disease, age and gender differences in AGP glycosylation have been studied with no 
significant differences related to age, but a lesser degree of branching in females.187 
In the context of cancer, increased branching and fucosylation on AGP has been 
correlated with poorer prognosis across multiple cancer types including hepatocellular 
carcinoma.195–197 In HCC, multiple groups discovered that fucosylation of AGP may 
identify HCC patients compared to cirrhotic and healthy controls.116,198–200 Researchers 
analyzed patient samples with HCC arising from 3 different etiologies (non-alcoholic 
steatohepatitis, alcoholic liver disease, and hepatitis C virus) and found a tri-fucosylated 
N-glycan on HCC to differentiate disease with ROCs ranging from 0.71-0.75.116   
 
1.3.3 Alpha-1-antitrypsin: Function and N-glycosylation 
 Alpha-1-antitrypsin (A1AT) is a 52 kDa anti-protease primarily secreted by 
hepatocytes that is important for protecting tissues from proteolytic degradation, 
particularly in acute inflammatory responses. Its primary target for neutralization is 
elastase secreted by neutrophils.201 Neutrophil elastase is inactivated and taken up by 
A1AT after interacting with a methionine residue inside its reactive center loop that cause 
an irreversible conformational change in A1AT.202 A positive acute phase protein, A1AT 
circulates in serum at concentrations at or above 1 mg/mL and is often elevated 3-4 fold 
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in the presence of inflammation and/or disease.180,201 Its anti-protease function is 
especially important in the connective tissue of the lung, and A1AT deficiency has been 
shown to contribute to numerous lung and liver pathologies.201,203 In particular, 
emphysema, chronic obstructive pulmonary disease, and liver dysfuction are some of the 
most common manifestations of A1AT deficiency.203 A1AT also has a role in 
inflammation, with anti-inflammatory functions against cells of both the innate and 
adaptive immune system.204  
A1AT contains 3 N-glycan sites at residues 70, 107, and 271.201 Its primary 
glycoforms contain bi- and tri-antennary glycans with sialic acid residues, but low levels 
of tetra-antennary glycans and fucosylated glycans do exist.205 The majority of A1AT 
glycan diversity has been reported on residue 107.201 Though glycans are often important 
for protein folding and stability, studies show that deglycosylated A1AT maintains its 
stability and flexibility.206 However, glycosylation of A1AT impacts its anti-
inflammatory function, particularly in its interactions with IL-8.202 While studies have 
shown the importance of glycans on A1AT for its immunomodulatory functions, in turn 
immune cells and inflammatory cytokines can impact the glycosylation of A1AT.207–209 
Immune mediators of A1AT glycosylation include monocyte-secreted IL-1, IL-6, TNF-a, 
TGF-b208 as well as INF-g and leukemia inhibitory factor.207 These findings illustrate 
how A1AT glycosylation participates in inflammation while also being affected by the 
immune-reactive environment, which would also be found with cancer progression. 
Certain glycan changes on A1AT have been observed in HCC, such as increased core 
fucosylation, which was shown to be a more specific marker for this cancer than AFP, 
increased sialylation, and increased branching.114,122 
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1.3.4 Clusterin: Function and N-glycosylation 
 Clusterin, also known as apolipoprotein J, is an 80kDa positive phase 
glycoprotein that can play a key role in carcinogenesis through modulatory functions on 
adhesion, angiogenesis, proliferation, apoptosis, DNA repair, and tissue remodeling.210,211 
This wide array of functions arises from clusterin’s localization both inside and outside of 
the cell.212 Clusterin also serves as an extracellular chaperone binding misfolded proteins, 
forming large complexes that are targeted for receptor-mediated endocytosis.212 This 
important function of clusterin is thought to prevent pathological states of protein 
aggregation such as Alzheimer’s Disease.212 Clusterin has anti-inflammatory properties 
and is often cited as a marker for oxidative stress.211 Overexpression of this protein has 
been reported in multiple cancers including HCC, with the most significant increases 
seen in metastatic HCC.210,213,214 Clusterin exhibits a cytoprotective role to cancer cells, 
conferring resistance to chemotherapy and radiation.211  
 Clusterin contains 6 N-glycosylation sites generally occupied by bi- tri- and tetra-
antennary glycans containing varying amounts of fucose and sialic acids.215 It is a highly 
sialylated glycoprotein, and a decreased sialic acid index value has been proposed as a 
potential biomarker for chronic alcohol consumption.216 The nonglycosylated form of this 
protein can be found in the cell’s nucleus and has proapoptotic functions, yet is unable to 
act as a molecular chaperone.211 In HCC, a decrease in triantennary glycans and 
subsequent increase in biantennary glycans has been observed.217 This alteration in 
clusterin glycosylation distinguished HCC patients from liver disease patients at the same 
level as current biomarker AFP.217 Additionally, increased fucosylation has been reported 
on clusterin in HCC.166 
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1.3.5 Haptoglobin: Function and N-glycosylation 
Haptoglobin is a positive acute phase glycoprotein secreted by hepatocytes as 
well as adipocytes, renal, and lung cells.218 Haptoglobin is a tetramer composed of two 
alpha and two beta chains (ranging from 95-112 kDa in total molecular weight) typically 
found in serum at 1.3 mg/ml.180,219,220 In the blood, it tightly binds to hemoglobin and the 
complex is cleared from the bloodstream by the reticuloendothelial system.178,218 This 
function serves to prevent oxidative stress due to hemoglobin’s ability to generate 
hydroxyl radicals and superoxides.180,218,221 Haptoglobin also serves to protect cells from 
infection218 and inhibits iron uptake by microbes, which has a bacteriostatic effect.178 
Haptoglobin can bind to a variety of immune cells, primarily macrophages and natural 
killer cells.218 It also can inhibit the respiratory burst activity of neutrophils.178 This 
protein also can be found in arterial tissue and plays a role in arterial restructuring and 
angiogenesis.218,222 The expression level of this protein has been reported to decrease in 
viral hepatitis and HCC, which could be due to liver damage decreasing production of 
this APP.178,223 Other studies report the opposite – an increase in haptoglobin serum 
levels and expression in tissue in the presence of HCC.224 Increased levels of haptoglobin 
have been observed in various other cancers such as ovarian and non-small cell lung 
cancer.225,226  
Haptoglobin contains 4 N-glycan sites on its b chains at residues 184, 207, 211, 
and 241.117,219,220 Bi-, tri-, and tetra-antennary N-glycans have all been observed, 
decorated with varying fucose and sialic acid residues.117,219 Increased sialic acid residues 
could extend the serum half-life of haptoglobin by preventing recognition from 
asialoglycoprotein and Kupffer cell receptors.227,228 Increased fucosylation (core and 
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outer arm) is a key N-glycan change on haptoglobin that has been reported in many 
cancers such as liver,117,219,229–232 colon,233 pancreatic,234,235 and prostate.236 An increase 
in branched N-glycans has also been observed in various cancers.237,238 In liver cirrhosis, 
which generally underlies HCC, increased fucosylation as well as sialylation have been 
reported.120,231,239  
A MS-based serum analysis of haptoglobin in HCC, cirrhosis, and healthy 
patients identified singly and doubly fucosylated tetra-antennary N-glycans to be 
significantly increased - or only found - in the serum of HCC patients.117 These results 
matched an earlier serum glycomic study (not protein-specific) that observed an increase 
in a fucosylated triantennary N-glycan in HCC patients compared to cirrhotic and healthy 
subjects.58 A small cohort of cirrhosis and HCC serum samples was used for an isomeric 
analysis of N-glycans on haptoglobin. They observed differences in sialic acid and fucose 
linkages between the two patient groups, but larger patient studies will be required to 
make clinically significant conclusions.240 Fucosylation appears to be the most striking 
N-glycan alteration that is seen on haptoglobin in liver disease and HCC. 
1.3.6 Hemopexin: Function and N-glycosylation 
Hemopexin is a 60 kDa positive acute phase glycoprotein that is responsible for 
binding heme with high affinity (Kd < 1 pM) for safe delivery through the 
bloodstream.176,180,241,242 The hemopexin-heme complex can be internalized by liver 
parenchymal cells for the catabolization of heme.180,241,242 After release of its heme 
binding partner, hemopexin returns back into circulation.242 Sequestration of heme and its 
iron prevents bacterial proliferation and oxidative stress.176,241 Protection from oxidative 
damage is the primary role of hemopexin, as it can also bind nitric oxide and carbon 
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monoxide.241,242 It is secreted by hepatocytes and its concentration in serum ranges from 
0.5-1.5 mg/ml.180,242 It is also expressed in the central and peripheral nervous system as 
well as the retina.241 Some studies have shown coordinating effects between hemopexin 
and haptoglobin in the clearance of hemoglobin and heme from the bloodstream.243,244 
Small amounts of hemopexin are also present in normal urine, about 0.02mg/ml.242 
Hemopexin contains 5 N-glycan sites at residues 64, 187, 240, 246, 453.180 The 
primary glycoforms on hemopexin are nonfucosylated biantennary structures with sialic 
acids, but studies have shown low levels of tri-antennary and fucosylated 
structures.110,119,242,245,246 Fucosylated N-glycans (core and outer arm) on hemopexin have 
been especially noted in patients with liver disease or HCC.110,246 Previous work in our 
lab using lectin analysis found that fucosylated hemopexin could identify HCC with 
extremely high sensitivity and specificity (92% and 92%).166 Another large cohort study 
using lectin reported much lower sensitivity and specificity (71% and 63%) of 
fucosylated hemopexin, but still a significant increase in HCC patients.247 This study 
observed no significant differences in levels of fucosylated hemopexin based on tumor 
stage.247 
1.3.7 Transferrin: Function and N-glycosylation 
Transferrin is a 79 kDa negative acute phase glycoprotein that has a very high 
affinity for iron (1020 M-1).176,179,248,249 The primary iron-transport protein in humans, 
transferrin chelates iron for safe delivery to cells.176,179,180 This places the iron in a redox-
inactive form to prevent oxidative damage to the body.179 Transferrin loaded with iron 
binds transferrin receptors on hepatocytes and rapidly dividing cells.250,251 Once 
internalized within an acidic endosome, the iron is released and the transferrin and 
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receptor complex are returned intact to the surface of the cell.251,252 Iron-free transferrin 
does not remain bound to the receptor, and the glycoprotein then circulates until it again 
contacts free iron.179,252 The endocytic turnover of transferrin is necessary to continue 
functioning as an iron carrier in the body – otherwise massive amounts of transferrin 
synthesis would be required daily to handle iron recycling.251 Under normal physiological 
conditions, circulating transferrin is generally about 30% saturated with iron.179 The 
serum concentration of transferrin ranges from 2-3 mg/ml, but this glycoprotein is also 
found circulating in cerebrospinal fluid.179,180 Transcription of transferrin is regulated by 
the HNF family.176 
Transferrin has been linked to various cell growth and differentiation processes.179 
Independent of its iron-transporting properties, transferrin has been observed to 
contribute to cancerous phenotypes such as increased cell growth,253 angiogenesis,254 
migration,254 and metastasis.255,256 These are generally achieved via paracrine action of 
transferrin to cells with highly expressed transferrin receptors.179 Iron-loaded transferrin 
may also contribute to cancer development – a study of ovarian carcinoma cells showed 
that transferrin blocked apoptosis when bound to iron.257  
Transferrin contains 2 N-glycan sites at residues 413 and 611, with varying 
degrees of branching and sialyation.179,249,258,259 Sialic residues play an important role in 
moderating the iron transport function of transferrin, affecting the binding of transferrin 
to hepatocyte receptors. Rat studies have shown that asialotransferrin (transferrin without 
sialic acid residues) is more rapidly endocytosed by hepatocyte transferrin receptors, 
sometimes leading to excessive iron loading.260,261 For decades the N-glycan content of 
transferrin has been observed to change in the serum of alcoholics – often presenting with 
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sialic acid-deficient glycans.262 This likely plays a role in the development of alcohol-
induced hepatic siderosis, a condition of excess iron in the liver.262 Glycoforms of 
transferrin containing minimal amounts of sialic acid residues (< 2% of the transferrin 
glycoforms found in healthy individuals) are collectively referred to as carbohydrate 
deficient transferrin (CDT) in the clinic.7,263 CDT levels in serum are proportional to 
excess alcohol consumption and this marker is used to test for alcohol misuse in patients 
with liver disease.7,263 In addition, transferrin circulating in cerebrospinal fluid generally 
contains N-glycans without terminal sialic acid residues under normal physiological 
conditions.258,259 
In the context of HCC, a few patient cohort analyses have looked at N-glycan 
changes on transferrin. A small patient cohort analysis observed an increase in core 
fucosylated biantennary N-glycans on transferrin in HCC patients, with one patient also 
having a unique core fucosylated bisecting N-glycan.264 Another study of HCC patients 
also found increased fucosylated as well as branched N-glycans on transferrin.265 In HCC 
cell line HepG2, increased branching was observed on secreted transferrin compared to 
stock human transferrin.111 These results suggest that expected transferrin N-glycan 
alterations in this cohort of HCC patients would likely be increased branching, 
fucosylation, and sialic acid residues. 
1.3.8 Immunoglobulin G: Function and N-glycosylation 
Immunoglobulin G (IgG) is a 150 kDa glycoprotein that consists of two heavy 
chains and two light chains that make up the crystallizable fragment (Fc) and antigen-
binding fragment (Fab).266 It is the primary immunoglobulin circulating in the blood at 
10-15 mg/mL and is able to diffuse into tissue.175,266 This antibody is secreted by B cells 
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in an adaptive immune response and exerts its functions by neutralization, opsonization, 
and complement cascade activation.175 Neutralization of pathogens occurs when IgG 
binding prevents a bacteria or virus from being able to bind to the surface of a cell.175 IgG 
binding can also mark a pathogen for phagocytosis through Fcg receptor recognition on 
macrophages, neutrophils and dendritic cells – a process called opsonization.175 Fcg 
receptors are also found on natural killer cells and IgG can trigger them to exert their 
cytotoxic response.175 IgG can also activate the complement system through the classical 
pathway (C1), mannose-binding lectin pathway, or alternate pathway (C3).175,267,268 
Through these interactions, IgG bound to antigens ultimately results in their destruction 
or elimination.175,267 While IgG is not normally produced in the liver, diseased livers such 
as those with cirrhosis or viral infections often have infiltrating lymphocytes that secrete 
large amounts of IgG from the liver parenchyma.269,270 One study suggested that IgG 
could actually be synthesized by diseased hepatocytes.271 
The N-glycosylation of IgG has been extensively studied in health and disease. 
The majority of IgG N-glycosylation occurs at residue 297 of the Fc regions, but N-
glycosylation has also been observed at a low level in the Fab regions.180,266,272–274 The 
most abundant glycoforms present on human IgG (90%) are core fucosylated biantennary 
N-glycans with varying degrees of galactosylation.266,275–278 Approximately 30% of IgG 
N-glycans are bisected.69,266 Terminal sialic acid residues are less common on this 
glycoprotein due to the protein’s conformation sterically hindering the sialyltransferase, 
but they do exist.266 Sialic acid residues often have an anti-inflammatory effect on IgG 
effector functions.278,279 It is thought that bisected and sialylated N-glycans are more 
commonly found on the Fab region, while the majority of N-glycan structures exist at the 
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Fc region.69 Fc N-glycans are necessary for IgG to efficiently bind both Fcg receptors and 
complement C1 to exert effector functions.249,266,267 N-glycosylation of the Fc region 
maintains IgG heavy chains in the open conformation for high affinity binding.249 
However, the structure of these N-glycans can impact the downstream functions of IgG. 
In particular, core fucosylated N-glycans can inhibit downstream antibody dependent 
cellular cytotoxicity by a 50- to 100-fold decrease on IgG1 binding to Fc receptors on 
natural killer cells and macrophages.280 
In chronic inflammatory diseases such as rheumatoid arthritis, vasculitis, 
inflammatory bowel disease, and hepatitis; IgG N-glycans have been shown to exhibit 
decreased amounts of galactosylation.249,275,278,281–283 This likely extends to inflammatory 
conditions of the liver such as cirrhosis and HCC.278 The different galactosylated versions 
of the biantennary N-glycan are referred to as G2, G1, and G0 for the number of 
galactose residues. Studies suggest that G0 IgG can activate MBL pathway, promote the 
formation of immune complexes, as well as enhance binding to Fcg receptors.249,275,276,278 
The absence of galactosylation on IgG were associated with disease and/or poorer 
prognosis in certain cancer such as colorectal, gastic, ovarian, lung, and liver.284–287 This 
is likely due to the underlying inflammation found in these cancers. Decreased 
galactosylation level of IgG is also associated with aging, which may contribute to an 







1.4 Clinical Mass Spectrometry 
1.4.1 Overview of Clinical MS 
Mass spectrometry can be a powerful addition to clinical workflows in its 
sensitivity, accuracy, and speed of detection, as MS can measure multiple analytes in one 
analysis. Turnaround time is one of the most essential criteria for clinical laboratories.289 
Additionally cost, ease of use, and test error are important considerations for the high 
quality nature of clinical assays.289 User-friendly and  inexpensive MS systems with a small 
footprint such as LC-MS paved the way for MS to enter clinical laboratories.290 Currently, 
clinical MS is used for the analysis of drugs, amino acids, steroids, proteins, as well as 
standardization of clinical assays.291 
Sample preparation steps are required on some level for most all clinical MS 
experiments and can significantly contribute to the hands-on time of the protocol.289 Patient 
samples such as blood, urine, plasma, and saliva generally require clean-up procedures to 
separate out the analytes (often proteins) from the remaining constituents. Proteins are 
often precipitated out of solution through a chemical additive (such as methanol) and can 
then be either removed or retained based on the type of assay. The sample can be further 
separated through solid-phase and/or liquid-liquid extraction.  
Liquid chromatography is a popular separation method coupled to MS analysis 
(LC-MS). This technique prevents interference from contaminant species not removed in 
sample preparation. LC-MS is often applied to the analysis of small molecules and provides 
high sensitivity and accuracy of detection.289 However, its application to larger 
biomolecules remains limited by the analysis time required for sufficient separation of 
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these components by traditional columns.289 Both size exclusion chromatography and 
capillary electrophoresis are common for the analysis of biologics by size or polarity.  
Immunoassays are prevalent in clinical laboratories, with the most common being 
enzyme linked immunosorbent assay (ELISA).289 They rely on colorimetric detection, 
generally via fluorescence of the reporter antibody or the analyte itself. MS as a detection 
method improves the inaccuracies of fluorescence due to interference as well as negates 
the need for chemical modification in order for the analytes to fluoresce. Coupling MS to 
immunoassays is a powerful way to detect analytes with high mass accuracy, sensitivity, 
and to remove the subjectivity of a color change.289 This is further discussed in 1.4.2 as 
well as provides the foundational goal for this work developing a novel translational MS 
method using antibody panels. One example of MS being used preferentially over 
immunoassay in the clinic is in the measurement of thyroglobulin for recurrent thyroid 
cancer. LC-MS based analyses remove the interference of anti-thyroglobulin antibodies 
that present a problem for traditional immunoassays.292 
A rapidly-growing field of clinical MS is point-of-care (POC) testing, which refers 
to devices that can be used directly at the patient bedside or in-office. Such devices/tests 
allow for important clinical decisions to be made quickly by significantly decreasing 
analysis time as well as providing easy-to-interpret results that can be read by 
nonexperts.289,292 In the field of MS this is accomplished through ambient ionization MS – 
meaning that sample analysis does not require a vacuum as do most MS devices. The initial 
two ambient MS techniques were desorption electrospray ionization (DESI) and direct 
analysis in real time (DART), with numerous additional techniques being developed and 
applied in the last 15 years.289 These techniques negate the need for sample preparation and 
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can produce results in under 2 minutes. These turnaround times are especially beneficial in 
critical settings such as surgery and can, for example, provide surgeons with insight into 
the cancer cell margin during removal of a tumor. Recently a surgically-compatible device 
termed the MassSpecPen was created that allows surgeons to do just that using water 
droplets for extraction of molecules from tissue and intraoperative decision making.293 
 
1.4.2 Clinical Applications of MALDI MS 
While not recognized for clinical utility until recent decades, MALDI MS provides 
unique clinical value due to its sensitivity and specificity for detection coupled to 
localization information.294 MALDI MS could be applied to complement histopathology, 
provide early detection of disease, and assess efficacy of therapeutic measures.134 Today 
MALDI MS is commonly used in clinical microbiology for quick identification of bacteria 
and fungi.295–298 This application of MALDI MS is cost effective in the clinic and can 
identify pathogens based on their protein composition.296 Inter-laboratory studies have 
revealed a high level of reproducibility for MALDI MS identification of bacteria.296 The 
acceptance of MALDI MS for microbial analysis highlights that these instruments can be 
successfully used in a clinical setting. 
MALDI MSI can also have significant potential for clinical impact with its 
spatialomic detection of analytes localized to a disease area. In the context of cancer, this 
technique has been used to look at lipid profiles of liver metastases,144 to classify liver 
tumors,105,299,300 brain tumors,301 prostate tumors,302,303 colorectal tumors,146 breast 
tumors,149 and ovarian tumors155,304. Characteristic N-glycans localized to tumor regions 
have also been correlated with survival outcome in cancers such as HCC and breast 
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cancer.105,305 N-glycans associated with necrotic regions of cancer tissue have also been 
reported.306 Identifying N-glycans that are specific to disease could lead to development of 
new biomarkers or act as therapeutic targets. Beyond N-glycans, MALDI MSI has been 
used to examine extracellular matrix changes between progressive changes in normal to 
cancerous tissue.143,307–309 MALDI MSI can also benefit drug development by visualizing 
the distribution of drugs, metabolites, and biomolecules in tissues.310,311  
Another approach to clinical MALDI is analyzing glycans and/or proteins from 
biofluids such as serum, urine, or CSF. This has been done through immunoprecipitation, 
immunocapture, or dried blood spot cards. Immunoprecipitation isolates a specific antigen 
to then be analyzed by MALDI MS. This has been used in the context of detecting diseases 
such as cancer, Alzheimer’s, and renal dysfunction; but these methods have yet to be 
readily adapted by the clinic.289,312–314 Immobilized antibodies have also been used to 
capture proteins out of solution for analysis. This sort of capture has been previously used 
to capture a single target protein for MALDI MS analysis.315,316 Some studies have 
multiplexed these strategies to detect 2 target antigens.317 This work expands this concept 
into multiplexed glycoprotein analysis on 7 proteins simultaneously. Often protein-specific 
analysis is not performed, as discussed in Section 1.2.4, and one group illustrated the high-
throughput potential for N-glycome analysis from blood spots using dried blood spots.318 
They showed successful detection of N-glycans and short term stability of the samples. A 
key limitation to MALDI analysis of biofluids directly is the presence of high salt (such as 
found in urine) and lipids (found in serum/plasma), which generally require some sort of 




1.5 Mass Spectrometer in this Dissertation 
The work done in this dissertation relied on a Bruker SolariX 7 Tesla FT-ICR MS 
equipped with a SmartBeam II ultraviolet laser operating at 2000 Hz with laser spot size 
of 25µm. Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry was 
invented in 1974.319 It is unique in that it uses a magnetic field to trap and detect ions in 
the mass analyzer. Typical to MALDI MS instruments, a laser is used to excite the 
MALDI matrix and transfer charge for analyte ionization.  Following ionization of the 
analyte, ions are guided from the low vacuum environment to the ultra-high vacuum 
analyzer though ion guides.320 A quadrupole ion guide allows only ions within a specified 
m/z range to go through to the hexapole. From there, ions are guided using optics into the 
ion cyclotron resonance (ICR) cell, a mass analyzer under high vacuum. The ICR cell 
consists of conductive walls (plates) that are surrounded by a large magnet that is 
supercooled with liquid helium.320 Magnetic fields are applied to the ICR cell and the 
ions are excited into cyclotron resonance – the strength of the magnet is proportional to 
sensitivity.321 (The cost of the magnet is also proportional to its strength, which limits the 
quality of magnet that can be obtained by various labs.320) The angular frequencies of the 
ions are determined by their m/z and can be detected as a function of time by the 
detection plates. The detected time domain functions are converted by Fourier transform 
to frequency domain functions, which correspond to their m/z ratios.136 A simple 
schematic of the ion path in this instrument along with the ICR cell is shown in Figure 9. 
The usage of ion angular frequency as a detection method gives FT-ICR 
instruments extremely high mass accuracy. This mass accuracy allows for identification 
of N-glycan compositions, which generally differ in size by well over 1 Da.322 It is noted 
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that FT-ICR instruments have a much longer delay between ion formation and detection 
compared to TOF instruments, which can lead to some fragmentation of the ions.320 
However, minimal fragmentation is generally observed of glycans by FT-ICR MS and is 
dependent on the pressure and temperature of the source to limit fragmentation.320  
 
Figure 9. Simplified schematic of the ion path and ICR cell in a FT-ICR MS. A. Ion path 
following ionization and B. ICR cell, this figure was taken from the SolariX User Manual 
(Bruker) rev 3, 2011. 
 
1.6 Broad Overview 
In summary, HCC is a highly lethal cancer that is difficult to treat effectively. 
HCC arises from chronic inflammation of the liver from conditions such as hepatitis B/C, 
fatty liver disease, alcoholic liver disease, and metabolic disorders. These produces a 
patient population who are/should be continually screened for the progression of liver 
disease to malignancy. The best approach for treating HCC is early detection of disease, 
for which current methods are lacking. Imaging by CT, US, or MRI are the current gold 
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standards for detecting HCC, with biopsies required for nodular uncertainty. All of these 
methods are expensive, limited in accessibility, and can cause discomfort to patients. The 
current blood-based biomarker for HCC is a glycoprotein, AFP. The expression of AFP is 
increased in many – but not all – cases of HCC. A change in the fucosylation of AFP 
detectable by lectins is a more sensitive marker for disease. N-linked glycosylation is a 
common modification on serum proteins and can reflect the state of the cell it was 
secreted from, as well as alter the functions of its carrier protein. Therefore, analysis of 
N-glycans on serum proteins could lead to the discovery of new biomarkers for this 
deadly disease.  
There are numerous methods for analysis of N-glycans including 
chromatography, lectins, and mass spectrometry. All of these techniques have been used 
to understand valuable information on the synthesis, structure, and functions of N-
glycans in the human body. Mass spectrometry is unique in its ability to analyze N-
glycans in a multiplexed format with high accuracy, potentially generating high-
throughput data. MALDI MSI is a type of MS that detects the spatial localization of each 
of its measured analytes, creating images that are heat map representations of each 
specific analyte. N-glycans are readily detectable by MALDI MSI on tissue sections, 
from patient serum, and from cells.  
Leveraging that MALDI MSI can be used to detect N-glycans from the solid 
surface of a tissue on a slide, we hypothesized that we could extend beyond traditional 
MS techniques to detect N-glycan profiles from target glycoproteins captured on a slide-
based antibody microarray panel. This would bridge the gap in linking N-glycan 
signatures to their proteins, as the location of the detected N-glycans along the slide array 
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would be linked with each immunocaptured glycoprotein they were released from. This 
method would obtain N-glycan profiles for each glycoprotein, rather than other targeted 
approaches analyzing only certain N-glycan motifs or one protein at a time. 
Acute phase serum proteins were chosen as the glycoprotein targets for this work 
as they are produced by hepatocytes and play significant roles in inflammation and 
disease. The functions of APPs range from anti-oxidative to protection of cells from 
damage by immune-released proteases. Most APPs do interact directly with immune cells 
to modulate the body’s immune response. Since they are secreted primarily from 
hepatocytes, APPs are well known to be altered in the presence of liver disease and/or 
HCC. Their N-glycan profiles also impact their function and thus are important to study 
in the context of liver cancer. Immunoglobulin G was also included as it is one of the 
most ubiquitously studied glycoprotein and provides important insight into the patient’s 
immune function. These proteins all have great potential to act as biomarkers for the 























The vast majority of cancer biomarkers used in the clinic today are glycoproteins, 
meaning that they are post-translationally modified with oligosaccharide structures, most 
commonly O-linked glycans to serine/threonine residues or N-linked glycans to asparagine 
residues.323 N-linked glycans in particular have been well-established as changing with the 
development and progression of many cancers and therefore have great potential as 
markers for disease.48,49,323 The glycoprotein alpha-fetoprotein, currently an FDA approved 
biomarker for hepatocellular carcinoma, illustrates the success of using serum 
glycoproteins as biomarkers, with a specific N-glycan change on this protein increasing its 
power for early cancer detection.27,50,51,324 However, there is both a glaring lack of N-glycan 
information on clinically relevant biomarkers along with a lack of powerful biomarkers for 
accurate detection of most cancers. 
While there are many studies that characterize N-glycan changes with cancer 
progression, most ignore the protein these glycans are linked to, thus remaining a barrier 
for biomarker discovery. The few methods used to analyze N-glycans and their protein 
carriers generally require large amounts of sample preparation and look at only one protein 
at a time. In response to this need for multiplexed biomarker analysis of protein-specific 
N-glycan changes, proposed here is a novel platform for the simultaneous analysis of 
potentially 100s of N-linked glycoproteins from biological fluids with the goal of 
discovering new clinically-relevant cancer biomarkers. Our overarching hypothesis is that 
a multiplex antibody-assisted mass spectrometry imaging platform will allow for the rapid 
detection of protein-specific N-glycan signatures that are associated with the development 
and progression of hepatocellular carcinoma. To address this hypothesis, we will be 
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developing a new platform for multiplexed analysis of N-glycoproteins from serum that 
requires little sample preparation or consumption.  
2.2. Specific Aims 
Specific Aim 1: Development and optimization of a novel method for multiplexed N-
glycoprotein biomarker discovery from human serum. The goal of this aim is to optimize 
a new array platform for analysis of antibody-captured glycoproteins that can be used for 
the discovery of new cancer biomarkers from biological fluids such as serum. We will use 
a novel combination of matrix assisted laser desorption/ionization (MALDI) mass 
spectrometry imaging (MSI) with plate-based antibody capture, like that of an enzyme-
linked immunosorbent assay (ELISA). This will allow for multiplexed analysis of captured 
N-glycoproteins with high mass accuracy. We will create a microscope slide-based array 
of antibodies for 6 glycoproteins. Confirmation of specific and reproducible capture of 
proteins and detectable N-glycan signal will initially be done with standard solutions of 
glycoproteins followed by stock human serum samples. Key milestones of this aim are i) 
N-glycan signal detected from captured glycoproteins at ≥ 10ng, ii) confirmation of 
capture specificity, and iii) orthogonal confirmation of the detected N-glycans. Results 
from this aim will be the successful creation of a new analytical tool for biomarker 
discovery, and preliminary data clearly illustrate that this technique has robust potential for 
N-glycoprotein analysis from biological samples.  
Specific Aim 2: Analysis of patient samples for N-glycoprotein biomarker discovery 
corresponding to hepatocellular carcinoma. The goal of this aim will be to use a MALDI 
MSI antibody platform for N-glycoprotein biomarker discovery from patient samples. 
Serum samples from patients with and without disease are already stored in-house. These 
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samples will be applied to the novel platform described in Aim 1 for N-glycan analysis of 
captured glycoproteins, with N-glycan internal standards spiked in for normalization 
among samples. N-glycan signals will be detected from specifically-captured glycoproteins 
and intensities compared for statistical significance between patient groups. Significant 
correlations between N-glycan structures and disease state will be identified as potential 
disease markers. The cancerous origin of these protein-specific N-glycan changes will then 
be confirmed with traditional MALDI MSI analysis of cancer tissue samples. Findings 
from these studies will result in novel biomarkers associated with HCC. 
Impact: The significance of this research lies in its potential for quick clinical impact to 
improve patient outcomes through the discovery of new and powerful biomarkers for a 
deadly cancer. Additionally, the development of this new method will be a powerful new 
technique for future analyses of various post-translational modifications beyond N-glycans 
from human biological samples. Through this research strategy and mentorship from 
sponsors, the applicant will develop the critical thinking and research skills to progress into 
a successful career of independent translational research. 
2.3 Research Strategy 
2.3.1 Significance 
Early detection of cancer before severe disease progression and/or metastasis is a key 
goal of cancer research. Blood-based biomarker screens, a form of liquid biopsies for early 
cancer detection, are growing in popularity and provide a non-invasive and less expensive 
modality than some imaging techniques.48,67,325 However, the sensitivity and specificity of 
such tests is often lacking, with few cancer blood tests being routinely used in the clinic 
such as prostate specific antigen (PSA) as an indicator for prostate cancer and alpha-
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fetoprotein (AFP) for hepatocellular carcinoma.40,67,303,326 There is therefore a dire need for 
more cancer biomarkers that can be employed for liquid biopsies with sufficient sensitivity 
and specificity for early cancer detection. Most protein biomarkers that have been 
discovered, such as PSA and AFP, are glycoproteins, suggesting that more emphasis needs 
to be placed on the glycosylation state of a protein for cancer-specific alterations that could 
serve as more specific biomarkers than the proteins alone.51,303,323 Glycosylation, the 
covalent addition of oligosaccharides (glycans) to molecules such as proteins, is one of the 
most common post-translational modifications. Glycans that are attached to asparagine 
residues are termed N-glycans and have been well-established to change with the 
progression of cancer, impacting a variety of biological processes such as cell signaling, 
adhesion, and immune evasion.48,49,323,327,328 
At present, most analyses for N-glycan cancer biomarkers are performed using free N-
glycans that were released from their carrier proteins in-solution, losing the functional 
protein information, and those that do retain protein information generally require large 
amounts of sample and/or are performed on one protein at a time.323 Therefore, the present 
proposal is significant because it will be the first to perform multiplexed analysis on N-
glycoproteins captured from patient serum samples using antibody arrays and mass 
spectrometry imaging for the identification of cancer biomarkers. This novel biomarker 
discovery tool will be translationally beneficial for parallel analysis of N-glycosylation 
across multiple proteins from patient samples, with the potential to greatly expand our 
knowledge of N-glycoproteins as disease biomarkers, specifically those for hepatocellular 
carcinoma (HCC). This cancer was chosen as it is difficult to detect at an early stage despite 
being amenable to liquid-based screening and is highly lethal once progressed. The 
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identification of new N-glycoprotein cancer biomarkers also opens the door for 
development of novel therapeutic targets for treatment of disease. 
2.3.2 Approach 
2.3.2.1 Specific Aim 1 
It has been well established that N-glycan structures change with cancer, with 
certain N-glycan signatures such as core fucosylation, branching, and polylactosamine 
extensions being indicated in certain cancers.48,49,148,149,323,328 Because of these observed 
patterns, N-glycan signatures on a glycoprotein can serve as biomarkers for early cancer 
detection. Indeed, the fucosylated form of serum AFP is clinically used as a biomarker for 
hepatocellular carcinoma (HCC).27,51,324 Serum proteins are of interest for biomarker 
discovery as they have potential to be a non-invasive detection assay but also because the 
majority of high abundance serum proteins are glycosylated.48,329 Current methods for 
discovery of N-glycan biomarkers are limiting in speed, sample consumption, and lack of 
carrier protein information.323 Proposed here is a biomarker discovery technique novel in 
its ability for multiplexed analysis of N-glycans in various human biofluids while 
maintaining their carrier protein identity and minimizing sample consumption. This new 
platform relies on a novel combination of immunoassay techniques with matrix assisted 
laser desorption/ionization (MALDI) mass spectrometry imaging (MSI). MALDI MSI 
obtains mass spectra in two dimensions across a microscope slide, allowing for an analyte 
to be localized to a distinct point on the slide, creating a heat map of an analyte’s intensity 
across the entire slide. This technique has traditionally been used for tissue sections, and 
N-glycan analysis workflows for tissue slides has been well-established by the labs of Drs. 
Drake and Mehta, co-sponsors of this project, as well as labs around the world.145–147,152,299 
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Here, MALDI MSI will be used to create a 2D image of N-glycans across an antibody slide 
array rather than a tissue sample, which allows for N-glycan detection localized to a 
captured glycoprotein along an array. Therefore, the objective of this aim is to develop and 
optimize a novel and robust platform for protein-specific N-glycan biomarker discovery 
using MALDI MSI of antibody arrays. The novel technique proposed here allows for 1. 
specific capture of glycoproteins for protein-specific N-glycan analysis 2. highly sensitive 
detection of N-glycan compositions and 3. detection of potentially hundreds of N-glycan 
structures across all the proteins simultaneously.  
2.3.2.2 Specific Aim 2 
Cancer associated changes in N-glycosylation have long been observed.48,49,323,328 
However, the protein carriers of these N-glycan changes remain unknown. Though much 
MSI analysis is performed on human cancer tissues for biomarker 
discovery,48,133,134,141,146,299,303,330,331 this technique is not as feasible for large analyses of 
patient samples. Additionally, it is important to identify biomarkers that can be used in a 
non-invasive clinical setting such as those from biofluids like serum. There is therefore a 
great need for new methods of biomarker discovery of protein-specific N-glycan signatures 
from patient biofluids. Serum is full of glycoproteins and the serum N-glycome is growing 
in popularity as a source of cancer biomarkers, however, most experiments with serum 
require laborious sample preparation to clean up the samples.332,333 Initial experiments done 
in our laboratory illustrate that MALDI MSI can detect a wide array of N-glycans in human 
serum with no additional sample preparation and the N-glycans we have detected show 
impressive concordance with those that have been observed in experiments with more 
laborious sample preparation methods.332,333 These preliminary data suggest that no sample 
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clean-up may be necessary for serum samples used in this assay, which would be a 
significant benefit to the field of human glycomic research and expedite the discovery of 
new cancer biomarkers. The objective of this aim will be to use patient serum samples in a 
pilot study to elucidate new HCC biomarkers, followed by confirmation of tissue origin 



















Array based platforms allow for analysis of many targets simultaneously. 
Glycoproteins are targets of clinical interest as the dynamic nature of glycosylation can 
reflect physiological changes due to disease. The array panel presented here consists of 
immunocaptured glycoproteins and is conceptually similar to an ELISA in its set-up. 
Rather than coating wells, antibodies are spotted to a slide as individual spots in an array 
format and incubated with biofluids such as serum. Common immunoassay procedures are 
performed such as blocking of the antibodies prior to sample addition. Antibodies 
specifically capture glycoproteins out of solution, retaining them to a unique position along 
the array panel. N-glycans are then enzymatically released by PNGase F, and MALDI mass 
spectrometry imaging is used to detect N-glycans localized to their position on the array. 
The data acquired from this technique is a profile of the N-glycans present on each 
glycoprotein target captured by the antibody panel. N-glycans can be easily identified 
based on their theoretical mass value, and quantifications of glycan signal can be 
performed. 
As a novel combination of antibody arrays and MALDI mass spectrometry, this 
method required the development and optimization of many parameters to create a 
successful workflow. The foundation of this work began using common immunoassay 
procedures as well as more recently developed N-glycan imaging workflows. The method 
necessitated slides that were fabricated for optimal protein binding so that antibody spots 
remained in their exact location. In order to allow multiple samples to be added per slide, 
removable well chambers were used. Additionally, mass spectrometry compatibility 
became an issue in choosing antibodies as well as detergents for wash steps. Antibody 
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quality was also paramount for this application and each individual antibody was validated 
using IR-labelled proteins to track specificity of capture. Adaptations to N-glycan MALDI 
MS imaging workflows were also made to optimize the signal of N-glycans released from 
spots rather than tissue. The various experiments discussed in this section led to the 
successful creation of Antibody Panel Based N-glycan imaging, and additional future 
directions are discussed. 
3.2 Slide and Well Set-up 
The slide type used for this method was an important parameter to optimize in order 
to get sufficient antibody retention to the slide. Initial experiments were set up on glass 
microscope slides, which are prevalent and inexpensive. These slides are not rated for 
protein capture and led to problems with spots smearing and proteins not adhering to the 
slides. In order to improve protein attachment, indium tin oxide (ITO), poly-L-lysine, and 
nitrocellulose coated slides were tested with IR-labelled proteins to visualize spot 
smearing. All of these coatings are used in various applications for protein retention to 
slides. The nitrocellulose coated slides rated for protein microarray applications were 
observed to retain protein to the slide significantly better than the other two types. These 
nitrocellulose slides were used for the successful development of this method. Manual 
nitrocellulose coating as well as commercial coating were tested. Both of these coatings 
were successful in adhering antibodies to the slide, but commercial coatings were far more 
uniform, as a nitrocellulose gradient was observed on the manually coated slides. Future 
work could be done using nitrocellulose coating on other slide substrates, such as ITO, to 
be used in instruments requiring conductive slides. 
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 In order to capture proteins by antibodies, some sort of wells were necessary to 
allow for sample incubation on the slide. While whole slides could be incubated in a 
sample, this would be impractical due to the large amount of sample consumption as well 
as limiting each slide to analysis of only one sample. Initial steps to create sample wells 
were attempted with borders drawn by hydrophobic markers - such as those used for 
immunohistochemistry. These boundaries did not remain after significant volumes of 
liquid were added and following repeated wash steps. Next, a wax hydrophobic grid was 
printed to slides by collaborator Dr. Brian Haab (Van Andel Institute), Figure 10A. This 
grid was successful for adding up to 10 µL of liquid to one antibody spot per well. Wash 
steps were performed by submerging the entire slide in blocking or washing solutions, 
which required 15-20 mL of these solutions. Results from this grid set-up allowed for 
preliminary experiments showing capture of proteins to individual antibodies, Figure 10B. 
Figure 10B illustrates N-glycan signal from captured A1AT in the column on the right 
where A1AT was added to its antibody in each well. However, this method was limited to 
one antibody per well, small sample volumes, and excessive consumption of wash 




Figure 10. Capture of alpha-1-antitrypsin to its antibody using well chambers created from 
printed wax grid. A. Nitrocellulose slide with printed wax grid. B. Imaging data from 
1663.7051 Da corresponding to a biantennary N-glycan found on A1AT. 
 
Removable well chambers were then explored to allow for larger sample volumes, 
multiple antibodies, and conserving blocking and wash solutions. Chambers were obtained 
from Grace Biolabs in formats 3x8, 1x8, and 1x4, Figure 11. The well chambers could be 
detached before the PNGase F application step and were reusable. (Chambers were soaked 
in a wash solution containing 0.1% OGS for a minimum of 30 mins after each experiment 
to remove any sample residue.) Slight problems with nitrocellulose peeling were 
occasionally observed after the removal of the chambers, primarily localized to the grid 
where the seal had been located. Care was taken that chambers be removed gently to 
alleviate this problem and prevent peeling from extending into the sample capture area. 
This issue did not ever impact patient data in the panels described in Chapter 5. These well 
chambers were used for the successful development of the antibody panel set-up and are 
shown in Figure 11. All 3 of these chamber sizes were used in this project, but final patient 
samples (Chapter 5) were run using the well modules shown in C. It is noted that the 
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commercial nitrocellulose slides used had a narrow strip to the left of each slide that did 
not contain nitrocellulose – preventing these well chambers from being used in entirety, so 
the leftmost column was not used in experiments and served as a label column for each 
slide. 
 
Figure 11. Detachable well modules used to create well chambers for sample incubation. 
3.3 Antibody Selection and Spotting 
Choice of high quality antibodies for specific protein capture was essential to the 
success of this method. If antibodies did not capture proteins specifically, the detected 
glycans may not actually correspond to the intended target protein. Additionally, the 
antibodies needed to have high enough affinity for their targets to capture enough protein 
for its glycans to be detected. While monoclonal antibodies are generally considered 
optimal, both monoclonal and polyclonal antibodies were found to be suitable for this 
technique. Antibody capture quality was assessed using IR-labelled proteins and an 
Odyssey CLx near-infrared imager (Li-cor Biosciences). Antibodies suitable for this 
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technique would result in one discrete circle of protein signal, as seen in Figure 12A-B. 
Nonspecific binding of the target protein to other antibodies would be visualized by signal 
present on more than one spot, as shown in Figure 12C. This would not only decrease the 
detectable glycan signal for the protein, but also lead to inconclusive results as to which 
protein was being detected at what antibody spot. Another important antibody parameter 
to consider was the individual antibody storage buffers. Antibodies stored in stabilizers 
such as glycerol were extremely slow to dry as a spot and led to spectral interference and 
ion suppression. This prevented these antibodies from being usable for this technique. 
Therefore, it was important to select antibodies that were preserved without stabilizer; 
however, minimal amounts of sodium azide in the buffer did not appear to present a 
problem.  
 
Figure 12. Visualization of IR-labeled proteins captured to antibody spots. A. A single 
antibody was spotted and signal is localized to a circle, indicating capture of IR-labeled 
protein to its antibody spot. B. Two antibodies were spotted side-by side and signal is only 
present in one circle, indicating specific capture of the IR-labeled protein by its antibody. 
C. Two antibodies were spotted side-by-side and protein signal is observed on both spots, 
indicating non-specific capture of IR-labeled protein.  
 
Infrared-labeled protein was used for some stages of the development of this assay. 
This dye conjugated to lysine residues of protein standards or antibodies and could be 
visualized using the near-infrared imager. Dye labeling was used to visualize antibody spot 
78 
 
uniformity, track protein binding, and validate specificity of antibody capture. Validation 
of antibodies and multiplexing this system is further discussed in Chapter 4. Infrared dye 
used was a custom dye derivative from Li-cor Biosciences that was compatible with 
MALDI matrix, however this custom product has since been discontinued. Proteins can 
still be labelled and visualized using their 800CW NHS Ester dye, but any spots containing 
these dye-labelled proteins cannot be prepared for MALDI imaging as the chemical 
properties of the dye prevent the matrix from adhering to those spots. 
Antibody spot size and concentration were optimized to obtain sufficient protein 
capture and N-glycan signal. Allowing the antibodies to adhere to the slide overnight at 
4°C in a humidity chamber was determined to be essential for spot uniformity. Air drying 
or desiccating the antibody spots immediately after spotting led to observation of donut-
like rings of signal, Figure 13A-B. This is illustrated by rings of high signal on the border 
of a spot, seen in both spotted protein standards (A) as well as antibody spots (B). These 
rings would lead to a lack of true signal obtained from each spot as well as decreased 
overall protein binding. The overnight incubation in a humidity chamber alleviated this 
issue. An electronic pipette was also introduced to the workflow to improve spot-to-spot 
uniformity. It was hypothesized that a larger spot size would increase the surface area for 
protein to be bound and imaged, leading to a higher signal. Results showed much higher 
N-glycan signal as well as a more linear capture concentration gradient from 3.0 µL 
antibody spots compared to the 0.5 µL spots, which had been used in initial experiments, 
Figure 13C-D. Data shown is from a glycan m/z 1485.5475 present on the captured IgG. 
This spot size (3.0 µL) was used until the system was multiplexed to contain multiple spots 
per well. The spot sizes were then decreased to 1.5 µL so that 2 spots could be fit side-by-
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side in the 3x8-size well module as shown in Figure 13E. An antibody concentration of 
200 ng per spot was chosen, resulting in antibody solutions of 133.3 ng/µL to be spotted. 
This concentration was chosen as higher concentrations of antibodies did not appear to 
adhere completely to the slide and would wash off or smear.  
Figure 13. Spotting issues and comparison of different antibody volumes for capture of 
IgG. A. Spotted IR-labelled IgG was immediately dried without adhering overnight, 
producing a donut-shaped ring of signal. Imaging data from the Odyssey CLx is shown on 
the top and MALDI MS image on the bottom, 1485.4876 Da. B. Anti-A1AT spotted in 
triplicate and dried immediately, which produced rings of signal. Data shown is from 
1663.6104 Da. C-D. Data shown is from m/z 1485.5475 Da, corresponding to a fucosylated 
biantennary glycan Peak intensity is represented by color (C) and quantifications 
performed by MATLAB (D). IgG capture bars represent triplicate samples and the 
antibody only bars are from single spots. Increased signal was observed from the 3.0µL 
antibody spots compared to 0.5µL, as well as a concentration-dependent trend of capture, 
with capture R2 values indicated on graphs. The ability to place two antibody spots side-
by-side with 1.5 µL spot volumes is illustrated in E. 
 
3.4 Immunocapture 
Blocking and wash steps were another parameter optimized for this novel 
combination of antibody arrays and mass spectrometry imaging. The blocking agent used 
was 1% bovine serum albumin, and it was effective in preventing non-specific binding to 
the slide, Figure 14. Mass spectrometry imaging data is shown in A, with a strong N-glycan 
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signal m/z 2289.7459 observed from A1AT in the non-blocked well, but little to no signal 
seen in the blocked well. Orthogonal confirmation of this experiment was done using IR-
labelled A1AT and scanned on the Odyssey CLx, B. Strong binding of A1AT was observed 
in the non-blocked well with minimal binding of A1AT observed in the blocked wells. 
Sufficient blocking was necessary to be sure that detected glycan signal was only obtained 
from specifically captured proteins rather than nonspecific binding. Additionally, 
insufficient blocking could lead to serum residue around the well as proteins stuck to the 
slide itself. 
 
Figure 14. Successful blocking of slide by bovine serum albumin. Wells were blocked with 
1% BSA for 1 hour. A1AT was added to wells with or without blocking, let adhere, and 
then nonbound protein was washed away. A. Mass spectrometry imaging data shown is 
from 2289.7459 Da, corresponding to a disialylated biantennary N-glycan found on A1AT. 
B. On a subsequent slide, IR-labelled A1AT was used for imaging by the Odyssey CLx. 
 
Drawing from standard immunoassay procedures, detergent washes and PBS were 
used after sample capture to remove any nonspecific binding to antibodies or the slide 
itself.173,334,335 An initial detergent wash of the spotted antibodies once they were dried was 
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found to be necessary to prevent spot bleeding during blocking and later washes. This was 
likely because an antibody spot is not a perfect monolayer, resulting in some antibody 
molecules not able to adhere to the slide and thus important to remove prior to sample 
addition. Detergent washes were also necessary following sample capture to remove any 
uncaptured or nonspecifically bound proteins from the wells. Preliminary experiments 
were done using the ubiquitous biological detergent Tween-20, however this created 
significant problems with ion suppression and spectral contamination in the MS analysis. 
The detergent octyl-β-D-glucopyranoside (OGS) was found to give significantly better 
results with a cleaner spectrum and more intense glycan signal, Figure 15. The data shown 
was from the same imaging run, so differences in signal correspond to the two detergent 
treatments as opposed to any variation in imaging runs. The superior detergent OGS was 
then also used to dissolve the blocking agent bovine serum albumin. The number of washes 
used was based on Dr. Haab’s work with lectin arrays and fine-tuned for this method.173 
Water washes were added to each step, along with a final water submersion. These washes 
were essential to remove any residual salt from the slide, as the PBS salts used throughout 
immunoassay would prevent reproducible matrix coating and lead to ion suppression. 





Figure 15. Selection of MALDI-compatible detergent. Detergents Tween 20 and octyl-beta-
D-glucopyranoside (OGS) were compared in the capture of IgG by its antibody as well as 
anti-A1AT as a non-specific capture control. Data shown is from 1809.6600 Da, 
corresponding to a core-fucosylated biantennary glycan FA2G2. Peak intensity is 
represented by color (A-B) and quantifications performed by MATLAB (C). IgG capture 
bars represent the average of 2 spots and anti-IgG and nonspecific capture bars are from 
one spot each. Increased signal was observed with the use of OGS instead of Tween 20, 
and A-B also illustrate a cleaner spectrum obtained with OGS. 
 
Sialylated glycans often present a problem in glycomic analyses due to the lability 
of the sialic acid bond. Terminal sialic acid residues are often lost under acidic or high 
temperature conditions, such as reductive amination used for some HPLC sample 
preparations or the high temperature of MALDI MS.336 Although they can still be detected 
on an FT-ICR MS, we elected to remove them to prevent reproducibility issues from 
inconsistent loss of this sugar residue.337–339 Serum samples were incubated with sialidase 
A, an exoglycosidase that cleaves sialic acids attached to the glycan via an alpha 2-3,6,8,9 
linkage. This recombinant enzyme was produced in-house. This incubation was performed 
prior to sample addition to the antibody panel and consisted of mixing patient serum with 
sialidase A for 2 hours at 37°C. Samples were then added to prepared antibody panels 
without any further sample clean-up. Figure 16 illustrates the complete removal of sialic 
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acids from these glycans as well as a corresponding increase in non-sialylated bi, tri, and 
tetra-antennary glycans. Therefore, this step not only removed reproducibility issues from 
sialic acid instability, A, but also increased the signal detected on other glycans, B. It is 
worth noting that this step could be performed with sialidase A conjugated to nickel beads 
for magnetic removal and reuse, but this was not done in these experiments to avoid sample 
loss and any potential contamination of samples. Sialidase A could also be mixed with 
PNGaseF and sprayed together at the N-glycan release step. This was tested once and 
appeared to successfully remove sialic acids from released glycans. 
Figure 16. Removal of sialylated glycans by pre-treatment of protein standard and serum 
with sialidase A. Samples were treated with 1.4 µg of sialidase A for 2hrs prior to addition 
to antibody panel containing anti-A1AT, anti-haptoglobin, anti-hemoglobin, and anti-
transferrin. A. Complete loss of sialylated glycans was observed from both haptoglobin 
and human serum. B. Significant increase in non-sialylated bi, tri, and tetra-antennary 







3.5 N-glycan Release and Matrix Application 
Following antibody panel creation and sample capture, N-glycan imaging was 
performed using previous work in the Drake, Mehta, and Angel laboratories as a 
foundation.145,147,150,299 A key difference in this platform was lower glycan signal, likely 
due to proteins being in their native state as opposed to the denaturing done on tissue 
samples. Therefore some of the MALDI sample preparation steps were altered to try to 
increase overall signal of detection. PNGase F application was performed as on tissue 
slides, but the incubation time was extended from 2 hours to overnight to increase N-glycan 
signal, Figure 17. This condition was tested early in the creation of this method and was 
only tested once. Future work could further explore this condition to find the most optimal 
incubation time, which may be less than overnight. Some labs implement microwave 
reactors to speed up this reaction.322 It is noted that the overnight incubation of PNGase F 
enzyme takes place in a heated humidity chamber. Therefore, the addition of too much 
water into the humidity chamber could lead to excessive condensation during the extended 
enzyme incubation. Large droplets may form on the top of the slide, which would 
delocalize released N-glycans from their captured protein. This was more likely to be a 
problem with the overnight incubation compared to the traditional 2 hours and was avoided 
by adding 3 mL or less of water to the chamber.  
85 
 
        
Figure 17. Comparison of PNGase F incubation times. Slides were spotted with anti-A1AT 
and anti-Fetuin A and then standard solutions of Fetuin A were added. PNGase F was 
sprayed on both slides and incubated in humidity chamber for either 2 hrs or overnight. 
Increased signal was observed from the overnight incubation on both antibody glycans as 
well as immunocaptured protein glycans. 
 
It is noted that lyophilized PNGase F was tested and occasionally used for these 
experiments. This form of PNGase F could be beneficial for the easy shipping and storage 
of this enzyme, and it was hypothesized that this form could even increase signal of 
detected glycans. The lyophilized form of PNGase F performed comparably to the frozen 
PNGase F generally used in this workflow, Figure 18. When lyophilized, 50 µg of the 
enzyme was added to a screw cap vial and placed on lyophilizer for a minimum of 3 hrs 
until the vial contained only loose powder. The vial was then stored at room temperature 
in a desiccator until reconstitution with 500 µL water. In further experiments, lyophilized 
PNGase F was tested up to 3 months following its lyophilization and still performed 
comparable to frozen enzyme. A longer storage time would require additional confirmation 




Figure 18. Comparison of frozen vs. lyophilized PNGase F. PNGase F used in this 
experiment was from the same lot at concentration 2.7 mg/mL. A1AT and IgG were spotted 
in triplicate at 500ng and sprayed with either frozen (F) or lyophilized (L) PNGase F. 
 
MALDI matrix application consisted of the same α-cyano-4-hydroxycinnamic acid 
matrix as used for tissue imaging, but with a decreased amount applied to prevent signal 
being drowned out by matrix peaks, Figure 19. Two passes of matrix were chosen for 
optimal balance of signal intensity while preserving spot clarity. This condition was also 
tested in the early stages of this project and could potentially be optimized in further work. 
The TM Sprayer (HTX Technologies) was essential for reproducible application of enzyme 
and matrix across slides. Uneven matrix coating or large matrix crystals would lead to 
variation in signal for the imaging results. Both the M3 and M5 TM Sprayers were used 
throughout this project and found to perform comparably. In final patient experiments, an 
internal standard of Glu-1-Fibrinopeptide B (Glu-Fib), a commonly used MS standard, was 
spiked into the matrix solution to use for quality control. Future experiments may benefit 
from also including a glycan standard, as Glu-Fib does not have the same ionization 




Figure 19. Comparison of number of matrix passes on spot clarity and signal. Spots of 
A1AT were spotted in triplicate at 1 µL volumes and coated with either 1, 2, or 3 passes of 
CHCA matrix. Imaging data is shown from 1809.6390 Da. 
 
3.6 Data Analysis 
 Initial stages of this project used a custom script written in MATLAB for 
quantification of N-glycan signal from each antibody spot with spot areas designated from 
the FlexImaging file. As the project progressed, all quantitation was then performed in 
SCiLS Lab using the area under peak function exported from each individual spot. This 
required drawing “New polygonal regions” around each spot in the software following 
analysis, Figure 20. Peak lists were generated for all N-glycan m/z values of interest with 
large enough filter windows to encompass any slight mass defects across slides. Area under 
the monoisotopic peak was then exported for each m/z on this list, from each created spot 




Figure 20. Designation of individual spot regions in SCiLS. Spot regions are manually 
drawn using the “Create new polygonal region” tool, highlighted with the red box. The 
yellow circles represent each individual spot region, drawn while looking at various mass 
values in order to see each spot. Data shown is from 2012.7395 Da, left, and 1866.6758 
Da, right. 
 
3.7 Future Considerations 
As mentioned above, nitrocellulose-coated slides were paramount to the success of 
this method. Future studies could be performed using conductive ITO slides that are coated 
with nitrocellulose for use on instruments requiring conductivity. These slides could be 
created in-house or available commercially. Initial experiments were performed using 
nitrocellulose-coated ITO slides made in-house, and successful capture and detection of 
IgG was observed using a MALDI-TOF system, Figure 21A. The glycan shown with m/z 
1485.3970 is also present on the capture antibody itself, however the decreased sensitivity 
of this TOF system did not detect these glycans – suggesting that this platform could 
actually help minimize background antibody signals without the need for pre-treatment of 
antibodies. Figure 21B illustrates the need for nitrocellulose coating, as ITO slides with no 
coating did not retain sufficient protein following wash steps. Additionally, poly-L-lysine 
coating could be optimized as a cheaper alternative to nitrocellulose, while still having 




Figure 21. Nitrocellulose-coated ITO slides for protein spotting and capture. A. IgG was 
added in triplicate to its antibody at concentrations listed above and imaged on the RapifleX 
MALDI-TOF MS. A capture concentration gradient was observed. B. IR-labelled A1AT 
and IgG were spotted in duplicate at 500ng on an ITO slide (I) and nitrocellulose coated 
ITO slide (N). Circles were drawn around each spot with permanent marker. Slides were 
imaged and then washed with PBS-OGS and water. Final imaging run indicated almost all 
protein was lost from the ITO slide with no nitrocellulose coating. Some signal smearing 
was still seen on slide N. The blue marks represent areas of max signal intensity for the 
imaging system. 
 
Deglycosylation of antibodies was a goal for the workflow in order to decrease the 
background signal of N-glycans present on the antibodies themselves. This would be 
especially helpful when analyzing IgG capture, as it contains many of the same N-glycan 
structures as its capture antibody. Removal of antibody glycans would also create clearer 
images, with spots corresponding just to the captured proteins. Initial attempts at antibody 
deglycosylation were performed by spotting PNGase F on top of antibody spots and 
incubating the slides at 37°C. Successful deglycosylation of antibodies and protein capture 
was observed, Figure 22A. While this procedure did remove glycans within the spot, it was 
extremely difficult to reproduce precise spotting location to be sure that the PNGase F spot 
completely covered each antibody spot. Instead, areas of glycan signal were often still 
observed in a crescent shape, Figure 22B, showing where the antibody spot and PNGase F 
spot did not align. Creation of a spotting template to pipette through was attempted but not 
successful. It is likely that this spotted PNGase F technique could be done successfully by 
a robotic printer that would ensure antibody spots and PNGase F spots were placed at the 
90 
 
identical location. Deglycosylation of antibodies was then attempted via in-solution 
treatment of antibodies with either PNGase F or Endoglycosidase S conjugated to nickel 
beads, which could be removed with a magnet following treatment. Endoglycosidase S 
(EndoS) is an endoglycosidase produced in-house that cleaves above the GlcNAc with core 
fucose on IgG molecules.340 Incubation with EndoS beads did remove antibody glycans, 
but also negatively impacted capture of proteins Figure 22C. This may have been to 
residual Endo S cleaving IgG glycans during sample capture or a decrease in antibody 
affinity. More promising results were seen with PNGase F beads added to antibody 
solutions prior to spotting or PNGase F incubated in the wells after antibodies were spotted 
to the slide Figure 22D. While PNGase F bead treatment did remove glycans, this treatment 
appeared to leave a smeared residue in the well. The wells incubated with PNGase F after 
antibodies were spotted to the slide produced much cleaner images. Slides were blocked to 
prevent PNGase F from adhering to the slide, and then PNGaseF (5 µg) was added to each 
well for 1 hr at 37°C. Results from this treatment illustrated deglycosylation of antibodies 
while preserving specific capture of proteins at their antibody spots, Figure 22D. It is 
hypothesized that trace amounts of PNGase F were still present across the well and may 
contribute to decreasing signal from nonspecific binding. Due to these complications, this 
antibody deglycosylation step was not added to the overall protocol. However, these initial 





Figure 22. Deglycosylation of antibodies prior to sample capture. A. Anti-hemopexin, anti-
haptoglobin, and anti-IgG were all spotted and either treated (T) with PNGase F at 25ng/µL 
in a 2 µL spot on top of spotted antibody or left untreated (UT). Following spotting with 
PNGase F, slides were incubated at 37°C for 2 hrs, PNGase F was pipetted off, and then 
wells were rinsed with OGS 0.2% and water to remove residual enzyme and released 
glycans. Successful deglycosylation of antibodies was observed while retaining protein 
capture. Imaging data shown is from m/z 1663.6119. B. Antibody spots were treated in the 
same manner as in A, however residual antibody glycans were observed in a crescent shape 
(white arrows) due to misalignment of PNGase F spots. Imaging data shown is from m/z 
1485.5495. C. Endo S beads were incubated with anti-A1AT and anti-IgG (right, red circle) 
prior to spotting. Mixtures of A1AT and IgG standards were then added to the antibody 
spots. Deglycosylation of antibodies was observed after Endo S treatment, but decreased 
capture signal from IgG. Imaging data shown is from m/z 1809.6226. D. Antibodies were 
treated with PNGase F either conjugated to beads prior to antibody spotting or added in-
solution to wells after antibodies were spotted. Both methods efficiently deglycosylated 
the antibodies (top). Serum was then added to wells and specific and clean capture was 
observed from the antibody panel that was treated with PNGase F within the well. Imaging 
data shown is from m/z 1850.6860 and 1976.6620.  
 
An internal standard could be added to each sample to allow for normalization 
across samples and slides. While not often seen, some evidence of signal fading was 
observed to occur even across one slide. Figure 23 shows the signal of an antibody glycan, 
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1850.6771 Da, that should remain constant across each well as the same amount of 
antibody was spotted to each well. However, this signal fading was not observed on every 
slide run, so it was apparent that standardization will be important with each sample run. 
A nonhuman glycoprotein, invertase from Saccharomyces cerevisiae, was spiked into 
serum samples and its antibody added to the panel. While this showed initial promise, 
reproducible capture of this glycoprotein was not achieved. However, future studies with 
this high mannose containing glycoprotein could be used as a numerical value for 
normalization of each sample. An additional normalization component could come from 
Glu-Fib spiked into the matrix, however in this work this was just used as a visual quality 








Figure 23. Signal fading observed across slide on FT-ICR MS run. Data shown is from a 
bisected glycan present on the antibodies only. The same panel of 7 antibodies (only 4 of 
which had this glycan) was spotted in each region, R1-5. A. Imaging data illustrates a 
decrease in signal with each subsequent region run. B. A decrease in peak intensity as well 
as an upward mass shift is seen with each region, which are shown in red, orange, yellow, 
green, blue, respectively. C. Quantitation of area under the peak also highlights the 
decrease in signal with each subsequent region. Internal spiked standard of Glu-Fib was 
not used in these experiments. 
 
 While sialic acids were removed for the final patient analysis (Chapter 5), future 
efforts could be done to stabilize these linkages so that they could be included in the 
analysis. Laboratories have developed derivatization methods of amidation-amidation, 
methylation, and ethyl esterification to stabilize these labile bonds and/or provide 
stereochemical information on the type of linkage using MALDI MS.154,341,342 A click-
chemistry based approach is currently being optimized in our laboratory for sialic acid 
stabilization and linkage information that could in the future be applied to this APB 
platform. However, the majority of these methods use harsh solvents that would denature 
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the antibody:protein complex, thus losing the glycoprotein capture capabilities of this 
assay. Future adaptations of these methods could be performed to stabilize these linkages 
under non-denaturing conditions. 
 Differentiation of isomers is a known limitation to current methods of N-glycan 
imaging by MALDI MS. While the high mass accuracy provides compositional 
information of what glycan residues are present, the types of linkage between the glycans 
is not known. However, the biology of N-glycan biosynthesis can be used to predict the 
majority of the glycan structures, leaving linkage of motifs such as fucosylation and 
sialylation still unknown. MS technology such as ion mobility could be used to separate 
isomers, but chemical and/or enzymatic methods can also be used to provide linkage 
information without increasing the difficulty of data analysis. Some of the sialic acid 
stabilization methods above can be used to detect different linkages of sialic acid residues. 
Core versus outer arm fucosylation can be elucidated through the use of endoglycosidase 
F3 (Endo F3), which cleaves only core fucosylated N-glycans and has been successfully 
used in the MALDI MS imaging of tissue sections.343 This enzyme was tested on the APB 
N-glycan imaging platform on a panel of A1AT and IgG capture from standard solutions 
and human serum, Figure 24. Successful detection of core fucosylated N-glycans was seen 
on IgG capture spots from both standards and serum in a dose-dependent manner. Imaging 
data shown is from m/z 1460.5847, which corresponds to the core fucosylation biantennary 
N-glycan with m/z 1809.64. As Endo F3 cleaves above the core GlcNAc that is core 
fucosylated, this produces a different m/z value from an outer arm fucosylated glycan of 
the same mass, which would still show up at m/z 1809.64. In this experiment, no glycan 
peak was observed at 1809.64, which indicates that all fucosylated biantennary structures 
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on IgG are core fucosylated. This is supported by a wealth of literature that shows core 
fucosylated N-glycans on IgG. 
 
Figure 24. EndoF3 cleavage of N-glycans on captured IgG. Endo F3 was sprayed on slide 
and incubated overnight at 37°C. Imaging data shown is from m/z 1460.5847, 
corresponding to a biantennary core fucosylated glycan as shown above. This glycan is 
observed localized only to IgG capture spots from mixtures of A1AT and IgG standards as 




The experiments described in this chapter illustrate the creation of a novel mass 
spectrometry-based immunoassay method for glycoprotein analysis. The completed 
workflow used for final patient analyses is shown in Figure 25. Antibodies were spotted to 
nitrocellulose coated slides containing removable well chambers. Within each well, 7 
antibodies were spotted, and the entire slide was blocked. Serum samples were treated with 
sialidase A and then added to the wells for 2 hours for sample capture. Wells were then 
thoroughly washed and well chambers were removed. Slides were sprayed with PNGase F 
for localized N-glycan release and then incubated overnight. MALDI matrix was sprayed 
across the slide containing a spiked Glu-Fib standard and then slides were imaged on a 
MALDI FT-ICR MS. Data were visualized using FlexImaging or SCiLS Lab (Bruker) and 
area under peak values for each individual spot were exported from SCiLS Lab for 
quantitative comparison.  
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The creation of this workflow is significant in its ability for multiplexed analysis of 
serum glycoproteins with minimal sample preparation. While most current methods 
analyze only one glycoprotein at a time, this platform allows for simultaneous analysis of 
a panel of glycoprotein targets. This has great value as both a research tool as well as 
potential translation to clinical laboratories as a screening method for early detection of 
diseases such as cancer.  
 
 

























Chapter 4: Multiplexing Antibody Panel Based N-glycan Imaging 
for Analysis of Serum Glycoproteins 
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A new platform for N-glycoprotein analysis from serum that combines matrix-assisted 
laser desorption/ionization mass spectrometry imaging (MALDI MSI) workflows with 
antibody slide arrays is described. Antibody Panel Based (APB) N-glycan imaging allows 
for the specific capture of N-glycoproteins by antibodies on glass slides and N-glycan 
analysis in a protein-specific and multiplexed manner. Development of this technique has 
focused on characterizing two abundant and well-studied human serum glycoproteins, 
alpha-1-antitrypsin and immunoglobulin G. Using purified standard solutions and one 
microliter samples of human serum, both glycoproteins can be immunocaptured and 
followed by enzymatic release of N-glycans. N-glycans are detected with a MALDI FT-
ICR mass spectrometer in a concentration-dependent manner while maintaining 
specificity of capture. Importantly, the N-glycans detected via slide-based antibody 
capture were identical to that of direct analysis of the spotted standards. As a proof of 
concept, this workflow was applied to patient serum samples from individuals with liver 
cirrhosis to accurately detect a characteristic increase in an IgG N-glycan. Successful 
capture of hemopexin from human serum and standard solutions was also shown across a 
6-antibody panel. This novel approach to protein-specific N-glycan analysis from an 
antibody panel can be further expanded to include any glycoprotein for which a validated 
antibody exists. Additionally, this platform can be adapted for analysis of any biofluid or 







            Glycosylation is one of the most common post-translational modifications and 
often consists of the covalent addition of an oligosaccharide (glycan) to either an 
asparagine (N-linked) or serine/threonine (O-linked) residue. N-linked glycans have been 
well-established to change with the progression of cancer and other diseases,48,49,323,344 and 
studies indicate that the N-glycan component of a glycoprotein may act as a specific disease 
biomarker more than the protein alone.49,345 This has been shown in the success of 
fucosylated alpha-fetoprotein (AFP) as a biomarker for liver cancer,51,346 yet most N-
glycan profiles present on protein biomarkers remain unexplored. Current techniques for 
analysis of N-glycan profiles and their carrier proteins are often time-consuming or require 
large amounts of sample,48,323,347,348 which limits the ability to analyze significant numbers 
of patient samples for the discovery of novel disease biomarkers. Some high throughput 
methods have utilized differential lectin binding to identify carbohydrate structural 
motifs,129,172,173 yet these are limited to the variable and low binding affinities of most 
lectins, and they cannot be used to report true structural composition or glycan carrier (i.e. 
N-glycan, O-glycan, or glycosphingolipid) information.129,172,173  
            The technology of matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry imaging (MSI) has emerged in recent decades to become a powerful 
technique for analyte detection and localization across tissue sections with high mass 
accuracy.137–141 This technique creates two-dimensional heat maps of an analyte’s intensity 
across a tissue sample on a slide. Our lab has previously developed a method for the spatial 
analysis of released N-glycans across tissue sections145–150 and related workflows have 
been implemented and adapted by multiple labs.152–155 However, as is common to any 
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method relying on enzymatic release of N-glycans, linking N-glycan signatures to their 
carrier proteins remains laborious and requires extensive additional analysis.152,349 
Leveraging that MALDI MSI can be used to detect N-glycans from the solid surface of a 
tissue on a slide, we hypothesized that we could extend beyond traditional imaging 
techniques to detect N-glycan profiles from target glycoproteins captured on a slide-based 
antibody microarray panel. This would bridge the gap in linking N-glycan signatures to 
their proteins, as the location of the detected N-glycans along the slide array would be 
linked with each immunocaptured glycoprotein they were released from. This method 
would obtain N-glycan profiles for each glycoprotein, rather than other targeted approaches 
analyzing only certain N-glycan motifs or one protein at a time. Here we report a novel 
biomarker discovery platform by Antibody Panel Based (APB) N-glycan imaging, which 
couples the analyte localization of traditional MALDI MSI with the protein capture 
specificity of an antibody array for use with patient biofluid samples. 
4.3 Materials and Methods 
4.3.1 Materials 
Nitrocellulose-coated glass microscope slides (PATH microarray slides) and well slide 
modules (ProPlate Multi-Array Slide System, 24-well) were obtained from Grace Bio-Labs 
(Bend, OR). Trifluoroacetic acid, a-cyano-4-hydroxycinnamic acid, octyl-b-D-
glucopyranoside, human alpha-1-antitrypsin, and normal human serum were obtained from 
Sigma Aldrich (St. Louis, MO). HPLC grade water, HPLC grade acetonitrile, bovine serum 
albumin, and phosphate buffered saline were obtained from Fisher Scientific (Hampton, 
NH). Peptide-N-glycosidase F (PNGase F) Prime TM was cloned, expressed, and purified 
in-house as previously described.147 Anti-human A1AT was obtained from Genway 
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Biotech (San Diego, CA). Human immunoglobulin G was obtained from Jackson 
ImmunoResearch (West Grove, PA) and anti-human IgG from Bethyl Laboratories 
(Montgomery, TX). Additional normal serum samples were obtained from SeraCare 
(Milford, MA). Cirrhotic patient serum was obtained from Dr. Amit Singal (University of 
Texas Southwestern Medical Center, Dallas, TX). Serum samples were obtained via a 
study protocol approved by the UTSW Institutional Review Board, with written informed 
consent obtained from each subject. Diagnosis of liver cirrhosis was based on liver 
histology or clinical, laboratory, and imaging evidence of hepatic decompensation or portal 
hypertension. Each patient had a normal ultrasound; if serum AFP was elevated, a CT or 
MRI showed no liver mass. Further patient details regarding these samples are found in 
our previous publication.350  
4.3.2 Antibody panel preparation 
Nitrocellulose-coated microscope slides were used and wells created by attaching a 24-
well slide module. Antibodies were diluted in PBS and manually spotted in wells at 200ng 
per 1.5µL spot. Spots were then left to adhere overnight at 4°C in a humidity chamber 
made from a 12x9x3.5cm western blot incubation box lined with a Wypall X 60 paper 
towel and 2 rolled KimWipes saturated with distilled water. Slides were then air dried at 
room temperature and rinsed with 0.1% octyl-b-D-glucopyranoside in 1X PBS (referred to 
as PBS-OGS) to remove any unbound protein from slide. Rinse consisted of 200 µL to 
each well for 1 minute. 
4.3.3 Sample Capture and N-glycan Release 
Wells were blocked with 200 µL of 1% BSA (prepared in PBS-OGS) for 1 hr with gentle 
shaking. Wells were then washed with 20 0µL PBS (3 mins x 2) and 200 µL double distilled 
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water (1 min x 1) and let air dry. Samples were added to wells and incubated at room 
temperature for 2 hours in humidity chamber with gentle shaking. All samples were diluted 
in PBS, with sample volumes of 100 µL added to wells. Slides were then washed with 200 
µL of PBS-OGS (1 min x 1), 200 µL PBS (3 mins x 2), and 200µL double distilled water 
(1 min x 1) and let air dry. After removing the well module, an additional wash was 
performed by submerging the slide into 50 mL of water for 30 seconds to remove any 
residual salt. In order to cleave N-glycans from captured proteins, PNGase F PrimeTM (0.1 
µg/µL in HPLC grade water) was applied to the slides using an automated sprayer (M3 
TM-Sprayer, HTX Technologies, Chapel Hill, NC) to retain localization with spraying 
parameters 15 passes at 45°C, 10 psi, flow rate 25 µL/min, and 1200 mm/min velocity. 
Slides were incubated overnight at 37°C in humidity chambers made in cell culture dishes 
with Wypall X 60 paper towels and 2 rolled KimWipes saturated with distilled water. 
4.3.4 MALDI MS Preparation and Imaging 
MALDI matrix a-cyano-4-hydroxycinnamic acid (CHCA, 7mg/mL in 50% 
acetonitrile/0.1% trifluoroacetic acid) was applied to slides using the same automated 
sprayer. Application parameters were 2 passes at 77°C, 10 psi, 1300 mm/min velocity and 
flow rate 100 µL/min. Slides were imaged on a solariX Legacy 7T FT-ICR mass 
spectrometer (Bruker) equipped with a matrix-assisted laser desorption/ionization 
(MALDI) source. Sampling was done using a SmartBeam II laser operating at 2000 Hz 
with laser spot size of 25µm. Images were collected using a smartwalk pattern at a 250µM 
raster with 200 laser shots per pixel. Samples were analyzed in positive ion, broadband 
mode using a 512k word time domain spanning m/z range 500-5000. An on-slide resolving 
power of 58,000 at m/z 1501 was calculated. 
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4.3.5 Data Analysis 
N-glycan localization and intensity were visualized using FlexImaging v4.1 (Bruker), with 
data imported at a 0.98 ICR Reduction Noise Threshold. Images were normalized to total 
ion current and N-glycan peaks were selected manually based on their theoretical mass 
values. Spectra were recalibrated using Data Analysis 5.0 (Bruker) with an 8-point linear 
function based on N-glycan theoretical masses. For quantification of peaks at individual 
spots, spectra were imported into SCiLS Lab software 2017a (Bruker). Each spot was 
designated a unique region and area under monoisotopic peak values were exported from 
each region. 
4.3.6 HPLC and Lectin Orthogonal Confirmation 
HPLC analyses on released labelled N-glycans were performed using a Waters Alliance 
HPLC system as previously described.122 Lectin analyses on spotted glycoproteins were 




Figure 26. Workflow for Antibody Panel Based N-glycan imaging by MALDI MS. A. 
Antibodies are spotted and slide blocked with BSA. Sample is added for capture of 
glycoproteins by their antibodies. B. N-glycans are enzymatically released in a localized 
manner followed by matrix application. C. Slides are imaged by a MALDI FT-ICR MS to 
obtain overall spectrum and individual images for each m/z peak, which show the 
abundance of each N-glycan in two-dimensions across the array. 
 
4.4 Results 
            The novel workflow for specific glycoprotein capture and APB N-glycan imaging 
is illustrated in Figure 26. The workflow is founded upon a similar MALDI mass 
spectrometry workflow for N-glycan imaging on tissue,147,150 and consists of three major 
steps. The first (Figure 26A) involves antibody spotting and glycoprotein capture localized 
to their antibody spots. The second (Figure 26B) consists of PNGase F enzymatic release 
of N-glycans in a localized manner and matrix coating of the slide, trapping released 
glycans in area of their release. Figure 26C shows the third step of MALDI MS analysis of 
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the slide, where an overall spectrum is obtained with images correlating to each m/z peak. 
Images obtained from MS analysis depict the abundance of an N-glycan across a slide with 
color intensity, creating a heat map for each N-glycan detected. This allows for the 
visualization of N-glycans released from immunocaptured glycoproteins in an array type 
format, where N-glycans of interest can be linked back to their protein carriers.  
            Initial experiments were done using human alpha-1-antitrypsin (A1AT) and 
immunoglobulin G (IgG) as they are abundant glycoproteins in human serum with well-
characterized N-glycosylation sites.122,180,205,277,352 These glycoproteins have distinct N-
glycan profiles from each other, as shown in Figure 27 with orthogonal HPLC and lectin 
confirmation of unique N-glycan profiles. The N-glycan profiles in Figure 27A were 
obtained from MALDI MS of A1AT and IgG spotted directly to the slide, and show all 
detected N-glycans comprising more than 1% of overall glycan signal. Proposed structures 
for these N-glycans are shown, with the core fucose linkage on IgG N-glycans assigned 
based on orthogonal HPLC and lectin characterizations of this glycoprotein (Figure 27B-





Figure 27. N-glycan profiles observed on human A1AT and IgG by MALDI, HPLC, and 
Lectin analysis of glycoprotein standards. A. Glycoproteins were spotted (500ng) to a slide 
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and imaged by MALDI FT-ICR MS for detection of N-glycans on each protein. Percentage 
of each N-glycan species was calculated by area under the peak divided by the total of all 
N-glycan peak areas. The proposed structures for all species comprising >1% of each 
protein’s N-glycome are shown above, and there are clearly distinct N-glycan structures 
on the two proteins. B. For orthogonal comparison of N-glycan profiles, A1AT and IgG 
were digested in-solution with PNGase F followed by HPLC analysis. C. Percentage of 
each N-glycan species was calculated by the peak area divided by the total of all N-glycan 
peak areas. D. Prediction of N-glycans on A1AT and IgG by lectin profiling. 
 
            Antibody capture of glycoproteins was performed similar to immunoassay 
procedures used in other array formats.173,353 Antibodies were manually pipetted at 200 ng 
per spot, each spot a 1.5 µL volume. Wells were created with clip- on well modules and 
antibodies spotted within these wells. Slides were blocked with 1% BSA to prevent 
nonspecific binding to the slide or other antibodies. Figure 28A illustrates that the slide is 
sufficiently blocked to prevent A1AT binding when the protein was spotted directly to the 
slide followed by a wash to remove unbound protein. When A1AT was added to a well as 
a 100 µL sample, capture specificity to its antibody was seen with A1AT N-glycans 
localized to anti-A1AT but not an adjacent anti-IgG spot, shown in Figure 28B. Circles 
were added to indicate the position of spotted anti-A1AT (red) and anti-IgG (blue) within 
the well. Figure 28C contains a dilution series of A1AT added to its antibody, illustrating 
the successful capture of a glycoprotein and N-glycan detection localized to capture spots. 
A major N-glycan signature was from m/z 2289.7619 (Hex5HexNAc4NeuAc2+3Na), 
which is depicted in 28C. This glycan represents approximately 47% of the total N-glycan 
pool on A1AT and this peak can be observed at 10 ng of captured protein. This correlates 
to approximately 3 femtomoles of that glycan, which highlights the sensitivity of this 
platform. N-glycan signal intensities within each spot were quantified using the area under 
the peak. As shown in Figure 28D, N-glycan signal from immunocaptured A1AT was 
detected in a concentration-dependent manner, with a signal plateau observed as the 
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antibodies neared saturation. The profile of the most abundant N-glycans detected on this 
captured glycoprotein showed extremely strong agreement with that of glycoprotein 
spotted directly to the slide rather than antibody-captured, Figure 28E. This was done to 
confirm that the glycoforms of A1AT present in solution are all captured by its antibody. 
N-glycan of m/z 1809.6923 (Hex5dHex1HexNAc4+Na) was excluded from this analysis 
as it is highly abundant on the capture antibody and thus would confound the comparison 
of spotted to captured profiles. An orthogonal analysis of the N-glycan profile of A1AT 
was performed with HPLC and lectin profiling, Figure 27.  
 
Figure 28. N-glycan detection by MALDI MSI of immunocaptured A1AT. A. A1AT was 
spotted (1µL) to slide with and without blocking (1% BSA). Imaging data is from the most 
abundant N-glycan observed on A1AT, which is not seen on the blocked slide. B. A1AT 
was added in a 100µL volume to a well containing both anti-A1AT and anti-IgG as adjacent 
spots, red and blue circles added for emphasis of antibody location. C. A dilution series of 
A1AT standard solutions (100µL) were added in triplicate to anti-A1AT. N-glycan signal 
is seen at antibody spots with an increase in color intensity observed as more glycoprotein 
was present. D. Quantifications of imaging data in C were performed by calculating the 
area under the peak for each sample. Each data point represents the average +/- standard 
deviation of three samples. E. Comparison of A1AT spotted directly to the slide versus 
antibody-captured. N-glycan profiles showed strong agreement. Percentages of each N-
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glycan specie were calculated by area under the peak divided by the total of all N-glycan 
peak areas. The proposed structures for the most abundant N-glycans on A1AT are shown. 
 
            To illustrate the potential of this platform to become a multiplex array for the 
simultaneous analysis of multiple glycoprotein targets, side-by-side capture of two 
glycoproteins was tested. Human A1AT and IgG were used and antibodies to the two 
proteins were spotted side-by-side within each well as depicted in Figure 29A. Mixtures 
containing both A1AT and IgG standards were added to wells in triplicate 100 µL volumes 
at the concentrations shown in Figures 29B-C, with red and blue circles added to indicate 
antibody positions. N-glycans were detected from both glycoproteins localized to their 
individual capture spots, with an N-glycan signature unique to A1AT shown in Figure 29B 
(m/z 2289.7635, Hex5HexNAc4NeuAc2+3Na) and unique to IgG in 29C (m/z 1485.5335, 
Hex3dHex1HexNAc4+Na). Quantifications to compare the protein signal to antibody 
background signal for these images are shown in Figure 29E. Specificity of capture was 
observed by the lack of protein-specific N-glycan signals on the opposite antibodies as well 
as the surrounding slide itself. As the goal of this platform is application to biological 
samples for biomarker discovery, human serum was also used for side-by-side capture of 
glycoproteins A1AT and IgG from a more complex mixture. Commercially-obtained 
normal human serum (Sigma) was diluted in PBS (1:100) and added to the wells containing 
both A1AT and IgG antibodies as previously shown. As both glycoproteins are present in 
serum at concentrations greater than 1 mg/mL,354 addition of 1 µL of serum per well was 
more than sufficient to saturate the 200 ng of capture antibodies spotted in each well. 
Figures 29D-E depict N-glycan signatures associated with both glycoproteins captured 
from just 1 µL of serum, again showing great specificity of capture. Quantifications of the 
captured proteins in Figure 29 are shown in Figure 30. To further illustrate the 
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reproducibility of this platform for serum analysis, four additional individual healthy 
patient samples (SeraCare) were added to the array and again showed specific capture of 
A1AT and IgG (Figure 31) with glycan profiles that are similar to those obtained from 
other healthy serum. An anticipated application for this new platform is the discovery of 
disease-specific changes in N-glycans on proteins captured from patient biofluid samples.  
 
Figure 29. Side-by-side capture of A1AT and IgG from standard solutions and normal 
human serum. A. Template of the well module used on nitrocellulose-coated microscope 
slides. Within each well both anti-A1AT and anti-IgG were spotted adjacently at 200ng 
per 1.5µL spot. B-C. Solutions containing a mixture of both A1AT and IgG standards were 
added in triplicate to the two antibodies, red and blue circles added to indicate positions of 
anti-A1AT and anti-IgG, respectively. An A1AT-associated N-glycan was observed 
localized to the left of each well, illustrating specific capture of this glycoprotein by anti-
A1AT. An IgG-associated N-glycan was observed localized to the right of each well, 
illustrating specific capture of this glycoprotein by anti-IgG. D-E. Normal human serum 
was diluted in PBS and added in triplicate to each well at only 1µL of serum per 100µL 






Figure 30. Quantifications of N-glycan peaks observed in Figure 29. A-D. Area under peak 
values were obtained for each region. Bars represent the mean +/- standard deviation of 3 
samples and highlight that significant N-glycan signal was observed from each sample 
beyond that of the antibody background signal. 
 
Figure 31. Capture of A1AT and IgG from healthy patient serum samples. Normal human 
serum samples from 4 individual donors (SeraCare) were added to the array in triplicate. 
Donors were confirmed negative for HIV, HBV, and HCV. Samples were diluted 1:100 in 
PBS for a total of 1µL serum added per well. Each well contained antibodies for anti-A1AT 
(left) and anti-IgG (right) as shown previously, spotted at 200ng per 1.5µL antibody spot. 
A. An A1AT-associated N-glycan was reproducibly observed localized to the left of each 





            As a proof of concept, serum from five patients with liver cirrhosis was pooled to 
normalize patient variation, and 1µL of the pooled sample (diluted 1:100 in PBS) was 
added to the array in the triplicate. Commercially-obtained normal human serum (Sigma) 
was added in the same manner for comparison. This concentration of serum again allowed 
for saturating amounts of these very-abundant proteins to be added to the antibodies, which 
is important to ensure detected glycan changes are not due to variations in protein levels. 
Glycoproteins were again specifically captured by their antibodies with detectable levels 
of distinct N-glycans, imaging data and overall N-glycan profiles of IgG shown in Figure 
32. Notably, an increase in an IgG nongalactosylated N-glycan m/z 1485.5356 
(Hex3dHex1HexNAc4+Na) was observed in the cirrhotic serum compared to normal 
human serum, Figures 32A-C. This particular N-glycan has been previously described to 
increase in cirrhotic serum355,356 and this new platform showed agreement with those 
findings. A subsequent decrease in galactosylated biantennary N-glycans (m/z 1809.6344 
Hex5dHex1HexNAc4+Na and 1647.5885 Hex4dHex1HexNAc4+Na) was also observed, 
illustrating the potential for comparison of glycan ratios that may change in the presence 
of disease (Figures 32B and 32C). For example, the ratio of glycans m/z 1485.5356 to 
1809.6344 increased from 0.35 to 0.68 in cirrhotic patient serum. Intensity value 
comparisons of these N-glycans are shown in Figure 33. Additional N-glycans were 
observed on IgG only from cirrhotic samples, which illustrates the potential for greater 
variance in glycan profiles as clinical samples are used. A list of all glycans observed in 
serum protein capture is shown in Table 2. A1AT was also successfully captured from 
these cirrhotic samples without a loss in binding specificity, as shown in Figure 32D. This 
experiment illustrates the future potential for this platform to be applied to patient samples 
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for detection of disease-related N-glycan changes for biomarker purposes. Together, these 
results describe the development of a new APB mass spectrometry platform for protein-
specific N-glycan analysis from biofluid samples in a clinically-relevant manner requiring 
minimal sample consumption. 
 
Figure 32. Potential for detection of altered N-glycosylation in patient serum samples. A. 
Stock human serum and serum pooled from 5 patients with cirrhosis were added in 
triplicate to wells containing both anti-A1AT and anti-IgG as shown previously. 1µL of 
serum was diluted in 100µL PBS for the addition to each well. An IgG-associated N-glycan 
was observed to increase in the cirrhotic samples compared to the stock serum, which has 
been previously reported. B-C. IgG N-glycan profiles in stock human serum and cirrhotic 
patient serum illustrating an increase in the nongalactosylated fucosylated biantennary N-
glycan from A (red arrow) and a subsequent decrease in the galactosylated fucosylated 
biantennary N-glycans. Percentages of each N-glycan specie were calculated by area under 
the peak divided by the total of all N-glycan peak areas. D. An A1AT-associated N-glycan 
is shown to illustrate that this glycoprotein was also specifically captured out of both stock 





Figure 33. Quantifications of N-glycan peaks observed in normal and cirrhotic serum. A-
C) IgG N-glycan intensities were compared by the area under peak values for each spot. 
Bars represent the mean +/- standard deviation of 3 samples and illustrate that not all IgG 
N-glycans are increased in cirrhotic serum as would be expected if the protein levels were 
varying. D) Comparison of an A1AT N-glycan by area under the peak values. Bars 




Table 2. All N-glycans observed in serum protein capture of A1AT/IgG. This table lists 
the m/z values of all N-glycans observed on proteins captured from human serum. Those 








N-Glycan Composition Proposed N-glycan 
Structure 




1282.4543 1282.4531 0.9357 Hex3dHex1HexNAc3 + 1Na  
 
1298.4492 1298.4504 0.9242 Hex4HexNAc3 + 1Na  
 
1339.4757 1339.4799 3.1356 Hex3HexNAc4 + 1Na  
 




1444.5071 1444.5082 0.7615 Hex4dHex1HexNAc3 + 1Na  
 
1485.5337 1485.5356 1.2790 Hex3dHex1HexNAc4 + 1Na  
 




1647.5865 1647.5885 1.2139 Hex4dHex1HexNAc4 + 1Na  
 
1663.5814 1663.5885 1.9837 Hex5HexNAc4 + 1Na  
 
1688.6130 1688.6127 0.1777 Hex3dHex1HexNAc5 + 1Na  
 









            In order to address the goal of multiplexed analysis, the antibody panels were 
increased beyond just 2 antibodies per well. Larger sized wells were used for these panels, 
along with larger volumes to be added. Figure 34 illustrates a 6-antibody panel targeting 
A1AT, haptoglobin, hemopexin, IgG, low molecular weight kininogen, and transferrin; 
their locations are denoted by colored circles. The experiments shown here were conducted 
 
1809.6393 1809.6344 2.7077 Hex5dHex1HexNAc4 + 1Na  
 
1850.6710 1850.6658 2.8098 Hex4dHex1HexNAc5 + 1Na  
 
1976.6666 1976.6577 4.5023 Hex5HexNAc4NeuAc1 + 2Na  
 
2012.7187 2012.7190 0.1491 Hex5dHex1HexNAc5 + 1Na  
 
2028.7136 2028.7241 5.1757 Hex6HexNAc5 + 1Na  
 




2174.7715 2174.7776 2.8049 Hex6dHex1HexNAc5 + 1Na  
 
2289.7722 2289.7623 4.3236 Hex5HexNAc4NeuAc2 + 3Na  
 




2341.8090 2341.7946 6.1491 Hex6HexNAc5NeuAc1 + 2Na  
 







with glycoprotein standard solutions and 10µL of normal human serum diluted into PBS. 
The most abundant N-glycan observed on IgG was m/z 1809.6360 
(Hex5dHex1HexNAc4+Na), which is seen in capture of the glycoprotein standard as well 
as from human serum, Figure 34A. The location of IgG capture is indicated by a red circle. 
The antibody itself produces some background signal for this glycan, as evidenced by the 
addition of just PBS vehicle to the panel. An N-glycan of m/z 1976.6618 
(Hex5HexNAc4NeuAc1+2Na) was observed on hemopexin in capture of the glycoprotein 
standard as well as human serum, Figure 34B. The location of hemopexin capture is 
indicated by a green circle. This N-glycan can also be observed on other glycoproteins 
captured from the serum sample, alpha-1-antitrypsin and haptoglobin (yellow and blue 
circles, respectively). The appearance of an N-glycan signal on multiple spots is to be 









Figure 34. Capture of proteins by a 6-antibody panel. A) Data shown is from an IgG-
associated N-glycan with proposed structure shown. PBS vehicle, IgG standard solution 
(500ng), or human serum (1:70) was added to the antibody panel. This N-glycan is 
observed localized to the anti-IgG spot (red circle). Some background signal from this N-
glycan is observed on the antibody itself in the vehicle-treated well. B) Data shown is from 
a sialylated N-glycan found on hemopexin and other serum proteins. PBS vehicle, 
hemopexin standard solution (500ng), or human serum (1:70 in PBS) was added to the 
antibody panel. N-glycan signal is observed at the anti-hemopexin spot (green circle), as 
well as from other serum proteins. C) Template of the 6-antibody panel used in these 
experiments. D) Mass spectrum obtained from IgG showing the major N-glycan species 




           Described here is a new antibody panel based (APB) mass spectrometry platform 
for the multiplexed detection of N-glycans in a protein-specific manner from biological 
samples. The development of this technique was based on a well-established protocol for 
enzymatic release of N-glycans from tissue sections for MALDI MSI.145,147 The two-
dimensional analysis with detection by MSI allows for the mapping of N-glycan signals to 
their carrier proteins along a slide-based antibody array. In this platform, antibodies are 
essential for the specific capture of glycoprotein targets from a complex biological mixture, 
similar to an ELISA. Yet unlike an ELISA, no secondary antibody or lectin is needed for 
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this methodology as mass spectrometry provides sensitive and specific detection of distinct 
N-glycans. Antibody capture also negates the need for sample clean-up prior to MS 
analysis, which can be extensive.48,323,332,357,358 As is typical for serum-based assays, 
evidence for the presence of heterophilic antibodies in cirrhotic serum has been observed 
with nonspecific binding to some antibodies assayed, which can lead to false positives in 
clinical assays.350,359 However, as the heterophilic antibodies have a very distinct glycan 
profile, these can be accounted for in any given run and subtracted from the main spectra 
if required.  
           Antibody capture has been previously used to capture a single target protein for 
MALDI MS analysis,315,316 yet our novel multiplexed technique can be expanded for the 
analysis of potentially 100s or 1000s of different N-glycoproteins in one imaging run. Each 
run generates an immense amount of data, as spectra showing potentially hundreds of N-
glycan species are gathered localized to each glycoprotein on the array. Therefore, this 
method has powerful capabilities for the characterization of N-glycosylation across many 
target proteins simultaneously. 
           This new method extends the capabilities of existing N-glycan biomarker detection 
technologies. Lectin microarrays have been used for detection of changes in N-glycans in 
a biomarker setting,173,360–362 however our new APB N-glycan imaging method 
significantly increases the amount of information that can be obtained from such analyses. 
While lectins bind to N-glycan structural motifs, MALDI MS detects the compositions of 
N-glycans present. The method can be easily adapted to the use of other instrumentation, 
e.g., ion mobility, which will allow reporting on configuration of N-glycoforms. Current 
methodology using an FT-ICR MS does permit the detection of sialylated N-glycan 
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structures despite their labile bonds, as has been previously shown.299,337,363 Additionally, 
APB glycan imaging obtains a complete mass spectrum for each glycoprotein capture spot, 
allowing hundreds of potential N-glycan masses to be probed per glycoprotein target as 
opposed to a select few with targeted lectin analysis. Detection of the glycan heterogeneity 
present on each protein can be used for calculation of glycan ratios, which may represent 
important alterations in the overall glycosylation of a protein that can be clinically 
utilized.364,365 Though different glycans will vary in ionization efficiencies, these inherent 
properties are assumed to remain constant across different samples, thus having a 
negligible effect on ratio comparison. As previously mentioned, MSI analyses on tissues 
have been used for elucidating N-glycan changes in the presence of disease.148,149,157,299 
While tissue-based analysis is often used for prognosis and pathological examination, it is 
not as an accessible material for early detection of disease, as is serum or other biofluids. 
We hypothesize that our new biomarker discovery and validation platform may be used 
with readily available patient biofluids such as serum or urine.  
           Further work remains to increase the clinical power of this platform. More 
antibodies can be added so that more glycoproteins can be probed per analysis. This 
improvement will be limited by the quality of these antibodies – both in binding affinity 
and specificity – as is widely recognized in the field of antibody research. The addition of 
patient samples shown in Figure 32 highlights the importance of antibody quality in 
specifically capturing target glycoproteins from complex samples that have potential for 
great heterogeneity. Observed variance in clinical samples could occur due to poor 
antibodies, or it possible the sensitivity of our new platform could unveil novel disease-
related anomalies not previously recognized by current N-glycan analysis methods. Future 
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work will be performed to remove the N-glycans present on antibodies to limit background 
signal. Clinical relevance can also be improved by streamlining the workflow, as the 
current method requires 1.5 days. Additionally, translation of this technique to other mass 
spectrometry platforms will be important both for achieving complete structural 
information of the detected N-glycans as well as moving to more clinically-accessible 
MALDI MS instruments. The MALDI MS instrumentation used in this study does not 
uncover the full structural configuration of an N-glycan, rather its composition. While the 
N-glycan profiles of the two glycoproteins used here have been well-characterized by 
orthogonal methods, future work with less-studied glycoproteins will require additional N-
glycan structural characterization or orthogonal confirmation. Mass spectrometry analysis 
following trypsin digest to observe peptides rather than N-glycans will also be used to 
confirm glycoprotein binding specificity at each antibody. 
           The development of this novel platform suggests exciting potential for application 
in the clinic as both a biomarker discovery tool as well as a new screening platform for a 
number of diseases in readily available clinical biofluid samples. This platform was able 
to detect N-glycans on glycoproteins captured from only 1µL of human serum, illustrating 
its potential for use with very minimal patient sample consumption. N-glycans and their 
role in disease progression are quickly becoming recognized as an important new frontier 
for biomedical research. However, the applications of this new technique extend beyond 
just N-glycans and biofluid samples: this platform could be used with liquids such as cell 



















Chapter 5: Application of Antibody Panel Based N-glycan Imaging 






Alterations in N-glycosylation have been observed in many human diseases, 
ranging from diabetes to cancer. Glycoproteins, therefore, have potential to be powerful 
biomarkers for disease development and progression. The majority of FDA-approved 
cancer biomarkers are glycoproteins, yet the impact of their N-glycan components are 
often ignored.49 Various ways of analyzing N-glycans and their carrier proteins in patient 
serum samples have been developed.132 However, these analyses often require lengthy 
sample preparation and/or data analysis, preventing the ease of assaying multiple 
glycoprotein targets and/or large patient cohorts. 48,323 
Array based platforms allow for analysis of many targets simultaneously, with 
applications ranging from nucleic acids to proteins. The array panel presented here 
consists of immunocaptured glycoproteins and is conceptually similar to other N-glycan 
detection microarrays such as lectin binding.172,173 Antibodies to target glycoproteins are 
spotted to a microscope slide as discrete spots and incubated with serum samples. 
Glycoproteins are specifically captured and localized to a unique position along the array 
panel. N-glycans are then enzymatically released by PNGaseF, and MALDI mass 
spectrometry imaging is used instead of lectins to detect N-glycans localized to their 
position on the array. This MS detection method acquires compositional N-glycan 
information rather than simply motifs, which is valuable for identifying specific N-glycan 
changes occurring on captured proteins. The data acquired from this technique is a profile 
of the N-glycans present on each glycoprotein target captured by the antibody panel. N-
glycans can be easily identified based on their theoretical mass value, and disease-related 
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changes in protein glycosylation could lead to the discovery of clinically relevant 
biomarkers. 
This new platform for N-glycoprotein analysis from serum that combines matrix-
assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) workflows 
with antibody slide arrays was developed and described in Chapters 3-4. Antibody Panel 
Based (APB) N-glycan imaging allows for the specific capture of glycoproteins by 
antibodies on slides and N-glycan analysis in a protein-specific and multiplexed manner. 
The final portion of this work was the translational application of APB N-glycan imaging 
to patient samples for biomarker discovery, completing Specific Aim 2. The goal of this 
Aim was to use the newly-developed mass 
spectrometry antibody platform for analysis 
of HCC and cirrhotic patient serum, Figure 
35. These disease groups were chosen as 
HCC is a highly lethal cancer that is 
difficult to detect and generally occurs in 
the presence of cirrhosis, thus making them 
a valuable control population. Additionally, 
as a cancer of the liver, HCC is known to 
produce alterations in serum proteins – both 
in their expression as well as 
glycosylation.110,118,366–369 Eight serum 
glycoproteins were chosen for these 
experiments based on their relevance to 
Figure 35. Schematic overview of Aim 2. 
These experiments used serum for HCC and 
cirrhotic patients and analyzed them by 
APB N-glycan imaging for the creation of 
an HCC disease biomarker algorithm. 
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liver disease, glycosylation profiles, and most importantly, the quality of antibodies 
obtained for these proteins. The target proteins were alpha-1-antitrypsin, alpha-1-acid 
glycoprotein, clusterin, haptoglobin, hemopexin, immunoglobulin G, low molecular 
weight kininogen, and transferrin; with all except for low molecular weight kininogen 
used in the largest patient analysis Cohort 3. 
Three different patient cohorts of serum samples were analyzed, each under 
slightly different conditions. The number of patient samples used was increased with 
each cohort to increase the robustness of biomarker discovery. The specific antibody 
panels were also varied across the cohorts; however, antibodies for haptoglobin, 
hemopexin, immunoglobulin G, and transferrin were included in each cohort. The 
volume of serum to be used from each patient was also adjusted across the cohorts to 
provide sufficient signal with minimal nonspecific residue. 
This work was the first instance of APB N-glycan imaging being used for the 
analysis of patient serum samples for biomarker discovery. Multiplexed analysis of up to 
7 serum proteins by MALDI MS is significant as most glycan biomarker analysis is done 
on only one protein at a time or on released N-glycans with no protein carrier 
information. Additionally, this workflow and data analysis are relatively easy to perform 
and are amenable to being adapted to clinical workflows.  
 
5.2 Materials and Methods 
5.2.1 Materials 
Nitrocellulose-coated glass microscope slides (PATH microarray slides) and well slide 
modules (ProPlate Multi-Array Slide System, 24-well) were obtained from Grace Bio-
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Labs (Bend, OR). Trifluoroacetic acid (TFA), a-cyano-4-hydroxycinnamic acid (CHCA), 
and octyl-b-D-glucopyranoside (OGS), and glu-1-fibrinopeptide B (Glu-Fib) were 
obtained from Sigma Aldrich (St. Louis, MO). HPLC grade water, HPLC grade 
acetonitrile, bovine serum albumin, and phosphate buffered saline were obtained from 
Fisher Scientific (Hampton, NH). Peptide-N-glycosidase F (PNGase F) Prime TM was 
cloned, expressed, and purified in-house as previously described.147 Sialidase A was 
cloned, expressed, and purified in-house as described for PNGase F. Antibody 
information is listed below in Table 3. It is noted that not all antibodies tested were 
suitable for this platform, as discussed in Chapter 3. Many of these targets required the 
testing of up to 6 antibodies to find one that worked. 
Table 3. Product information for each antibody used in these experiments. 





























Custom order N/A 




5.2.2 Patient Samples 
Patient serum was obtained from Dr. Amit Singal (University of Texas 
Southwestern Medical Center, Dallas, TX) or Dr. Yuko Kono (University of California 
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San Diego, CA). Serum samples were obtained via study protocols approved by the 
UTSW or UCSD Institutional Review Boards, with written informed consent obtained 
from each subject. Diagnosis of liver cirrhosis was based on liver histology or clinical, 
laboratory, and imaging evidence of hepatic decompensation or portal hypertension. Each 
patient had a normal ultrasound; if serum AFP was elevated, a CT or MRI showed no 
liver mass. Each non-HCC patient had a normal ultrasound; if serum AFP was elevated, a 
CT or MRI showed no liver mass. For HCC patients, the diagnosis of HCC was made by 
histopathology or imaging (magnetic resonance imaging [MRI] or computed tomography 
[CT]) showing a vascular enhancing mass with delayed washout. Tumor staging was 
determined using the Milan Criteria. Demographic and clinical information were 
obtained, and a blood sample was collected from each subject. A 20 mL blood sample 
was drawn from each subject, spun, aliquoted, and serum stored at −80°C until testing. 
Blood samples for HCC patients were drawn prior to initiation of HCC treatment.  
Samples in Cohort 3 (UCSD) were all treated with Sialidase A prior to addition to 
antibody panels. This was performed by adding 1 µg recombinant Sialidase A to 10 µL of 
serum and incubating at 37°C for 2 hours on a rotator. No additional clean-up was 
performed following incubation and samples were stored at 4°C until addition to panels. 
5.2.3 Antibody Panel Preparation 
Nitrocellulose-coated microscope slides were used and sample wells created by 
attaching an 8-well slide module. This resulted in 6 samples added per slide, as one well 
did not contain complete nitrocellulose coverage and another well was used as an antibody 
blank. Antibodies were diluted in PBS and manually spotted in wells at 200 ng per 1.5 µL 
spot. Spots were then left to adhere overnight at 4°C in a humidity chamber made from a 
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12x9x3.5 cm western blot incubation box lined with a Wypall X 60 paper towel and 2 
rolled KimWipes saturated with distilled water. Slides were then dried in desiccator at room 
temperature and rinsed with 0.1% octyl-b-D-glucopyranoside in 1X PBS (referred to as 
PBS-OGS 0.1) to remove any unbound protein from slide. Rinse consisted of 600 µL to 
each well for 1 minute. Wells were then blocked with 600 µL of 1% BSA (prepared in PBS-
OGS) for 1 hr with gentle shaking. Wells were then washed with 600 µL PBS (3 mins x 2) 
and 600µL double distilled water (1 min x 1) and let air dry.  
5.2.4 Sample Capture and N-glycan Release 
Samples were added to wells and incubated at room temperature for 2 hours in 
humidity chamber with gentle shaking. Cohort 1 samples consisted of 20 µL patient serum 
diluted in 480 µL PBS, and samples in Cohorts 2-3 consisted of 5 µL patient serum diluted 
in 495 µL PBS, with sample volumes of 500 µL added to wells in all experiments. Slides 
on Cohort 2 were then washed with 600 µL of PBS-OGS (1 min x 1), 600 µL PBS (3 mins 
x 2), and 600 µL double distilled water (1 min x 1) and let air dry. The washing protocol 
for Cohort 3 slides was altered just slightly to be 600 µL of PBS-OGS 0.2% (1 min x 3), 
600 µL PBS (3 mins x 3), and 600 µL double distilled water (1 min x 1) and let air dry. 
After removing the well module, an additional wash was performed by submerging the 
slide into 50mL of water for 1 min to remove any residual salt. Spots were let dry and then 
rinsed by pipetting HPLC water over the spot to remove any residual salt. In order to cleave 
N-glycans from captured proteins, PNGase F PrimeTM (0.1 µg/µL in HPLC grade water) 
was applied to the slides using an automated sprayer (M5 TM-Sprayer, HTX Technologies, 
Chapel Hill, NC) to retain localization with spraying parameters 15 passes at 45°C, 10 psi, 
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flow rate 25 µL/min, and 1200 mm/min velocity. Slides were incubated overnight at 37°C 
in humidity chambers made in cell culture dishes with Wypall X 60 paper towels and 2 
rolled KimWipes saturated with distilled water. 
5.2.5 MALDI MS Preparation and Imaging 
MALDI matrix a-cyano-4-hydroxycinnamic acid (CHCA, 7 mg/mL in 50% 
acetonitrile/0.1% trifluoroacetic acid) was applied to slides using the same automated 
sprayer. Application parameters were 2 passes at 79°C, 10 psi, 1300 mm/min velocity and 
flow rate 100 µL/min. Slides were imaged on a solariX Legacy 7T FT-ICR mass 
spectrometer (Bruker) equipped with a matrix-assisted laser desorption/ionization 
(MALDI) source. Sampling was done using a SmartBeam II laser operating at 2000 Hz 
with laser spot size of 25 µm. Images were collected using a 75 µm smartwalk pattern at a 
250 µm overall raster with 300 laser shots per pixel. Samples were analyzed in positive 
ion, broadband mode using a 512k word time domain spanning m/z range 500-5000.  
5.2.6 Data Analysis 
N-glycan localization and intensity were visualized using FlexImaging v4.1 
(Bruker), with data imported at a 0.98 ICR Reduction Noise Threshold. Images were 
normalized to total ion current and N-glycan peaks were selected manually based on their 
theoretical mass values. Spectra were recalibrated using Data Analysis 5.0 (Bruker) with 
an 8-point linear function based on N-glycan theoretical masses. For quantification of 
peaks at individual spots, spectra were imported into SCiLS Lab software 2019 (Cohorts 1 
and 2) or 2020 (Cohort 3) (Bruker). Each spot was designated a unique region and area 
under monoisotopic peak values were exported from each region. SCiLS 2020 (used for 
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Cohort 3 only) required that average area under monoisotopic peaks values were exported. 
Box plots were created using Microsoft Excel.  
Algorithms were created using the software package R by biostatistician Mengjun 
Wang. Descriptive statistics were applied for each cohort, which was used in the 
development of the algorithm and external validation. Central location of each predictor of 
cohort was represented by “mean”, its dispersion was described as “standard deviation”.  
Significant difference of each predictor between HCC and cirrhosis patients of each 
predictor was checked by student’s t-test, Wilcoxon rank sum test, or Chi-squares test, 
depending upon the data distribution. In all cases p<=0.05 was regarded as significant in 
this study. 
Feature selection (FS) was used to remove redundant features (variables) and 
reduce multicollinearity. It was also used to improve prediction accuracy and enhance 
learning efficiency of an algorithm. Potentially nonlinear relations between the logit and 
predictors was tested by generalized additive models, restricted cubic splines and partial 
residuals10, and second-degree interactions between predictors were thoroughly evaluated. 
We implemented these methods using freely available software such as Weka (Waikato 
Environment for Knowledge Analysis) package (3-7-1) and various R packages, such as 
FSelector, bestglm, stepPlr, robustbase, penalizedSVM, glmBfp, BMA etc. We also applied 
market basket analysis to check the results from feature selections. We obtained the 
frequency of each variable, strength of links among variables and strong linked subsets to 







Figure 36. Layout of each patient cohort analyzed with the antibody panels spotted, 
number of patients, and amount of serum used.  
 
The results of these 3 cohorts illustrated that patient serum could be successfully 
analyzed by APB N-glycan imaging with specific capture of serum glycoproteins. Brief 
descriptions of each cohort and the antibody panels used are shown in Figure 36. Cohort 
1 was the smallest patient cohort analyzed with only 11 samples in each patient category 
with a 7-antibody panel. Clinical information is not discussed as it was lacking with this 
dataset. However, results indicated that some protein-specific glycan changes could be 
observed between the two patient groups. The primary glycan modification seen on HCC 
patient proteins was increased sialylation, Figure 37. Specifically, sialylated glycans m/z 
2341.7919 on A1AT, 1976.6655 on hemopexin, 2289.7314 on LMWK, and 2341.7919 
on transferrin were elevated in HCC compared to controls. While none of these values 
were statistically significant, they highlighted a trend that was to be followed in future 
cohorts. A key problem encountered in Cohort 1 was the poor quality of panel images, 
with significant smearing and serum residue observed throughout the wells, Figure 37. 
This was likely due to the high volume of serum added to each well and would be 




Figure 37. Results from Cohort 1. A. Imaging data shown is from glycans m/z 1663.5782, 
1976.6655, and 2341.7919. Some clear spots are observed along with smeared residue in 
the top half of the wells. B. Quantitative comparisons of sialylated glycans in cirrhotic 
versus HCC patients. Cirrhotic samples are represented by yellow boxes (n=11) and HCC 
samples represented by red boxes (n=11). Increased sialylation was observed on all 4 
target proteins. 
 
Analysis of Cohort 2 was performed with 39 total patients with a smaller 4-
antibody panel used: targeting proteins haptoglobin, hemopexin, immunoglobulin G, and 
transferrin. Clinical characteristics of this cohort are shown in Table 4-5, with Table 4 
indicating the HCC group divided based on time of diagnosis. This was done as 
approximately half of the HCC samples were collected 3-6 months prior to HCC being 
large enough to be detected and diagnosed by imaging. This particular subset was 
therefore not as suitable for direct comparison against current detection methods. Because 
of this, the HCC samples that were collected at a detectable time point (n=11) were 




Table 4. Clinical characteristics of Cohort 2. AST = aspartate aminotransferase, ALT = 
alanine aminotransferase, ALK = alkaline phosphatase, AFP = alpha-fetoprotein 
 
 
Table 5. Clinical characteristics of Cohort 2 with the HCC group split based on time of 
sample collection compared to the time of cancer diagnosis. AST = aspartate 





A key trend observed in the Cohort 2 data was increased fucosylation on HCC 
proteins, Figure 38. This was seen with individual glycans such as m/z 1809.6432 on IgG 
and m/z 2320.8200 on transferrin, Figure 38C. Elevated levels of fucosylation could also 
be seen in ratios of fucosylated glycans to their non-fucosylated counterparts, m/z 
2539.9032 to 2393.8557 on haptoglobin and m/z 2174.8124 to 2028.7200 on hemopexin, 
Figure 38B. A significant increase in a fucosylated glycan m/z 2320.8200 and 2539.9032 
on hemopexin was observed when only the detected HCC patients were compared to the 
cirrhotic controls, Figure 38D. The trend of increased sialylated glycans from Cohort 1 
was not observed in this cohort, instead a loss of sialic acid signal was observed across 
almost all samples, with only one slide showing measurable sialylated glycan signal, 
Figure 38A-B.  
 
Figure 38. Results from Cohort 2. A. Imaging data shown is from glycans m/z 1663.5933, 
2539.9032, and 1976.6800. Clean spot morphology is seen from m/z 2539.9032, while 
nonspecific serum residue is seen from 1663.5933. Very little signal is observed from the 
sialylated glycan m/z 1976.6800. B. Imaging data is shown across all slides from 
disialylated glycan m/z 2289.7682. Minimal signal of this glycan is observed, with 
significant signal only detected from one of the slides analyzed. C. Quantitative 
comparisons of fucosylated glycans in cirrhotic versus HCC patients. Increased 
fucosylation was observed on all 4 target proteins. D. Quantitative comparisons of 




The data acquired from the glycans across all proteins in Cohort 2 was used to 
develop a biomarker algorithm for detection of HCC compared to cirrhosis via neural 
networking machine learning. Neural networking is essentially a computer-blinded 
approach of fitting the data to produce the most significant difference between the two 
patient groups. It is done with a series of trees/nodes where every value is tested 
branching out to every other value. The values that produce the most discriminating 
results are retained, without being informed by biological significance. This provides a 
level of rigor to the analysis as the algorithm is developed from the data alone without 
any biological biases. However, this blinded approach can cause hesitation among 
statisticians as this method does not detail the mathematical relationships among the 
nodes/trees and informing a model with biological reasoning can potentially improve its 
performance. This algorithmic modeling was not performed with the split cohort due to 
the small sample sizes, so the model represented in Figure 39 was created from the 
patient groups described in Table C. Five individual glycan signatures were used across 3 
of the 4 target proteins in this cohort. The signatures incorporated into the biomarker 
algorithm were glycans with m/z 1809.6432 on IgG, 2341.8007 and 1976.6800 on 
haptoglobin, and 2539.9032 and 1460.5004 on hemopexin. This neural networking 
technique produced an AUROC of 0.9289, which is a substantial improvement over the 




Figure 39. Creation of biomarker algorithm for prediction of HCC from cirrhosis using 
protein-specific glycan signatures and clinical information. Patient samples from Cohort 
2 (n=39) were used for the development of this algorithm. A. Neural network combining 
5 glycan signatures across 3 glycoproteins, age, gender, and AFP levels. B. ROC curve 
generated by algorithm shown in A. An AUROC of 0.9289 was calculated for this 
method.  
 
Cohort 3 was the largest patient cohort analyzed in this work and contained 
samples that were approximately matched for gender, race, etiology, and age. Clinical 
characteristics of this cohort are shown in Table 6. Of note is the very low levels of AFP 
in these patients, making these cancers especially difficult to detect. The spot morphology 
of this Cohort was very clean, with discrete spots seen for each captured protein, Figure 
40. Especially remarkable were the clean images obtained from m/z 1663.5444, as this 
extremely abundant serum glycan is often seen in residue around the well. Following 
analysis by the FT-ICR MS, some of these samples were also run on a timsTOF fleX MS 
(Bruker) at a higher spatial resolution with raster size 75 µm, Figure E-F. The glycans 
shown in E-F match those shown in A-B that were collected on the FT-ICR MS. Again, 
glycans were detected in very clear spots, although some markings were observed from 
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the laser shots in the prior MALDI MS imaging run as would be expected. This 
highlighted the ability of APB N-glycan imaging to be performed with either a MALDI 
FT-ICR or TOF instrument. The most pronounced disease-specific glycan changes for 
this cohort were detected on AGP, Clust, Hapt, and Hemo. Increased fucosylated glycans 
were again observed in HCC patients. AGP in particular showed an increase in all 
detected fucosylated glycans, Figure 41. Increased fucosylated glycans are depicted in A-
F, with control non-fucosylated glycans in G-I illustrating minimal to no increase in HCC 
samples. A decrease in non-fucosylated tetra-antennary m/z 2393.8200 was actually seen, 
which indicates that more tetra-antennary glycans are being fucosylated than not in these 
samples. 
Table 6. Clinical characteristics of Cohort 3. AST = aspartate aminotransferase, ALT = 






Figure 40. Representative glycan images from Cohort 3. Glycans with m/z 2393.8200, 
1663.5444, 2540.8627, and 1688.5800 are shown localized to capture spots. A-D were 
imaged on the MALDI FT-ICR at 250uM raster. E-F were imaged on the MALDI 
timsTOF at 75uM raster. Different color schemes were due to the different programs 







Figure 41. Elevated fucosylated glycans observed on AGP in Cohort 3. Yellow box 
represents the cirrhotic samples (n=30) and red box represents the HCC samples (n=30). 
A-F. Increased levels of fucosylated glycans were seen in HCC serum samples. G-I. 
Minimal to no increase in non-fucosylated glycans were seen in HCC serum samples. 
Glycan data was obtained from m/z 1663.5444, 1809.6278, 2028.6945, 2174.7512, 
2320.7820, 2393.8200, 2540.8627, 2685.9216, and 2833.2200. 
 
Acquired data from Cohort 3 was again used to create a biomarker algorithm for 
distinguishing HCC from cirrhosis in these samples. As these samples are considered 
AFP negative (serum AFP levels less than 20 ng/mL), cancer would be undetectable by 
current serum protein biomarkers. The algorithm created for Cohort 2 was not applied to 
this cohort as the sialylation step changed the workflow and glycan profiles for Cohort 3. 
While haptoglobin did not show as striking increases on all fucosylated glycans as AGP 
did, elevated levels were still seen, Figure 42, which were then found to work well for 
algorithmic modeling. While the individual glycan signatures did not show statistically 
significant increases in the cancer patient samples, incorporating them into algorithms 
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can highlight the significant relationships between these signatures.  Linear regression 
and neural networking, as discussed above for Cohort 2, were applied to these data using 
glycans m/z 1809.6278, 2393.8200, and 2833.2200 along with patient’s AFP levels. 
These three individual glycan signatures were found on haptoglobin, one of the 7 target 
proteins in this cohort. Comparisons of the performance of each model are shown in 
Figure 43. AFP alone led to an AUROC of 0.6378, which had only 27% sensitivity to 
detect cancer with a specificity of 90%, 43A. Combining the 3 glycans with AFP in a 
linear regression model produced an AUROC of 0.7589, which had 50% sensitivity to 
distinguish cancer from cirrhosis with a specificity of 90%, 43B. A neural network was 
created using the 3 glycan signatures on haptoglobin, AFP levels, and the patients’ age, 
as shown in 43C. This neural networking technique produced an AUROC of 0.9278, 
which had 75% sensitivity to detect cancer with a specificity of 90%, 43D. This is a 
substantial improvement over the performance of AFP for distinguishing HCC from 






Figure 42. Elevated fucosylated glycans observed on haptoglobin in Cohort 3. Yellow 
box represents the cirrhotic samples (n=30) and red box represents the HCC samples 
(n=30). A-F. Increased levels of fucosylated glycans were seen in HCC serum samples. 
G-I. Minimal to no increase in non-fucosylated glycans were seen in HCC serum 
samples. Glycan data was obtained from m/z 1663.5444, 1809.6278, 2028.6945, 




Figure 43. Creation of biomarker algorithms for prediction of HCC from cirrhosis using 
haptoglobin glycan signatures and clinical information. Patient samples from Cohort 3 
(n=60) were used for the development of this algorithm. A. Performance of AFP alone in 
these samples with an AUROC of 0.64. B. Linear regression combination of AFP with 3 
glycan signatures. C. Neural network combining 3 haptoglobin glycan signatures, age, 




 Hepatocellular carcinoma is an aggressive cancer of the liver that generally arises 
in the presence of liver disease such as cirrhosis. Patients with liver disease are therefore 
recommended to undergo routine surveillance and screening for disease progression 
and/or cancer development. Screening for HCC involves a combination of imaging 
modalities like CT and ultrasound as well as serum-based biomarkers AFP, AFP-L3, or 
des-g-carboxy prothrombin. However, all of these techniques suffer from a lack of 
sensitivity/specificity to detect HCC in all cases. Particularly cancers that have low to 
null serum levels of AFP are often missed by physicians. This suggests that new serum-
based screening markers are necessary to increase the accuracy of HCC detection and 
ultimately to improve patient outcomes.  
This work was a novel analysis of serum glycoproteins using multiplexed 
antibody panels and MALDI MS across 3 cohorts of patients with either HCC or 
cirrhosis. Patients with liver cirrhosis were used as controls in all 3 cohorts because HCC 
generally arises in the presence of cirrhosis, making them the ideal screening population 
in need of a cancer biomarker. Additionally, the use of these controls ensured that glycan 
signatures observed were not solely due to inflammation of the liver as opposed to 
cancer. It is possible that some of these cirrhotic patients may have had undetected very 
early stage HCC, but to address this problem the patients were followed for additional 
time after sample collection. Patients from Cohorts 1 and 3 were followed for 2 years and 
Cohort 2 patients were followed for 3 years to be sure they didn’t develop HCC.  
 Results of Cohort 1 clearly indicated that 20 µL serum was too much to add to 
these size wells, as significant residue was observed even after washing steps. Larger size 
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well chambers (such as the 1x4 chambers pictured in Chapter 3) may be able to 
accommodate a larger amount of serum. The main glycan modifications seen in Cohort 1 
were increased sialylated glycans, both mono- and di-sialylated bi- and tri-antennary 
structures. However, none of these changes were statistically significant and required 
further exploration in larger patient cohorts.  
 Cohort 2 illustrated the successful analysis of 4 serum glycoproteins as well as 
creation of a biomarker algorithm to differentiate HCC from cirrhotic patients. For this 
cohort, only 5 µL serum was used for each patient sample in order to improve image 
quality of the panels. Increased fucosylation on the 4 proteins was the primary type of 
modification seen in HCC patient serum, Figure 37. Two of these fucosylated signatures 
were incorporated into a biomarker algorithm that differentiated HCC from cirrhosis with 
an AUROC of 0.9289. Although two sialylated structures were also included in the 
algorithm, this study highlighted the complications of analyzing sialylated glycan 
structures by MALDI MS. Very little sialylated glycan signal was observed across all 
slides used in this experiment, with one particular slide having significantly more sialic 
acid signals than the other seven, Figure 37C. This presented a problem for analysis and 
suggested that sialic acid residues may need to be completely removed in future 
experiments for more reproducible analysis.  
 An additional aspect to Cohort 2 was the ability to break HCC patient samples 
into 3-6 months prior to detection vs at time of detection. While detection of HCC before 
its detectable by imaging techniques is the goal of biomarker research, these early 
samples do not allow for a true comparison between the current gold standard and this 
assay. The data was therefore split and the 11 samples obtained at the time of HCC 
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detection were compared against the cirrhotic controls in order to more realistically 
represent the current screening population. 
 Cohort 3 was the largest patient cohort analyzed and conditions had been 
optimized from previous experiments. They key changes made for this cohort were using 
only 5 µL serum, increased concentration of detergent washes following sample capture, 
and pre-treatment of all samples with sialidase A to remove sialic acid residues. Removal 
of sialic acids was performed in order to increase reproducibility of slides as well as 
boost the signal of non-sialylated glycans. This suggested that the primary glycan 
modifications we would observe were in branched and fucosylated glycans.  
 Results from Cohort 3 did indeed show very clean images with discrete spots and 
minimal to no residue in the well, likely due to the amount of serum used and increased 
detergent wash. These spots allowed for the analysis of approximately 15 glycans per 
protein, which was slightly less than previous analyses due to the loss of all sialylated 
species. Increased fucosylation was observed on the majority of glycoproteins in the 
HCC patient samples. This was often coupled with a decreased in non-fucosylated 
glycans, such as the tetra-antennary m/z 2393. This emphasizes that a biosynthetical 
switch has occurred in these patients where more of these glycans are being fucosylated 
than not. Increased fucosylation has been reported in many cancers and can often be 
traced back to increased expression of fucosyltransferases.48 Three glycan signatures on 
haptoglobin (2 containing fucoses) were used to create a neural network algorithm for 
distinguishing HCC from cirrhosis with an AUROC of 0.9278. This corresponds to a 
75% sensitivity to detect cancer with 90% specificity, which is a significant improvement 
over AFP in this cohort. It is noted that A1AT did not show any remarkable changes with 
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HCC, and it is possible that this correlates with the poor performance of AFP in this 
sample set, which has been anecdotally observed in the past. Some patients showed very 
few glycan changes at all, which emphasizes the heterogeneity of HCC that will need to 
be addressed as future biomarker panels are developed. This suggests that additional 
proteins may need to be included in the panel to pick up other subtypes of the cancer.  
 An additional aspect of Cohort 3 was imaging on the MALDI TOF instrument. 
Slides were run on this instrument following imaging analysis on the FT-ICR. Very 
distinct spots were again observed on this MS platform, with captured proteins localized 
to their antibody spots. This versatility in suitable platforms for APB glycan imaging is 
significant as MALDI TOF MS are more suitable for clinical use. The speed of analysis 
on the timsTOF was significantly faster than the FT-ICR, while also acquiring greater 
spatial resolution. This could allow for smaller sized spots to be added to the panel, 
potentially accommodating many more antibodies per well. Beyond the increase in 
throughput, platforms such as the timsTOF also provide the capability for ion mobility 
spectra to be acquired. Ion mobility could be used to differentiate glycan isomers, which 
cannot currently be done on the FT-ICR. 
 Further analyses will be required to validate the algorithms and neural networks 
produced from these cohorts. Increased numbers of samples will increase the power of 
these results, with particular emphasis being put on increases in the fucosylated glycans. 
We expect that larger patient studies will also allow for multiple glycoproteins to be 
successfully included in these biomarker algorithms, as the data presented for Cohort 3 
relied on glycan signatures from just one protein. This was due to confounding effects 
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from the various signatures across all 7 proteins, which will likely improve with a larger 
sample set. 
 A key limitation to this technique is the quality of antibodies used to capture 
target glycoproteins. Antibodies most show high specificity and have a strong affinity for 
their antigen. All antibodies used in these experiments were validated using IR-labelled 
protein standards as described in Chapter 3. An additional consideration with the choice 
of antibodies is the storage buffers, as stabilizers can lead to significant ion suppression 
in the mass spectrum, so antibodies stored without glycerol and tween are necessary. It is 
also noted that antibodies do contain glycans that can produce background signal for this 
assay. Future work will be done to remove antibody glycans prior to sample capture, but 
antibody blanks were included in the current analyses to control for this issue. 
 The analysis of patient samples shown here illustrates the clinical relevance of 
using an antibody-assisted mass spectrometry imaging platform for serum biomarker 
discovery. While the experiments detailed here only look at up to 7 proteins at a time, the 
panels could easily be expanded to contain antibodies for 100s of glycoproteins. The 
antibody panels could then be optimized to include only the most relevant glycoproteins 
for a given disease state, or have separate panels for high versus low abundance proteins. 
Beyond a biomarker discovery tool, this platform could be translated into clinical 
laboratories to use as a screening tool for HCC once the biomarker algorithm is further 
validated with larger external patient cohorts. It is possible that only 2-3 glycoproteins 
containing the primary glycan modifications would need to be included in these panels to 
obtain clinically relevant results, which would allow for the panels to be miniaturized and 






























The work described here was the creation, optimization, and application of a novel 
biomarker discovery platform combining mass spectrometry imaging and antibody arrays. 
We hypothesized that this platform could be developed to specifically capture serum 
proteins for multiplexed protein-specific N-glycan analysis by MALDI MS. This method 
was developed to address current barriers in N-glycan research as well as clinical 
application: the difficulty of sample preparation and analysis of N-glycans in a protein-
specific and clinically relevant manner. Many current techniques require laborious sample 
preparation to isolate glycoproteins from serum or other biological fluids, leading to time-
intensive workflows that prevent researchers from analyzing large numbers of samples 
with significant throughput. Other methods separate N-glycans from their protein carriers, 
which can be quicker in sample preparation but loses the functional link to the individual 
proteins. 
Aim 1 focused on the development and optimization of a novel method termed 
Antibody Panel Based (APB) N-glycan imaging for multiplexed analysis of glycoproteins. 
The many parameters tested and adjusted throughout the development of this platform are 
described in Chapter 3. APB N-glycan imaging is performed by creating antibody panels 
within wells on a microscope slide, blocking the panel, adding serum or other biofluids for 
glycoprotein capture, localized release of N-glycans, MALDI matrix coating, and then 
imaging by a MALDI MS. Imaging data generated from this method can be visualized as 
a heat map for each glycan’s localization and intensity across the antibody panel. The signal 
from each spot can be quantified by exporting the area under the peak for each glycan. All 
the data used in the development and application of this method were collected on a 
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MALDI FT-ICR MS, but two MALDI-TOF MS systems were also tested and shown to 
successfully detect N-glycans from this platform (Chapters 3 and 5). 
 APB N-glycan imaging successfully showed specific glycoprotein capture and N-
glycan analysis on glycoproteins captured out of standard solutions or human serum. 
Chapter 4 describes the functionality of this method with sufficient slide blocking and 
sensitivity to detect N-glycans in a concentration-dependent manner. Glycan signals were 
detected from as little as 10 ng of glycoprotein, which corresponds to just femtomole values 
of glycan. Reproducibility of capture was also assessed and found to produce CV < 10%. 
The platform was then further multiplexed to 2 antibodies and successful capture of both 
glycoproteins by their specific antibodies was observed from both standard solutions as 
well as human serum. These results were again seen when the antibody panel was expanded 
to contain 6 antibodies per well. Multiplexing the antibody panels to successfully capture 
proteins from serum was a major goal of this research to move beyond current analytical 
tools for serum glycomics. 
The translational applications of this novel platform are in response to the dire need 
for serum biomarkers to sensitively and specifically detect early-stage HCC. HCC is a 
highly lethal cancer of the liver, primarily due to its difficulty to detect. Early detection 
remains the most successful treatment for HCC, yet current biomarkers are lacking in 
accuracy. Most serum proteins are glycoproteins and it has been well-established that 
glycans are altered in the presence of diseases such as cancer. Thus, we aimed to perform 
multiplexed analysis on serum glycoproteins to observe changes in glycosylation that 
corresponded to early-stage HCC. Most serum glycan analysis is performed on only one 
protein at a time or on released glycans uncoupled from their protein carriers, thus our 
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method is novel in its throughput. From these analyses we have developed a biomarker 
algorithm that differentiates HCC from cirrhosis with an AUROC of 0.9278. This was a 
very significant improvement on current biomarker AFP, which differentiated HCC with 
only an AUROC of 0.67 in this cohort of 60 patients. This algorithm will continue to be 
validated on additional, larger patient cohorts. 
 One key glycan signature that was observed to be elevated in the presence of HCC 
was fucosylation. Fucosylation, the addition of a fucose residue to the core or outer arm of 
an N-glycan, is an important glycan modification that impacts a variety of biological 
functions. Within the context of immune responses, fucosylation is especially important 
for antibody functions. For example, core fucosylation on IgG significantly reduces its 
binding to Fc receptors found on natural killer cells and macrophages, diminishing 
antibody dependent cellular cytotoxicity.280 Serum proteins with elevated fucose residues 
are seen in many cancers, but particularly in HCC have been correlated with 
disease.148,234,370 This ranges from the currently-approved glycoprotein biomarker AFP to 
other proteins such as haptoglobin, alpha-1-acid glycoprotein, hemopexin, and alpha-1-
antitrypsin.51,53,115,117,198,247 Fucosylation can impact cell growth, proliferation, and 
signaling, all of which may contribute to the development and progression of cancer.75,82,346 
Increased sialic acid residues on HCC proteins were also observed in one of the 
patient cohorts included in this work. Sialylation can impact biological functions such as 
conferring anti-inflammatory properties to IgG.279  This immunomodulatory function of 
sialic acids was mirrored in a study of transferrin sialylation in septic shock, where patients 
with decreased transferrin sialylation tended to develop more severe disease.371 Our results 
in Cohort 1 indicated the opposite – that increased sialylation was seen as patients 
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progressed from cirrhosis to HCC. This could be due to the opposing role of sialic acid 
residues as extending the serum half-life of most acute phase proteins, which would allow 
them to continue to circulate and exert functions on the body longer than necessary.372 
Given the inflammatory properties of acute phase proteins, it is likely that their increased 
circulation would create a conducive environment for cancer development and progression. 
It is noted that results from Cohort 1 arose from a very small set of patients and will require 
further validation in larger cohorts. To do this by APB N-glycan imaging, some method of 
sialic acid stabilization will be necessary, as sialylated glycans were not reproducibly 
detected across slides as we progressed to larger cohorts. 
6.2 Limitations and Future Directions 
The most abundant glycan changes observed across the patient cohorts were not 
found in every single patient sample. Some samples had very few glycan changes at all, 
which likely is reflective of a certain subtype of cancer. This reflects the heterogeneity seen 
in all cancers, including HCC. It is possible that these patients have extremely de-
differentiated tumors that do not retain many secretory properties of hepatocytes and thus 
do not produce as many of these glycoproteins into serum. In this case, the glycan 
signatures may not be able to detect all cancers by themselves. Including clinical data such 
as age, gender, liver enzyme levels, and co-existing health conditions may continue to 
increase the power of algorithms to catch these more difficult cancers.  
The future of this work will exist in two avenues: 1) continued improvement and 
optimization of APB N-glycan imaging as a research tool and 2) commercialization of this 
method for clinical implementation as a disease screening platform. This methodology has 
exciting implications in both directions – to be used in academic research labs for 
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glycoprotein analysis of biofluids as well as clinically for early detection of diseases such 
as cancer. The limitations of this assay differ in the two directions, with the primary 
limitation for the clinic being time and simplicity of analysis. Research laboratories are 
more forgiving towards time constraints and would instead require more detailed 
information to be obtained from the platform and/or translation to other biofluids. 
6.2.1 Research 
APB N-glycan imaging has endless possibilities to be used in academic research. 
The set-up of this platform allows for the analysis of any target glycoprotein with a 
validated antibody and could be amenable to a variety of biofluids and liquids added for 
sample capture. The analysis of different liquids such as urine, ascites, saliva, cerebrospinal 
fluid, or tears could all provide unique insights to various organ systems and diseases. 
Beyond human biofluids, cell supernatants could also be analyzed to evaluate alterations 
in cell-secreted glycoproteins. This application was briefly explored and found to be 
successful. Cell culture is ubiquitous in academic research and the implementation of this 
novel method with cell supernatants could provide important findings for many biological 
researchers. Additionally, cells themselves could likely be captured along the antibody 
panel and allow for cell-specific N-glycan analysis. 
With each new biofluid added to the panel, it is likely that some sample preparation 
steps will need to be optimized. For example, the high salt content in fluids such as urine 
may require additional water washes throughout the workflow, or even some level of 
desalting prior to sample addition. As discussed in Chapter 3, the presence of salt interferes 
with the MALDI matrix coating as well as leads to ion suppression during the MS analysis. 
Fluids containing cells to be captured will also require specialized sample conditions, as it 
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will be essential to keep the cells from lysing prior to antibody capture. If the cells lyse due 
to being in a hypotonic solution, the capture of cells for localization of the detected glycans 
will be lost. It is also unknown how many cells would need to be captured in order to 
achieve a detectable N-glycan signal from their surface glycoproteins. This may require 
that larger or more concentrated spots of antibodies be added to the panel.  
As a research tool, this method can be improved to provide more detailed structural 
information of detected N-glycans, whether by ion mobility or enzymatic treatments. This 
platform is compatible with the MALDI timsTOF fleX (Bruker), Chapter 5, which has ion 
mobility capabilities to distinguish isomers. This would increase the intensity of data 
analysis required to interpret these spectra. Enzymatic and/or chemical treatments could be 
performed on the samples prior or following addition to the antibody panels. Examples of 
these include endoglycosidase F3, which specifically cleaves core fucosylated and could 
be used to differentiate which fucose residues are present on the outer arm versus core of 
the glycan.343 Rather than removing sialic acids with sialidase A, sialic acid linkages could 
be stabilized using chemical methods that are currently being developed in our lab. This 
would provide not only the ability to retain these biologically important residues, but also 
give linkage information as there are three primary types: a2,3; a2,6, and a2,8. While 
these additional treatments may not be as conducive for streamlined clinical workflows – 
or perhaps even necessary for clinical signatures –  they could provide researchers with 
more detailed information on the types of glycan changes occurring on these proteins in 
the presence of disease.  
 Many of the limitations against chemical treatments/modifications of APB N-
glycan imaging are due to the importance of retaining the antibody capture of each 
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glycoprotein. This is essential when considering treatments that involve submerging the 
slide, where glycoproteins could be released from their antibodies and would no longer be 
detectable and the 2D localization is what provides the protein information in this assay. 
However, denaturing reactions that do not require liquid covering the slide (and thus no 
delocalization of proteins and/or glycans) could still be amenable to this format. For 
example, PNGase F is sprayed as a molecular coating that should not cause any 
delocalization across the slide. If the slides were incubated at a temperature high enough 
to denature some of the captured proteins (and antibodies), but not affect PNGase F enzyme 
activity, this would likely still work for detecting glycans in the array format. Additionally, 
PNGase F could be sprayed to slides that are heated from below via a heated tray as part 
of the HTX sprayer which may loosen some of the proteins for more efficient cleavage of 
glycans in a shorter amount of time. 
 To continue answering clinical questions from serum glycoprotein analysis, 
disease-specific glycan alterations observed in patient serum could be further explored on 
tissue sections containing tumors. Previously established MALDI imaging workflows for 
N-glycan analysis could easily be applied to a cohort of tissue samples. This would uncover 
if the cancer-specific signatures found in serum arise from the tumor tissue itself or the 
surrounding tumor microenvironment. Matched samples of both serum and tissue from 
patients would be ideal in observing these relationships. In particular, many HCC tissue 
samples are subtyped based on molecular signatures. Matching these subsets to the glycan 
changes seen in serum could help uncover glycoprotein targets that are most beneficial for 
detecting HCC in each individual subtype.  
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 The APB platform should also not be limited to solely N-glycan analysis. While 
the clinical relevance N-glycans is well-established, there are other post-translational 
modifications that could also impact clinical biomarker research. N-glycans were an 
important first target as MALDI imaging workflows have already been developed for these 
sugars. However, other sugar types such as O-glycans could be probed by this method – if 
there were an efficient way to cleave O-glycans using the automated sprayer system. 
Current O-glycosidase enzymes are not as prevalent as PNGase F for cleavage of N-
glycans, but they do exist and could be applied to this platform as well. This would be 
especially beneficial for the analysis of mucins, which were the target proteins briefly used 
in our cell supernatant analysis with collaborator Dr. Haab. Even beyond glycans, this 
platform could be adapted for the analysis of other post-translational modifications that are 
amenable to cleavage and MS analysis. 
  
6.2.2 Clinical Implementation 
A key area for improvement in order for APB N-glycan imaging to be implemented 
in the clinic is time. This method currently spans 3 days with a hands-on time of about 10 
hours. This duration could likely be shortened at several steps such as antibody 
adherence/drying, sialidase treatment, sample addition, and PNGaseF treatment. While an 
overnight incubation (approximately 16 hrs) for the antibodies to adhere uniformly to the 
slides has worked well, this could likely be shortened to even 2-6 hrs. The key outcome of 
this step are antibodies that remain attached to the slide and dry to form a complete circle, 
rather than a ring/donut around the exterior of the circle. The sialidase pre-treatment of 
samples could certainly be shortened from 2 hrs to 1 hr or less, as long as the sialic acid 
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residues are completely removed. Incubating this enzyme at a higher temperature than 
37°C could also speed up this step. Additionally, if sialic acid linkages are stabilized in a 
later step, this pre-treatment with sialidase could be removed completely. The addition of 
samples for 2 hrs at room temperature was never tested to see if a shorter or longer 
incubation time would be best. This incubation could also likely be shortened with the 
addition of a slight temperature increase. Well size may also affect the incubation time. 
The PNGase F treatment, as described in Chapter 3, was preliminarily tested and observed 
to provide stronger glycan signal when incubated overnight. This incubation 
(approximately 16 hrs) could also be tested to find a shorter time point that still showed 
sufficient glycan release. Some commercially available PNGase F is marketed as rapid and 
boasts deglycosylation in under 15 minutes.373 The rapid nature of this reaction is likely 
due to denatured proteins that are reacted in-solution with PNGase F at a high temperature, 
however a slight temperature increase could still be performed in this assay without 
harming the antibody:antigen bond. Another contributor to the time of this workflow is the 
duration of the MALDI imaging run. The MALDI FT-ICR is one of the slower mass 
spectrometry imaging platforms. Translating this technique to a MALDI TOF instrument 
(such as illustrated in Chapters 3 and 5) would allow for quicker run times in the analysis 
of these slides. 
 The other secret for this platform to be successful in the clinic will be simplicity. 
The currently described methodology is not only too long, but also requires significant 
hands-on attention. Certain aspects of this method could be automated to be performed in 
a clinical setting. Key examples are antibody spotting, PNGase F spraying, matrix 
application, and MALDI MS analysis. While antibodies are currently spotted manually, 
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many robotic printing/spotting platforms are available that could be programmed to 
fabricate the antibody panels. Not only would this be quicker, but also it would eliminate 
some aspects of human error and improved reproducibility of spot placement. The current 
manual spotting process requires a lot of focus and steady hands to ensure that each 
antibody is spotted in the correct location. This naturally results in some slight variations 
in the distances between spots, though the arrangement is kept constant. A robotic printing 
system would lead to uniform panels that contained no variation in the antibody spot 
placement. The spraying platform used for both PNGase F and MALDI matrix application 
is a robotic system, but still requires attention to manually clean and flush the lines, check 
flow rate, and start the spraying process. Depending on sprayer maintenance, this can add 
an additional 30 minutes to the workflow. An automated sprayer platform that could wash 
the lines, monitor the flow rate, and be controlled through computer scripts would greatly 
influence the clinical relevance of this workflow, as well as add a level of quality control. 
Analysis by the MALDI MS also requires trained users to establish methods, teach the 
sample areas, and calibrate prior to each imaging run. Slides that contained a digital 
directive (such as the barcodes currently being developed by Bruker) could be used that 
would automate the method selection, teaching process, and calibration for each imaging 
run. This would again provide a level of quality control to the analyses. The data analysis 
itself could also be automated, with programming to recognize visual patterns of glycan 
signatures across the panel or numerical thresholds of glycan intensity. Current data 
analysis requires manual designation of each antibody spot as a unique region, peak 
picking, and then exporting area under peak values from each antibody spot and arranging 
these values to be compared. This process is quite laborious when large sample sets (even 
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the 40 used in Cohort 2) assaying multiple proteins. The data analysis will also likely 
benefit from simplification in ignoring linkage information such as sialic acid linkages 
unless the linkage truly is a valuable marker for disease. 
 In order to be realistically accepted into clinical screening workflows, this method 
would need to illustrate superior performance over currently used biomarkers. In the case 
of HCC, this method would need to outperform AFP as well as other suggested biomarkers 
such as des-g-carboxy prothrombin. Significant external validation will be required with 
larger patient cohorts encompassing a wide range of age, gender, race, disease etiology, 
AFP levels, and the presence of other health conditions in order to rule out potential false 
positives and false negatives. The experimental method and results presented in Chapter 5 
will serve as the foundation for future works in validating the described algorithms.   
 A question often asked about the future for this assay in the clinic is how 
many/which cancers it will be able to detect. Pan-cancer assays that probe for many 
different cancers have especially gained popularity in recent years, with platforms such as 
CancerSEEK receiving public attention.67 CancerSEEK uses a combination of protein and 
DNA biomarkers to detect and localize cancer to specific organs. While assays such as this 
have a lot of flash, their practicality can be disputed. Most patients receiving initial 
diagnoses for cancer have symptoms that can aid physicians in pinpointing the origin of 
their disease. Non-invasive methods such as imaging are also successfully used to pick up 
many of these cancers. The likelihood of a physician being unsure if a patient has liver, 
lung, or brain cancer is pretty rare due to the aid of imaging and symptomatic assessment. 
While a pan-cancer assay could be helpful when primary or metastatic origin is ambiguous, 
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they are not suitable for standard detection of early cancers. Therefore, I believe the future 
for the APB platform lies in discrete panels for each type of cancer.  
 The creation of multiple APB assays for different cancers and/or diseases will 
achieve the greatest clinical impact due to their versatility and specificity for a given 
disease. Separating out the diseases to different antibody panels will allow for 
organ/disease-specific proteins to be targeted in each panel. This will not only benefit the 
specificity of the assay, but also reduces unnecessary data analysis. For example, if 45 
different proteins are needed to detect 5 different types of cancer, having to analyze glycan 
signatures across all 45 proteins will significantly increase the difficulty of data analysis. 
If, instead, panels were created with 4-8 proteins that are most relevant to each given 
disease, the data analysis would be much more focused and less laborious. While a large 
antibody panel is useful in a research setting, simplicity again will be key for the clinic. 
Using different panels will also lead to customization of the type of biofluid added as well 
as the amount. Small amounts of serum (such as the 5 µL used in this work) may be 
sufficient for diseases such as liver cancer that will heavily affect serum proteins. However, 
cancers such as lung or prostate may only lead to minor alterations on less-abundant 
proteins, and thus require more serum to be added in order for changes to be detectable. 
Additionally, biofluids such as urine, expressed prostatic secretions, or saliva may be more 
helpful for these diseases. 
 It is also possible that translation of this technique to the clinic will move away 
from MALDI MS completely. If certain glycan motifs are found to be indicative of disease, 
they could be probed along the antibody panels with lectins instead of MALDI MS. This 
is already seen in the clinic with the AFP-L3 test for HCC, which uses the lectin Lens 
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culinaris agglutinin to measure the level of fucosylation observed on AFP. While lectins 
do not have the specificity of MS and certainly could not replace MS in this assay as a 
research tool, they could provide the simplicity desired in clinical laboratories. 
Additionally, performing lectin reactivity tests is far cheaper than MALDI MS and requires 
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